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Summary 
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Summary 
Chronic stress is a crucial risk factor for the development of numerous psychiatric 
diseases. One major finding in many depressed patients is an impaired regulation of the 
hypothalamic-pituitary-adrenal (HPA) axis, which is mediated via the glucocorticoid 
receptor (GR). FK506-binding protein 51 (FKBP51) has been shown to decrease ligand 
binding sensitivity of the GR, thereby directly affecting stress system (re)activity. Single 
nucleotide polymorphisms of FKBP51 have been linked to psychiatric disorders and 
antidepressant treatment response. Thus, FKBP51 has emerged as a novel potential drug 
target for the treatment of psychiatric disorders. This thesis aimed to investigate the 
function of FKBP51 as a mediator of the stress response system, its role in the 
development of stress related diseases and antidepressant responsiveness, as well as its 
potential as a novel treatment approach in psychiatric disorders. Therefore, I first 
subjected FKBP51 knockout mice to acute and chronic stress paradigms. Lack of FKBP51 
resulted in a more stress-resistant phenotype, especially with regard to neuroendocrine 
parameters, which was most likely due to an enhanced GR sensitivity. Interestingly, mice 
lacking one allele of FKBP52 (FKBP52+/- mice), which is FKBP51’s close homologue and 
functional counter-player, demonstrated a mixed phenotype of stress susceptibility and 
resilience. Furthermore, FKBP51 knockout mice were less responsive to acute and chronic 
treatment of the antidepressant drug paroxetine. Searching for novel molecular actions 
of FKBP51 linked to antidepressant effects, we found that FKBP51 is involved in priming 
autophagic pathways, which are necessary for full antidepressant potency. In addition, I 
also investigated brain-region specific functions of FKBP51, by overexpressing the gene 
via virus-mediated gene transfer. While FKBP51 overexpression in the dorsal 
hippocampus did not result in a strong phenotype, mice with an overexpression in the 
basolateral amygdala showed an increased anxiety-related behavior. Interestingly, I could 
also demonstrate that pharmacological inhibition of FKBP51 resulted in an anxiolytic 
phenotype in mice. Thus, the findings presented in this thesis provide a strong basis for 
further research investigating the role of FKBP51 in psychiatric disorders and might pave 
the way for drug development of selective FKBP51 inhibitors. 
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Zusammenfassung 
In den letzten Jahren wurde eine Reihe von Studien veröffentlicht, die genetische Varianten 
(Einzelnukleotid-Polymorphismen) des Gens FKBP51 mit dem Auftreten von psychiatrischen 
Erkrankungen wie der Depression, sowie mit der Responsivität für Antidepressiva 
assoziieren. Das molekulare Co-Chaperon FKBP51 reguliert die Signaltransduktion von 
Steroidhormonrezeptoren, wie z. B. dem Glukokortikoidrezeptor (GR), welcher ein wichtiger 
Mediator der hormonellen Stressantwort über die Hypothalamus-Hypophysen-
Nebennieren (HHN) Achse des Körpers ist. Dabei verringert FKBP51 die Bindungsaffinität des 
GR für Stresshormone (Cortisol bei Menschen und Corticosteron bei Mäusen). Ein 
wiederholt auftretender Befund bei vielen psychiatrischen Erkrankungen wie der 
Depression ist eine Störung der HHN-Achse. FKBP51 rückte deshalb als potentielles neues 
Zielprotein zur Behandlung von psychiatrischen Erkrankungen vermehrt in den Fokus der 
Forschung. In der vorliegenden Arbeit untersuche ich die zugrundeliegenden Effekte von 
FKBP51 auf das Stresssystem im Körper und seine Verwicklung in psychiatrischen 
Erkrankungen. Hierfür habe ich transgene Mäuse, denen das FKBP51 Gen fehlt (FKBP51 
knockout Mäuse), verschiedenen akuten und chronischen Stressoren ausgesetzt. Ich konnte 
zeigen, dass FKBP51 knockout Männchen und Weibchen eine geringere Stressanfälligkeit 
aufweisen als Kontrollmäuse, was vor allem durch die stets sehr niedrigen 
Corticosteronwerte deutlich wurde und auf eine verbesserte negative Rückkopplung der 
HHN-Achse schließen lässt. Um das molekulare Umfeld von FKBP51 weiter zu verstehen, 
habe ich außerdem seinen wichtigsten molekularen Gegenspieler und engsten Verwandten, 
das FKBP52, näher untersucht. Ich konnte zeigen, dass Mäuse mit nur einem Allel für FKBP52 
(ein kompletter FKBP52-Knockout ist letal), in manchen Parametern stressanfälliger waren, 
bemerkbar z. B. durch erhöhtes Angstverhalten, gleichzeitig zeugten geringe basale 
Corticosteronwerte aber auch von einer gewissen Stressresistenz. Auf Grund der 
genetischen Assoziation zwischen FKBP51 Einzelnukleotid-Polymorphismen und 
Antidepressiva-Responsivität in klinischen Studien, unterzog ich FKBP51 Knockout Mäuse 
außerdem einer akuten und chronischen Behandlung des Antidepressivums Paroxetin. 
Hierbei konnte ich zeigen, dass FKBP51 knockout Mäuse weniger auf Paroxetin reagieren. 
Dieses Ergebnis spiegelt die klinische Situation wider, in der depressive Patienten mit 
erhöhten FKBP51 Werten schneller auf Antidepressiva reagieren. Wir konnten daraufhin 
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neue FKBP51-abhänginge Signalwege der Autophagie identifizieren, über die Antidepressiva 
(neben ihrer gängigen Funktion zur Verstärkung der Wirkung von Neurotransmittern) 
alternativ wirken können. Um FKBP51 als mögliches Zielprotein zur Behandlung von 
psychiatrischen Erkrankungen weiter zu validieren, habe ich außerdem Hirnregion-
spezifische Funktionen des Co-Chaperons untersucht. So konnte ich zum Beispiel zeigen, 
dass eine Virus-vermittelte Überexpression von FKBP51 in der basolateralen Amygdala zu 
erhöhtem Angstverhalten in Mäusen führt. Ich konnte zudem zeigen, dass die 
Verabreichung von kürzlich entwickelten FKBP51 Antagonisten zu verringertem 
Angstverhalten in Mäusen führt. Die vorliegende Arbeit bietet daher eine exzellente 
Grundlage für weitere Forschungsarbeiten, die sich mit der Rolle von FKBP51 in 
psychiatrischen Erkrankungen beschäftigen und ebnet den Weg für die Entwicklung von 
Antidepressiva mit neuen Wirkmechanismen. 
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1. General introduction 
1.1. Mood and anxiety disorders 
Every year more than a third of the population in the European Union (EU) suffers from 
brain disorders. Adjusted to age and comorbidity, this corresponds to 164.8 million 
persons affected, with mood disorders (7.8 %), such as major depression, and anxiety 
disorders (14.0 %), such as generalized anxiety disorder and post-traumatic stress disorder 
(PTSD), being the most frequent disorders (Wittchen et al., 2011). Interestingly, women 
are more susceptible to develop these diseases than men (Solomon and Herman, 2009; 
Bangasser, 2013). The total EU cost burden of disorders of the brain for both genders was 
estimated at €798 billion in 2010, of which €113.4 billion were attributed to mood 
disorders and €74.4 billion to anxiety disorders. These numbers highlight that disorders 
of the brain must be considered to be Europe’s foremost health care challenge of the 21st 
century (Gustavsson et al., 2011). 
Clinical depression refers to a condition of intense sadness, melancholia or despair, 
accompanied by anhedonia (loss of interest or pleasure), irritability, cognitive 
disturbances and abnormalities in appetite and sleep (Krishnan and Nestler, 2008). The 
condition can be chronic, with periods of good health interspersed with relapses; the 
recurrence of depressive episodes tends to increase over time, with increasing severity of 
each successive bout of illness (Yu et al., 2008). The diagnosis of depression is based on 
the documentation of a certain number of symptoms that significantly impair functioning 
for a certain duration. These diagnostic criteria overlap with other conditions such as 
anxiety disorders, which have substantial co-morbidity with depression (Nestler et al., 
2002; Rocha et al., 2013).  
Although antidepressant drugs are the most effective treatment for depressive disorders, 
pharmacotherapy still suffers from modest efficacy, the delayed onset of clinical 
improvement and high relapse rates. Despite intensive efforts in the development of 
antidepressants, major breakthroughs have only been achieved on the reduction of side 
effects of these drugs. Treatment efficacy can be enhanced by a combination of different 
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antidepressant drugs, but adequate therapy response rates, i.e. full remission, are yet to 
be reached (Binder and Holsboer, 2006; Thase, 2006).  
Epidemiologic as well as family and twin studies show that there is a substantial genetic 
risk to develop depression with an estimated heritability, i.e. genetic factors, of 30% to 
40% (Fava and Kendler, 2000). However, depression is a complex phenomenon, as these 
studies also point to a polygenetic nature of the disorder, which implies that individual 
genes are likely to exert only a relatively small effect and that the interaction of several 
genes with each other determines the phenotype (Nestler et al., 2002; Klengel and Binder, 
2013b). In addition, susceptibility to depression is only partly genetic, with environmental 
factors also being important. Exposure to aversive life events, such as traumatic 
experiences and chronic stress have consistently been established in the pathophysiology 
of this disorder (McEwen, 2004; Chrousos, 2009). The childhood period seems to be 
particularly sensitive to negative environmental factors, such as early life stress or child 
abuse, that increase the risk to develop depression later in life (Heim et al., 2010; Rocha 
et al., 2013). 
It is important to note that depression is a multifactorial disease. A genetic predisposition 
or environmental risk factor per se is not sufficient to cause depression. It is generally 
accepted that in most people, depression is caused by interactions between a genetic 
predisposition and some environmental factors. Thus, studies investigating gene x 
environment interactions that aim at assessing the joint contribution of genetic and 
environmental factors for developing depression are an important focus of recent 
research in the field of mood disorders (Nestler et al., 2002; Klengel and Binder, 2013b). 
However, knowledge about the molecular neurobiology of depression is rather 
rudimentary compared to knowledge of other common chronic and potentially fatal 
multifactorial diseases such as type 2 diabetes, due to the fact that observing pathological 
alterations within the brain remains markedly more difficult than for all other organs 
(Krishnan and Nestler, 2008). To further elucidate the complex nature of mood disorders, 
mouse models have proven extremely useful not only regarding the validation of 
neurobiological underpinnings, but also with respect to the identification and 
improvement of therapeutic substances (Nestler and Hyman, 2010). 
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1.2. Modeling mood disorders in mice 
It is extremely difficult to envision a mouse model that perfectly mimics the human 
condition of depression with respect to its etiology, symptomatology, treatment and 
biological basis. For instance, many of the symptoms used to diagnose depression in 
humans, such as sadness, guilt and suicidality, cannot be convincingly assessed in animals 
(Deussing, 2006). Thus, it is highly unlikely that an animal model can mirror all the salient 
characteristics of human mood disorders. Nonetheless, these models can be successfully 
used if questions related to specific key symptoms prevalent in human depression are 
addressed (Müller and Holsboer, 2006). Therefore the scientific community established a 
framework of the three minimal requirements for a valid disease model. An animal model 
should fulfill (1) face validity, i.e. the similarity of disease symptoms in humans and 
rodents, (2) construct validity, which requires that the symptoms produced in the mouse 
model are based on the same underling neurobiological mechanisms as in humans, and 
(3) predictive validity, referring to the ability of the animal to respond to pharmacological 
treatments in a manner that predicts the effects of those treatments in humans 
(McKinney, Jr. and Bunney, Jr., 1969; Nestler and Hyman, 2010; Dedic et al., 2011). 
Most mouse models of mood disorders rely either on targeted genetic manipulations or 
on environmental challenges. One possibility is to use the intrinsic heterogeneity of whole 
populations (outbred strains). Hereby, one or more characteristics are investigated and 
the animals are selected into subpopulations based on molecular or behavioral 
parameters, which would also reflect genetically or defined populations (Schmidt et al., 
2010b; Scharf and Schmidt, 2012). Such subpopulation selection can further be used as a 
particular factor for selective breeding to presumably enhance the differences in the 
subgroups and isolate the genetic component transferred over the germ line (Touma et 
al., 2008). However, one of the most common approaches is to modify the murine 
genome, resulting in knockout (KO) or transgenic (knock-in) mice specific for selected 
candidate genes (Müller and Holsboer, 2006). The refinement of techniques for directed 
genetic mutations or gene targeting, such as the propagation of the Cre-Lox 
recombination technology, has allowed an increasingly precise control of spatial (e.g. 
brain region or cell-type specific) and temporal (e.g. during or after development) gene 
expression (Dedic et al., 2011). Other popular and frequently used methods are 
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conditional manipulations including RNAi technology and virus-mediated gene transfer 
which also enable the control over spatial and temporal gene expression, as well as 
optogenetically mediated stimulation or inhibition of distinct cell populations in specific 
brain regions (Glaser et al., 2005; Fenno et al., 2011).  
Besides genetic manipulations, many animal models of mood disorders focus on 
environmental risk factors, such as chronic stress, which have crucially been implicated in 
the cause of depression in humans. There are a number of mouse models that have been 
designed on the basis of chronic stress, which fulfill the criteria of face, construct and 
predictive validity. Such chronic stress paradigms comprise, among others, restraint-
based chronic stress (Kim and Han, 2006), chronic mild stress (Willner, 1997), intruder 
stress (Tornatzky and Miczek, 1994), prey and predator stress (Adamec and Shallow, 
1993), sleep-deprivation stress (Pokk et al., 2000), conditioned emotional stress (Gomita 
et al., 1983; Katsura et al., 2002), chronic social stress (Schmidt et al., 2007; Sterlemann 
et al., 2008) and chronic social defeat (Berton et al., 2006). Especially the chronic social 
defeat paradigm is very useful (Figure 1.1), since the animals are exposed to a permanent 
stress situation, which is not limited to a defined time period per day. Moreover, there 
are no adaptations in response to the stressor as observed in other paradigms such as the 
chronic restrained stress. Furthermore, the stressor of the defeat paradigm is of social 
nature, taking into account the etiology of human stress-associated disorders (Golden et 
al., 2011). 
Figure 1.1: Chronic social defeat stress paradigm. Schematic overview of the social defeat procedure. 
The experimental mouse is placed into the cage of a dominant resident mouse. After physical defeat, 
a divider allows only sensory contact. After 24 hours experimental animals are introduced to another 
unknown resident.  
General introduction 
5 
It is important to note that some individuals are more susceptible to chronic stress, while 
others show a marked resilience. Along this line, it is rather unlikely that a single genetic 
variant is responsible for a specific disorder. However, the combination of environmental 
challenges and genetic predispositions are thought to play a central role for the 
development of depression (Gillespie et al., 2009; Pitchot et al., 2012; Klengel and Binder, 
2013a; Klengel and Binder, 2013b). Therefore many studies apply the concept of gene x 
environment interactions in preclinical research, which is more likely to reflect the 
pathophysiological mechanisms of mood disorders. One approach to address such gene x 
environment interactions is to expose mouse lines with a genetic manipulation of a gene 
hypothesized to be a risk factor for the development of stress-related disorders to 
situations that induce symptoms of psychopathologies in mice. Indeed, such studies could 
show that disease associated genetic alterations per se do not necessarily have to be 
beneficial or pathological under basal conditions. However, in combination with chronic 
stress, these genetic alterations turned out to enhance resilience or susceptibility towards 
the development of depression-like phenotypes in mice (Berton et al., 2006; Vialou et al., 
2010; Wagner et al., 2011; Wang et al., 2011a; Donahue et al., 2014).  
1.3. Stress and stress response systems 
Stress is a term often used to describe situations that are emotionally and physiologically 
challenging. In biological terms, stress is characterized as a state of disturbed body 
homeostasis. Hans Selye, a pioneer of stress research, defined stress as the ‘non-specific 
response of the body to any demand for change’ and introduced the so called ‘General 
Adaptation Syndrome’ (Selye, 1936), which is comprised of three stages. First, an alarm 
reaction to prepare the body to fight or flight is initiated, after which a resistance to the 
stress is built and finally it comes to an exhaustion state due to a too long stress exposure. 
Later on, Sterling and Eyer introduced the state of allostasis as the process of achieving 
stability, or homeostasis, through physiological or behavioral changes (Sterling and Eyer, 
1988; McEwen, 1998). The body’s adaptive systems respond to the internal state (e.g. 
sleeping or exercising) and to the external environment. Those mechanisms promote 
adaptation to activities such as locomotion but also to aversive stimuli including noise, 
isolation, hunger and threats. Usually, the mediation of a stress response is beneficial, as 
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long as the adaptive systems are activated for a short period of time and efficiently shot 
off again, without being chronically overstimulated. Nevertheless, several circumstances 
that lead to a permanent overstimulation or an inactivity of allostatic systems that are 
normally involved in adaptation to environmental challenges can be maladaptive. 
McEwen introduced such a condition as ‘allostatic load’, which can lead to impaired 
immune system function, obesity and atrophy of nerve cells in the brain (McEwen, 1998). 
Taken together, it should be highlighted that averse experiences and excessive challenges 
such as chronic stress clearly impose a major risk factor for the development of depression 
and other stress-mediated disorders (Holsboer, 2000; van Praag, 2005; de Kloet et al., 
2005a). In order to completely understand the mechanisms that cause depression, it is 
necessary to study the systems mediating the stress response in great detail. 
1.4. The HPA axis 
The major control module of the stress response in mammals, besides the autonomic 
nervous system, is the hypothalamic-pituitary-adrenal (HPA) axis. Upon stress, the HPA 
axis is activated and thereby cortiocotropin-releasing hormone (CRH) and vasopressin 
(AVP) are secreted from neurons of the paraventricluar nucleus into the portal blood 
system that is connected to the anterior part of the pituitary gland (Sapolsky et al., 2000). 
At the pituitary, CRH and AVP bind to their respective receptors and synergistically trigger 
the synthesis and release of pro-opiomelanocortin (POMC), the precursor for andreno-
corticotropic hormone (ACTH). Circulating ACTH reaches the secretory cells of the zona 
fasciculate and the zona reticluaris of the adrenal cortex via the blood stream and 
stimulates them to synthesize and secrete glucocorticoids (GCs) into the systemic 
circulation. Glucocorticoids (cortisol in humans and corticosterone in rodents), the main 
hormonal end products of the HPA axis, are then acting on numerous organ systems, 
including the brain, to modulate physiology and behavior (Figure 1.2). Among other things 
they mediate cardiovascular activation, energy mobilization from storage sites, anti-
inflammatory effects and suppress reproductive and digestive functions (Sapolsky et al., 
2000; Sorrells and Sapolsky, 2007). 
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Figure 1.2: Hypothalamic-pituitary-adrenal axis. Activation of the HPA axis leads to the secretion of 
hypothalamic corticotropin-releasing hormone (CRH) and vasopression (AVP), which in turn trigger the 
release of adrenocorticotropic hormone (ACTH) from the anterior pituitary. ACTH simulates the 
secretion of glucocorticoid hormones (cortisol in humans and corticosterone in rodents). GCs target 
various tissues and organs in the body, but also regulate HPA axis activity via corticosteroid receptors 
(GR and MR).  
 
The nature of a stressor can differ largely and therefore the stress response, mediated via 
the HPA axis, arises from interactions of several distinct stress-sensitive brain circuits and 
neuronal populations of the PVN. This nucleus appears to be a major player in the central 
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regulation of the HPA axis, since lesion studies of the PVN revealed markedly decreased 
portal CRH- and stress-induced ACTH and corticosterone levels (Herman and Cullinan, 
1997). The stress-sensitive pathway of the catecholaminergic system projects directly to 
the CRH-containing neurons of the PVN (Cunningham et al., 1990), is mainly stimulated 
by direct threats like hemorrhage, hypotension and respiratory distress, and might play a 
role in the ATCH responses to immune challenges (Ericsson et al., 1994). Furthermore, it 
has been suggested that serotonin can also affect local neuronal circuits projecting to the 
PVN, given the fact that serotonergic neurons project to regions adjacent to the PVN 
(Leonard, 2005). Additionally, psychological stressors that require interpretation and 
processing by higher brain structures are mainly channeled through limbic structures like 
the amygdala and the hippocampus (Sinha et al., 2004). These central brain regions are 
associated with emotion as well as learning and memory and are connected to the bed 
nucleus of the stria terminalis (BST), which in turn projects to the PVN (Cullinan et al., 
1993; Choi et al., 2008). It is suggested that the amygdala activates the HPA axis, since 
lesion studies displayed decreased ACTH and corticosterone secretion following stress, 
whereas amygdala stimulation led to increased HPA axis output (Herman et al., 2005). 
Persistent stress that is not resolved through coping or adaptation (termed distress) can 
lead to a dysregulation of the HPA axis and may cause depression-like behavior (Holsboer, 
2000). In order to recover the HPA axis to its basal activity and to prevent it from being 
pathologically over-activated it is necessary to terminate the stress response on time. 
Several negative feedback mechanisms are involved in normalizing the activity of the 
stress system (Figure 1.2). Numerous studies have shown that hippocampal stimulation 
reduces glucocorticoid secretion, whereas hippocampal lesion increases GC release (Dunn 
and Orr, 1984; Herman et al., 2005). These lesion effects are most pronounced during the 
recovery phase of stress-induced glucocorticoid secretion, suggesting a critical role of the 
hippocampus in the feedback inhibition of the HPA axis (Jacobson and Sapolsky, 1991). 
Moreover, GCs act directly on different levels of the HPA axis, like the PVN and the 
pituitary, in order to repress CRH and ACTH release, respectively, and therefore regulate 
their own secretagogues (Sapolsky et al., 2000). GCs exert these negative feedback effects 
on the HPA axis by binding to different receptor subtypes, the mineralocorticoid receptor 
(MR) and the glucocorticoid receptor (GR). 
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1.5. Corticoid receptors 
The corticoid receptors GR and MR are both members of the ligand-dependent 
transcription factor family (De Kloet and Reul, 1987; Mangelsdorf et al., 1995). MRs bind 
GCs with a 10-fold higher affinity than GRs, suggesting different roles for each receptor 
type in the regulation of HPA axis activity. Hippocampal MRs are already extensively 
bound to their ligands under basal levels of GCs and are therefore mainly responsible for 
basal regulation of the HPA axis, whereas GR occupation occurs at the circadian peak of 
glucocorticoid secretion and following stress (De Kloet et al., 1993; Joels and De Kloet, 
1994). Furthermore, both receptors are expressed in different tissues of the body’s 
periphery. In the brain, the main function of both receptors, among others, is the 
mediation of the negative feedback control of the HPA axis. MRs and GRs mediate such 
regulation mainly in the hypothalamus and the pituitary, but also on the level of the 
hippocampus (De Kloet et al., 1998; Ulrich-Lai and Herman, 2009). The proper negative 
feedback via the GR appears to be critical for a healthy stress response and prolonged or 
excessive activation of this system have been implicated in the pathogenesis of mood and 
anxiety disorders (Holsboer, 2000; Pariante and Miller, 2001). One of the most robust 
biological abnormalities observed in such mood disorder is an impaired signaling via GR, 
which often leads to an impaired negative feedback regulation and thus to partial 
glucocorticoid resistance. In order to better understand the negative feedback loop of the 
HPA axis and its mediation via MRs and GRs it is necessary to obtain a better 
understanding of the molecular mechanisms underlying those receptors. 
Corticoid receptors are intracellular transcription factors that bind to DNA following 
activation by means of ligand-binding in order to regulate the expression of specific target 
genes. They contain a DNA-binding domain (DBD), located in the central part of the 
polypeptide chain, a ligand-binding domain (LBD) which is a large C-terminal domain and 
a N-terminal domain, that contains a transcriptional activation function (Ma et al., 1999). 
In the absence of a ligand, steroid receptors are typically associated with a dimer of the 
heat shock protein 90 (hsp90) and additional components of the molecular chaperone 
machinery (Cheung and Smith, 2000). Upon ligand activation, the receptor is subjected to 
several conformational changes that lead to its dissociation from the cytoplasmic 
chaperones. After transportation to the nucleus by a group of nuclear translocation 
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proteins, the receptor dimerizes. The formed homodimers bind to their cognate DNA 
sequences, called glucocorticoid response elements (GREs), and induce the transcription 
of GRE-containing genes. Moreover, transcription can be decreased by interaction of the 
dimer with other transcription factors or binding to negative GREs (Beato et al., 1995; De 
Bosscher et al., 2003; Liberman et al., 2007). 
1.6.  Molecular chaperones and the hsp90 complex 
Molecular chaperones are proteins that assist other proteins (both newly synthesized 
polypeptide chains and assembled subunits) in various steps of protein maturation to 
avoid misfolding. Moreover, they participate in the ubiquitin-proteasome and autophagy 
systems, which mediate the timely removal of irreversibly misfolded and aggregated 
proteins. The protein quality control network and the maintenance of proteome 
homeostasis are crucial for cellular and organismal health. (Hartl and Martin, 1995; Hartl 
et al., 2011). Hartl and colleagues defined a molecular chaperone as any protein that 
interacts with, stabilizes or helps another protein to acquire its functionally active 
conformation, without being present in its final structure (Hartl, 1996; Hartl and Hayer-
Hartl, 2009).  
Molecular chaperones belong to the heat-shock proteins (hsps), since they are 
synthesized in dramatically increased amounts after a short exposure of cells to an 
augmented temperature (Georgopoulos and Welch, 1993). The main groups of 
chaperones in mammals are the hsp60, hsp70 and hsp90-families, which are usually 
classified according to their molecular weight (Pratt and Toft, 1997; Fink, 1999; Hartl et 
al., 2011). Hsp90 is one of the most abundant proteins in the cytoplasm of eukaryotes, 
representing up to 1 % of soluble protein even in the absence of heat-stress (Welch and 
Feramisco, 1982). Chaperones exist in the cytosol as multiprotein heterocomplexes 
independent of their association with receptors and are the center of a dynamic, 
multifunctional and multicomponent chaperone machinery (Buchner, 1999). 
In the absence of a ligand the GR resides in the cytoplasm. Numerous molecular 
chaperones assemble the receptor in a successive and ATP-dependent manner to a 
conformational state capable of binding a hormone with high affinity (Pratt and Toft, 
1997). The mature GR complex consists of an hsp90 dimer, hsp70 and the hsp90-binding 
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protein p23. Moreover, several co-chaperones bind via their tetratricopeptide repeat 
(TPR) domains to a universal TPR binding domain on hsp90 during GR complex maturation. 
These include among others the mammalian FK506-binding proteins (FKBPs), FKBP51 
(also called FKBP5) and FKBP52 (also called FKBP4) (Tai et al., 1992; Cheung and Smith, 
2000; Wochnik et al., 2005). One important task of the hsp90-heterocomplex is to assist 
the folding of the LBD of the receptors into a high-affinity ligand-binding state. The direct 
interaction of hsp90 with the LBD of the receptors appears to account for an inhibition of 
receptor function that is relieved upon subsequent binding of the ligand (Pratt and Toft, 
1997). 
 
1.7. The immunophilins FKBP51 and FKBP52 
Immunophilins are ubiquitous and conserved proteins that are targeted by 
immunosuppressant drugs, like FK506, rapamycin and cyclosporine (Schreiber, 1991). 
There are two immunophilin subfamilies: the cyclophilins (CyPs) bind cyclosporine A, 
whereas the FKBPs represent binding proteins for compounds such as FK506 and 
rapamycin. Immunophilins have been identified in many eukaryotes from yeast to 
humans and all members of this family exhibit a peptidyl-prolyl isomerase (PPIase) 
activity, suggesting that they may be involved in protein folding in the cell (Trandinh et al., 
1992). 
In mammals, FKBP51 and FKBP52 share more than 70% sequence identity, but they 
contrary regulate GR signaling via hormone binding and nuclear translocation (Wochnik 
et al., 2005; Binder, 2009; Schmidt et al., 2012). The murine FKBP51 is a 51 kDa protein 
encoded by the Fkbp5 gene (also known as Fkbp51) and its expression is strongly 
hormone-dependent (Hubler et al., 2003; Vermeer et al., 2003). FKBP51 was first 
identified in the progesterone receptor complex (Smith et al., 1990) and has co-chaperone 
activity, since it is participating in the hsp90-complex (Schiene-Fischer and Yu, 2001). 
Increased levels of FKBP51 in COS cells have been reported to diminish the binding affinity 
of GR and therefore reduce the transcriptional activity of GR after hormone exposure 
(Denny et al., 2000). In addition to this reduction of hormone binding it has been shown 
in mammalian cells that the mechanism for the inhibitory action of FKBP51 on GR involves 
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an impairment of nuclear translocation (Wochnik et al., 2005). Furthermore, FKBP51 may 
also regulate the nuclear translocation of the nonactive beta-isoform of the GR, thereby 
diminishing overall GR signalling (Zhang et al., 2008). In neurons, siRNA knockdown of the 
gene encoding for FKBP51 was associated with elevated baseline GR nuclear localization 
(Tatro et al., 2009a). Taken as a whole, FKBP51 acts as a negative regulator of GR activity. 
However, it is important to note that FKBP51 is also involved in various other intracellular 
processes, besides its regulatory function of the GR (Pei et al., 2009; Blair et al., 2013). 
The murine FKBP52, a 52 kDa protein, is encoded by the Fkbp4 gene (also referred to as 
Fkbp52) and its expression can be increased via exposure to heat or chemical stress, 
determining itself as heat shock protein (Sanchez, 1990). Like FKBP51, it is associated with 
the hsp90-heterocomplex (Tai et al., 1992). Moreover, it is localized in the cytoplasm as 
well as in the nucleus (Czar et al., 1997). Upon hormone binding, FKBP51 is replaced by 
FKBP52 in the cytosolic GR-hsp90-complex (Davies et al., 2002). Subsequently, FKBP52 
interacts with the motor protein dynein, which is part of a transportosome, a protein 
heterocomplex that leads the GR along cytoskeletal tracts to the nucleus (Galigniana et 
al., 1998; Silverstein et al., 1999; Galigniana et al., 2004). Moreover, Rein and colleagues 
showed that elevated levels of FKBP52 attenuated the impairment of GR nuclear 
translocation induced by FKBP51 (Wochnik et al., 2005). Furthermore, siRNA knockdown 
of FKBP52 inhibited cortisol-activated GR nuclear translocation in neurons (Tatro et al., 
2009a). 
Taken together, FKBP51 binds to hsp90 during the maturation of the GR-complex, which 
leads to a decreased GR-complex affinity for glucocorticoids (Figure 1.3). Upon hormone 
binding, FKBP51 is replaced by FKBP52, which recruits dynein into the complex, facilitating 
its nuclear translocation and transcriptional activity (Binder, 2009; Storer et al., 2011). As 
mentioned previously the expression of FKBP51 is stimulated by steroids, such as GCs, as 
part of an intracellular ultra-short negative feedback loop for GR activity (Vermeer et al., 
2003; Hubler et al., 2003). Therefore, augmented transcription and translation of FKBP51 
following corticoid receptor activation reduces GR sensitivity. 
The suggested role of immunophilins in GR signal transduction also involves novel 
potential possibilities to elucidate GR impairment associated with many psychiatric 
disorders, like PTSD and depression (Holsboer, 2000). It is well established that 
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malfunction of GRs due to low affinity ligand binding can be the consequence of mutations 
of the GR receptor itself or of limited hsp90 action (Picard et al., 1990; Bohen and 
Yamamoto, 1993; Brönnegard et al., 1996). Since FKBP51 can contribute to augmented 
GC levels and thereby modulating GR sensitivity, it was suggested to mediate gene-
environment interactions relevant in mood and anxiety disorders. 
 
 
Figure 1.3.: Interaction and function of FKBP51 and FKBP52 with the GR-complex. (a) When FKBP51 
is bound to the GR-complex via hsp90, the receptor has lower affinity for glucocorticoids. (b) Upon 
ligand binding, FKBP51 is replaced by FKBP52, (c) which promotes the translocation into the nucleus 
and (d) subsequent DNA binding. (e) The GR can then increase FKBP51 transcription and translation 
via intronic response elements. (f) Increased FKBP51 levels confers higher GR resistance, completing 
an ultra-short negative feedback loop on GR sensitivity. 
1.8. FKBP51 in human studies 
In 2004, Binder and colleagues were the first that put genetic variants of FKBP51 into the 
context of psychiatric disorders. They could show that risk allele carriers of the single 
nucleotide polymorphism (SNP) rs1360780 in the gene encoding FKBP51 were linked to 
elevated FKBP51 protein expression and increased recurrence of depressive episodes 
(Binder et al., 2004). Since then, numerous independent studies confirmed the association 
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of FKBP51 polymorphisms with mood disorders such as major depression (Lekman et al., 
2008; Tatro et al., 2009b; Zobel et al., 2010; Lavebratt et al., 2010; Velders et al., 2011; 
Menke et al., 2013) or bipolar disorder (Willour et al., 2009; Leszczynska-Rodziewicz et al., 
2014). Other studies also reported associations of FKBP51 SNPs with suicidal behavior 
(Brent et al., 2010; Supriyanto et al., 2011) as well as interactions with childhood trauma 
on suicide attempt (Roy et al., 2010; Roy et al., 2012). Along these lines, it has been shown 
that adverse early life experiences, such as child abuse, moderate the effects of FKBP51 
SNPs on vulnerability to adult depression (Appel et al., 2011) and the interaction of early 
trauma and FKBP51 gene variants can furthermore predict onset of depression 
(Zimmermann et al., 2011). Klengel et al. reported that childhood trauma-dependent 
allele-specific FKBP51 DNA demethylation increased the risk of developing stress-related 
psychiatric disorders in adulthood. In more detail, they addressed the functionality of 
FKBP51 SNP rs1360780, showing differential chromatin folding of the risk allele. Altered 
three dimensional folding of the gene enhances interaction of a GRE positioned in FKBP51 
intron 2 with RNA polymerase at the transcription start site of the gene. This elevates 
FKBP51 transcription, decreasing GR sensitivity and finally resulting in decreased 
efficiency of the negative feedback loop of the HPA axis (Klengel et al., 2013). 
Several studies also report that FKBP51 polymorphisms affect the response to 
antidepressant drug treatment. The initial analysis by Binder et al. demonstrated that 
depressed patients that were homozygous carriers of the risk allele of rs1360780 
responded faster to antidepressant treatment than depressed individuals with the other 
genetic variations (Binder et al., 2004). Thereby, differences in response to 
antidepressants seemed to be independent of the type of drug, since it was observed in 
groups of patients treated with either mirtazapine, selective serotonin reuptake inhibitors 
or tricyclic antidepressants. Although three smaller studies could not replicate such 
associations, probably due to lack of statistical power (Papiol et al., 2007; Tsai et al., 2007; 
Sarginson et al., 2009), numerous other studies reported significant associations between 
FKBP51 SNPs and enhanced response to antidepressants in independent samples (Lekman 
et al., 2008; Kirchheiner et al., 2008; Zou et al., 2010; Horstmann et al., 2010; Ellsworth et 
al., 2013).  
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Besides their significant roles in mood disorders and antidepressant treatment response, 
FKBP51 polymorphisms have also been associated with an increased risk to develop post-
traumatic stress disorder. It has been shown that adults abused during their childhood 
who carry risk alleles of FKBP51 SNPs are at a higher risk for developing PTSD to 
subsequent trauma exposures (Binder et al., 2008; Xie et al., 2010). PTSD has been 
associated with enduring changes in HPA axis reactivity, especially with enhanced 
sensitivity of the GR (Yehuda et al., 2004; Yehuda et al., 2006). In line with this, people 
exposed to the World Trade Center attacks on 9/11 demonstrated reduced expression of 
FKBP51 in patients with PTSD, which is consistent with enhanced GR responsiveness 
(Yehuda et al., 2009; Sarapas et al., 2011).  
Studies performed in healthy volunteers further underline the importance of FKBP51 
polymorphisms in stress physiology. The Trier Social Stress test was performed with 
healthy individuals, homozygous for the previously described FKBP51 risk alleles, to 
evaluate their psychosocial stress response (Ising et al., 2008). Risk allele carriers show 
significantly slower recovery of stress related elevations of cortisol levels as well as more 
anxiety symptoms in the recovery phase than healthy controls with different alleles, 
suggesting that these subjects are at a greater risk to develop stress-related psychiatric 
disorders. Moreover, associations of FKBP51 SNPs and mother-infant attachment have 
been shown to predict cortisol reactivity in infants (Luijk et al., 2010). Genetic variants of 
FKBP51 have also been suggested to affect personality traits such as harm avoidance and 
cooperativeness in a gender-specific fashion in healthy volunteers (Shibuya et al., 2010).  
Taken together, genetic variations of FKBP51 seem to be crucially involved in stress 
physiology, the susceptibility to mood and anxiety disorders, as well as antidepressant 
treatment response.  
1.9. FKBP51 in animal studies 
The profound involvement of FKBP51 in psychiatric disorders further encouraged 
preclinical research to study the mechanistic role of FKBP51 in HPA axis functioning and 
disease using rodent models.  
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Initially, the role of FKBP51 in stress regulation has been discovered in Squirrel monkeys. 
Compared to other monkeys and primates, including humans, these New World primates 
have markedly increased plasma cortisol levels, but they lack signs of detrimental 
glucocorticoid excess. Endogenes overexpression of FKBP51 and thus, decreased 
hormone-binding affinity of the GR has been demonstrated to be a reason of 
glucocorticoid resistance in these animals (Denny et al., 2000; Scammell et al., 2001; 
Westberry et al., 2006). 
In the mouse brain, there is an ubiquitous basal FKBP51 mRNA expression, with increased 
expression levels in specific GR-rich brain areas, such as the hippocampus (Scharf et al., 
2011). Both in rats and mice, FKBP51 mRNA expression and protein levels can be induced 
by the glucocorticoid agonist dexamethasone, by corticosterone and by stress paradigms 
such as restraint stress, food deprivation, chronic mild stress and chronic social defeat 
stress (Lee et al., 2010; Scharf et al., 2011; Lee et al., 2011; Wagner et al., 2012; Yang et 
al., 2012; Guidotti et al., 2013). Thus, elevated GCs levels alter FKBP51 levels as part of the 
ultra-short feedback loop (Figure 1.3), thereby decreasing GR sensitivity. Along these 
lines, Scharf et al. could also show that regions with low basal FKBP51 expression such as 
the PVN and the amygdala showed a higher increase in FKBP51 mRNA following induction 
than regions with a high basal expression such as the hippocampus, further supporting 
the hypothesis that GR sensitivity is modulated by FKBP51 (Scharf et al., 2011).  
Chronic exposure to corticosterone also caused significant demethylation within fkbp51 
in blood as well as in the hippocampus and hypothalamus of mice (Lee et al., 2010). 
Furthermore, the same authors reported an interaction of corticosterone induced fkbp51 
demethylation and anxiety, as demethylation in the intron 1 region of fkbp51 correlated 
with reduced time spent in the closed arms of the elevated plus maze (Lee et al., 2011). 
Interestingly, virus-mediated knockdown of FKBP51 in the basolateral amygdala of mice, 
led to reduced anxiety-related behavior, when these mice were previously restraint 
stressed for 6 hours (Attwood et al., 2011).  
A conventional knockout mouse line lacking the FKBP51 gene has previously been 
generated (Tranguch et al., 2005) and young adult FKBP51 knockout (FKBP51-/-, also called 
51KO) males have been characterized under basal and acute stress conditions for 
neuroendocrine reactivity as well as in several tests on anxiety- and depression-related 
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behavior. (Touma et al., 2011). Lack of FKBP51 decreased HPA axis reactivity and GR 
expression changes in response to acute stressors, shaping the neuroendocrine profile of 
these mice. Under basal conditions, ablation of FKBP51 did not reveal an overt behavioral 
phenotype compared to wild type mice. However, after an intense stressor (restraint 
stress), FKBP51 knockout mice showed an enhanced active stress coping behavior in the 
forced swim test (FST). This is in line with findings of O’Leary and colleagues, who 
demonstrated that aged mice of this mouse line displayed the same anti-depressant 
phenotype in the tail suspension test and FST (O'Leary, III et al., 2011). Interestingly, 
FKBP51 deletion also resulted in a pro-resilience sleep phenotype, as sleep architecture 
of knockout mice was nearly opposite to sleep profiles observed in human depression 
(Steiger and Kimura, 2010; Albu et al., 2013). 
The genetic associations of FKBP51 with psychiatric disorders in humans as well as the 
protective effect of FKBP51 knockout and knockdown on stress physiology, stress-coping 
behavior and sleep architecture in animal models, promoted the emergence of FKBP51 as 
an interesting therapeutic approach in the context of stress-related psychiatric diseases.  
1.10. FKBP51 as a drug target 
In recent years, FKBP51 arose as a promising novel drug target for psychiatric disorders. 
However, the design of efficient ligands has proven extremely challenging in drug 
development. The inability to pharmacologically differentiate against the highly 
homologues functional counter-player FKBP52, substantially complicated drug discovery 
for FKBP51 and all known FKBP ligands such as rapamycin or FK506 lack selectivity and 
show strong off-target effects (Gopalakrishnan et al., 2012). A high-throughput screening 
of 350 000 compounds also did not provide any suitable chemical starting points, raising 
doubts on the feasibility of FKBP51 as a drug target (Wang et al., 2013b). However, Hausch 
and colleagues including us, recently reported the development of the first potent and 
highly selective inhibitors of FKBP51, SAFit and SAFit2. Using these ligands to selectively 
inhibit FKBP51, we were able to enhance neurite elongation in neuronal cultures as well 
as improve neuroendocrine feedback and stress-coping behavior in mice. Thus, these 
compounds may trigger a new line of antidepressant drug development, the first truly 
based on basic scientific insight (Gaali and Kirschner et al., unpublished data).  
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2. Aim of the thesis 
The current thesis aimed to further unravel the role of FKBP51 in mood and anxiety 
disorders. To achieve this, we first investigated the involvement of FKBP51 in the 
behavioral and neuroendocrine effects of chronic stress using a conventional FKBP51 
knockout mouse line (Chapter 1). In addition, we studied female FKBP51 knockout mice 
under basal and acute stress conditions, to elucidate potential gender differences in 
FKBP51-dependent modulation of the HPA axis (Chapter 2). Next, we investigated the 
behavioral and neuroendocrine relevance of FKBP52, the close homologue but functional 
counter-player of FKBP51, with respect to chronic stress in a FKBP52 knockout mouse line 
(Chapter 3). To further elucidate the function of FKBP51 in stress recovery and 
antidepressant response, we studied the ability of FKBP51 knockout mice to recover from 
chronic stress and examined the effects of a chronic antidepressant (paroxetine) 
treatment during the 3-week recovery period (Chapter 4). Unraveling the molecular 
mechanism of antidepressant-FKBP51 interaction, we continued to study the acute 
effects of paroxetine in FKBP51 knockout mice and elucidated a possible FKBP51-
dependent mechanism priming antidepressant efficacy (Chapter 5). Finally, we 
investigated the amygdala-specific role of FKBP51 with regard to anxiety-related behavior 
by genetic and pharmacological intervention of FKBP51 (Chapter 6). In summary, this 
thesis gives novel and substantial insight into the involvement of FKBP51 in mood and 
anxiety disorders and provides a profound basis for future studies aiming to develop novel 
treatment strategies in the context of personalized medicine. 
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Abstract 
Chronic stress is increasingly considered to be a main risk factor for the development of a 
variety of psychiatric diseases such as depression. This is further supported by an impaired 
negative feedback of the hypothalamic-pituitary-adrenal (HPA) axis, which has been 
observed in the majority of depressed patients. The effects of glucocorticoids, the main 
hormonal endpoint of the HPA axis, are mediated via the glucocorticoid receptor (GR) and 
the mineralocorticoid receptor. The FK506-binding protein 51 (FKBP5), a co-chaperone of 
the Hsp90 and component of the chaperone-receptor heterocomplex, has been shown to 
reduce ligand sensitivity of the GR. This study aimed to investigate the function of FKBP5 as 
a possible mediator of the stress response system and its potential role in the development 
of stress-related diseases. Therefore, we assessed whether mice lacking the gene encoding 
FKBP5 (51KO mice) were less vulnerable to the adverse effects of three weeks of chronic 
social defeat stress. Mice were subsequently analyzed with regards to physiological, 
neuroendocrine, behavioral and mRNA expression alterations. Our results show a less 
vulnerable phenotype of 51KO mice with respect to physiological and neuroendocrine 
parameters compared to wild-type animals. 51KO mice demonstrated lower adrenal 
weights and basal corticosterone levels, a diminished response to a novel acute stimulus 
and an enhanced recovery, as well as more active stress-coping behavior. These results 
suggest an enhanced negative glucocorticoid feedback within the HPA axis of 51KO mice, 
possibly modulated by an increased sensitivity of the GR.  
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Introduction 
In daily life, humans are repeatedly exposed to periods of stress. The short-term effects of 
stress are mostly beneficial by promoting adaptation, as long as the stress response is 
efficiently shut off. In contrast, excessive challenges like chronic stress clearly impose a 
major risk factor for the development of a variety of psychiatric diseases such as anxiety 
related disorders and depression (McEwen, 2004; de Kloet et al., 2005a).  
The major control module of the stress response in mammals, besides the autonomic 
nervous system, is the hypothalamic-pituitary-adrenal (HPA) axis. Glucocorticoids (GCs), 
which are the main hormonal endpoint of the HPA axis, regulate the activity of the HPA axis 
through negative feedback via the glucocorticoid receptor (GR) and the mineralocorticoid 
receptor (MR). MRs and GRs mediate this regulation mainly in the hypothalamus and the 
pituitary, but also on the level of the hippocampus and other limbic structures (De Kloet et 
al., 1998; Ulrich-Lai and Herman, 2009). The proper negative feedback via the GR is critical 
for a healthy stress response. One of the most robust biological abnormalities observed in 
the majority of depressed patients is altered signalling via the GR, which often leads to an 
impaired negative feedback regulation and thus to partial glucocorticoid resistance 
(Holsboer, 2000; Pariante and Miller, 2001). 
The GR is a member of the ligand-dependent transcription factor family (De Kloet and Reul, 
1987). Upon ligand binding, the receptor undergoes a conformational change, translocates 
from the cytosol to the nucleus and modulates gene transcription. The process of GR 
activation, trafficking and subsequent GR action on gene transcription is regulated by a 
multiprotein complex that assembles around the molecular chaperone heatshock protein 
90 (hsp90) (Pratt et al., 2006). The hsp90 complex is crucial for proper folding, maturation, 
translocation and DNA binding of the GR and consists of numerous co-chaperones (Grad and 
Picard, 2007). These include, among others, the immunophilins FK506 binding protein 51 
(FKBP5) and FK506 binding protein 52 (FKBP4). Recent studies have shown that FKBP5 is a 
key player of the GR-hsp90 complex. Once FKBP5 is bound to the GR complex via hsp90, the 
receptor’s affinity for cortisol is decreased (Riggs et al., 2003; Wochnik et al., 2005). Upon 
ligand binding, FKBP5 is replaced by FKBP4, which in turn binds to dynein. This promotes the 
translocation of the GR complex into the nucleus and subsequent DNA binding (Davies et 
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al., 2002; Wochnik et al., 2005; Binder, 2009). In neurons, siRNA knockdown of the gene 
encoding FKBP5 is associated with elevated baseline GR nuclear translocation (Tatro et al., 
2009a). The endogenous overexpression of FKBP5 in squirrel monkeys has been 
demonstrated to be causative for their glucocorticoid resistance (Denny et al., 2000; 
Scammell et al., 2001; Westberry et al., 2006). Moreover, the expression of FKBP5 is 
stimulated by steroids, such as GCs, as part of an intracellular ultra-short negative feedback 
loop for GR activity (Vermeer et al., 2003; Hubler and Scammell, 2004). Therefore, 
augmented transcription and translation of FKBP5 following corticoid receptor activation 
reduces GR sensitivity. In addition, FKBP5 mRNA expression has recently been shown to be 
increased in brain regions such as the hippocampus, central amygdala and PVN of mice, after 
a single dexamethasone treatment (Scharf et al., 2011).  
The suggested role of FKBP5 in GR signal transduction may represent a new possibility to 
elucidate GR impairment associated with many psychiatric disorders such as depression 
(Holsboer, 2000). It is well established that malfunction of GRs due to low affinity ligand 
binding can be the consequence of mutations of the receptor itself or of limited hsp90 action 
(Picard et al., 1990; Bohen and Yamamoto, 1993; Brönnegard et al., 1996). In humans, 
genetic variations of FKBP5 have been associated with a major risk factor for the 
development of posttraumatic stress disorder (PTSD) (Segman et al., 2005; Binder et al., 
2008; Yehuda et al., 2009). Furthermore, the same alleles have been linked with the 
regulation of the HPA axis in depression, with an enhanced recurrence of depressive 
episodes, and with a faster antidepressant treatment response. In addition, these 
polymorphisms predispose individuals to increased sensitivity to psychosocial stress (Binder 
et al., 2004; Ising et al., 2008; Kirchheiner et al., 2008). Specifically, it has been shown that 
the risk alleles result in a higher FKBP5 expression, thereby lowering GR sensitivity, which is 
suggested to be the underlying mechanisms for the increased sensitivity to psychosocial 
stress.  
It is still largely unclear why some individuals are more susceptible to develop a stress-
related disorder, while others turn out to be resilient. Recent studies suggest that genetic 
predispositions interact with environmental demands such as chronic stress (Pezawas et al., 
2005; Binder, 2009; Gillespie et al., 2009; Schmidt et al., 2010a). However, the molecular 
mechanisms underlying individual susceptibility or resilience to chronic stress are still poorly 
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understood. Given the fact that FKBP5 has been suggested to be a possible mediator of the 
stress response system and its potential role in the development of stress-related disorders, 
we hypothesised that mice lacking the FKBP5 gene may show a lower vulnerability to chronic 
stress exposure. To test this hypothesis, we analyzed the response of conventional FKBP5 
knockout (51KO) mice to a chronic social defeat stress (CSDS) paradigm at the behavioral, 
neuroendocrine and molecular level.  
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Materials and Methods 
Animals and housing conditions 
The FKBP5 knockout mouse line (51KO) was previously generated (Tranguch et al., 2005). 
Since fkbp5 is too large to efficiently target all coding sequences, a lacZ/neomycin cassette 
was inserted in place of sequences from exons 1-2. The partially disrupted gene retains the 
endogenous FKBP5 promoter and expresses β-galactosidase in-frame with the FKBP5 
initiation codon (Supplemental Fig. 1A). Details of the generation of the 51KO mice are 
provided in the supplemental material. Genotypes were verified by PCR and Southern 
analysis of tail DNA, and the absence of FKBP51 protein was verified by fluorescence 
immunohistochemistry and western blotting of mouse tissue extracts (Supplemental Fig. 1B 
and C). Since most of the fkbp5 exons were retained and could potentially encode a 
truncated protein in transgenic mice, Westerns were repeated with four anti-FKBP5 
monoclonal antibodies having distinct epitopes and with a rabbit polyclonal antibody 
prepared against full-length FKBP5; none of these antibodies detected an FKBP5 protein 
product (results not shown). 51KO mice did not show overt reproductive failures and no 
abnormalities in the survival rate. The genotypes of the offspring corresponded 
approximately to the Mendelian ratios and sex was equally distributed. Only male mice were 
used for the experiment, obtained from heterozygous breeding pairs. Animals were 13 
weeks old at the start of the experiment. Mice were singly housed as adults at least two 
weeks prior to the experiment. Maintenance and experiments were performed under a 12 
h light, 12 h dark cycle (lights on at 7:00 am) and constant temperature (23 ± 2 °C) conditions. 
Food and water were provided ad libitum. 
Male CD1 mice (19 - 21 weeks old) serving as residents were held under the same conditions 
as described above and were allowed to habituate to the social defeat cage for two weeks 
before the onset of the experiments. The experiments were performed in accordance with 
European Communities Council Directive 86 / 609 / EEC. All efforts were made to minimize 
animal suffering during the experiments. The protocols were approved by the committee 
for the Care and Use of Laboratory Animals of the Government of Upper Bavaria, Germany. 
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Chronic social defeat stress paradigm 
The CSDS paradigm was performed as described previously (Wagner et al., 2011). In short, 
mice were subjected to daily bouts of social defeat by a resident mouse, which was 
physically superior and specifically trained for aggressive behavior towards intruders. The 
animals were separated as soon as the aggressive confrontation was accomplished, or after 
a maximum of 5 min. Subsequently, the animals spent 24 h in the same cage (45 cm x 25 
cm), which was divided by a mesh partition, to prevent physical, but allow sensory contact. 
Every day, stressed animals were introduced to a new resident cage, in order to exclude a 
repeated encounter with the same resident throughout the experiment. Experimental mice 
were always defeated by resident males during the course of the experiment. Control mice 
were held in their home cages for the entire experimental period. All mice were handled 
daily; fur status and weight were determined every 3-4 days before social defeat was 
enforced. 
The condition of fur was assessed by an experienced investigator as described previously 
(Mineur et al., 2003). In short, scores were classified according to a 4-point scale, where 1 
stands for a perfect, clean fur, while 4 represents a disheveled, scruffy fur, often including 
traces of wounds and scurf. Ratings of 2 and 3 demonstrate intermediate fur states, 
respectively.  
Experimental design 
Initially, 24 wild-type (WT) and 21 51KO mice were split into four groups (n = 13 WT control, 
n = 11 51KO control, n = 11 WT stress and n = 10 51KO stress) and subjected to the CSDS 
paradigm for 21 days. The daily defeat occurred between 12:00 pm and 4:00 pm; varying 
starting times limited the predictability of the stressor and therefore minimized a potential 
habituation effect. During the third week of the procedure, all behavioral tests were 
performed.  
Behavioral analysis 
Behavioral tests were carried out between 08:00 am and 12:00 pm in the same room where 
the animals were housed. All tests were performed using an automated video-tracking 
system (Anymaze 4.20, Stoelting, IL, USA). 
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Open-field test 
The open-field (OF) test was conducted on day 15 of the CSDS paradigm. Testing was 
performed in an empty open-field arena (50 cm x 50 cm x 50 cm) made of gray polyvinyl 
chloride (PVC), which was evenly illuminated with 15 lux. Testing duration was 15 min, 
divided into three segments of 5 min each. Parameters of interest included the total distance 
traveled and the time of immobility. 
Elevated plus-maze 
On day 16 of the stress procedure, the elevated plus-maze (EPM) test was performed. The 
apparatus consisted of a plus-shaped platform with two opposing open arms (30 cm x 5 cm 
x 0.5 cm) and two opposing enclosed arms (30 cm x 5 cm x 15 cm), made of gray PVC, which 
were connected by a central area (5 cm x 5 cm). The whole device was elevated 50 cm above 
the floor. Illumination was less than 10 lux in the enclosed arms and 25 lux in the open arms. 
The trial duration was set to 5 min and mice were placed into the center zone facing one of 
the closed arms at the beginning of the test. The time spent in the open arms compared to 
the time spent in the closed arms and the total distance traveled were analyzed. 
Forced swim test 
The forced swim test (FST) was performed on day 19 of the CSDS procedure. Each mouse 
was placed into a 2 liter glass beaker (diameter: 13 cm, height: 24 cm) filled with tap water 
(21 ± 1 °C) to a height of 15 cm, so that the mouse could not touch the bottom with its hind 
paws or tail. Testing time was 6 min. The parameters floating, swimming and struggling were 
scored by an experienced observer, blind to genotype, condition or treatment of the 
animals. 
Acute stress response 
The FST on day 19 was used as acute stressor in order to determine the stress response by 
measuring corticosterone plasma concentrations. After the FST, all mice were placed into a 
novel cage to recover from the acute stressor. Blood samples were collected by tail cut 15 
min (stress response) and 90 min (stress recovery) after the onset of the FST (Fluttert et al., 
2000). Samples were gathered in 1.5 ml EDTA-coated microcentrifuge tubes (Kabe 
Labortechnik, Germany). After the recovery period and the second tail cut, mice were 
returned to their initial home (for controls) or social defeat (for stressed animals) cages. All 
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blood samples were kept on ice and later centrifuged for 15 min at 8000 rpm and 4 °C. 
Plasma was transferred to new, labelled microcentrifuge tubes and stored at -20 °C until 
further processing.  
Sampling procedure 
All animals were sacrificed by decapitation following quick anaesthesia by isolflurane. Trunk 
blood was collected in labelled 1.5 ml EDTA-coated microcentrifuge tubes (Kabe 
Labortechnik, Germany). All blood samples were kept on ice until centrifugation at 4 °C and 
8000 rpm for 15 min. After centrifugation, the blood plasma was transferred to a new, 
labelled 1.5 ml microcentrifuge tube. All plasma samples were stored frozen at -20 °C until 
the determination of corticosterone by radioimmunoassay (MP Biomedicals Inc; sensitivity 
6.25 ng/ml). Brains were removed, snap-frozen in isopentane at -40 °C, and stored at -80 °C 
for in-situ hybridization. Adrenal and thymus glands were removed, dissected from fat and 
weighed. 
In-situ hybridization 
Frozen brains were sectioned at -20 °C in a cryostat microtome at 18 µm, thaw mounted on 
Super Frost Plus slides, dried and stored at -80 °C. In-situ hybridization using 35S UTP labeled 
ribonucleotide probes (CRH, AVP, GR, MR) was performed as described previously (Schmidt 
et al., 2007). Briefly, sections were fixed in 4% paraformaldehyde and acetylated in 0.25% 
acetic anhydride in 0.1 M triethanolamine/HCl. Subsequently, brain sections were 
dehydrated in increasing concentrations of ethanol. The antisense cRNA probes were 
transcribed from a linearized plasmid. Tissue sections were saturated with 100 μl of 
hybridization buffer containing approximately 1.5 × 106 cpm 35S labeled riboprobe. Brain 
sections were coverslipped and incubated overnight at 55 ºC. The following day, the sections 
were rinsed in 2 × SSC (standard saline citrate), treated with RNAse A (20 mg/l) and washed 
in increasingly stringent SSC solutions at room temperature. Finally, sections were washed 
in 0.1 × SSC for 1h at 65 ºC and dehydrated through increasing concentrations of ethanol. 
The slides were exposed to Kodak Biomax MR films (Eastman Kodak Co., Rochester, NY) and 
developed. Autoradiographs were digitized, and expression was determined by optical 
densitometry utilizing the freely available NIH ImageJ software. The mean of four 
measurements of two different brain slices was calculated for each animal. The data were 
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analyzed blindly, always subtracting the background signal of a nearby structure not 
expressing the gene of interest from the measurements.  
For AVP, slides were dipped in Kodak NTB2 emulsion (Eastman Kodak Co., Rochester, NY) 
and exposed at 4 °C for 8 h. Slides were developed and examined with a light microscope 
with both bright and dark field condensers. Expression of AVP mRNA in the parvocellular 
part of the PVN was determined by optical densitometry as described above. 
Statistical analysis 
The data presented is shown as means ± standard error of the mean (SEM), analyzed by the 
software SPSS 16.0. For body weight and fur status progression as well for the time-
dependent behavioral parameters assessed in the open field tests, 3-factorial analyses of 
variance (ANOVA) with repeated measures was performed. Thereby genotype and condition 
were two between-subjects factors and time a within-subjects factor. Two factorial 
multivariate ANOVAs were employed for thymus, adrenal gland weight, neuroendocrine, 
and other behavioral variables and for gene expression contrasts as well. Whenever 
significant main or interaction effects were found in the ANOVAs univariate F-tests or tests 
with contrasts followed for specifying and locating simple effects. For some simple 
comparisons, t-tests for dependent or independent samples were performed. As nominal 
level of significance was alpha = 0.05 accepted and adjusted according to Bonferroni 
correcture by all posteriori tests (univariate F-tests, test of simple effects or contrasts). 
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Results 
Physiological parameters 
At the start of the experiment, statistical analysis showed significantly lower body weights 
for 51KO mice compared to WT animals (T43 = 2.279, p < 0.05) (Fig. 1A). For body weight 
progression, ANOVA with repeated measures revealed a significant effect of time (F6, 
36 = 17.613, p < 0.0001) as well as a time x condition interaction (F6, 36 = 2.593, p < 0.05). 
Subsequent analysis of simple effects identified a significant increase especially at the days 
8, 11 and 21 in the body weight of stressed WT mice compared to their littermate controls 
(tests with contrasts in ANOVA, p < 0.05). A significant increase at the days 8, 11 and 18 in 
body weight was also revealed in stressed 51KO mice compared to their littermate controls 
(Fig. 1B). 
For the animals fur state, ANOVA with repeated measures found a time effect (F6, 36 = 7.403, 
p < 0.0001), a condition effect (F1, 41 = 29.828, p < 0.0001) and a time x condition interaction 
(F6, 36 = 7.805, p < 0.0001). Further investigation of the simple effects revealed a significant 
decrease in fur state quality of stressed animals compared to their respective genotype 
controls throughout the experiment from day 4 to day 21 (tests with contrasts in ANOVA, p 
< 0.05) (Fig. 1C). No differences between both genotypes were observed. 
Organ weights were measured on the day of sacrifice. Adrenal gland weight showed a 
condition effect (F1, 41 = 95.170, p < 0.0001) as well as a genotype effect (F1, 41 = 18.651, 
p < 0.0001). Following chronic social stress, significantly increased adrenal gland size could 
be shown regardless of genotype (Mean ± SEM: control: WT = 0.134 ± 0.004, 51KO = 0.117 
± 0.005; defeat: WT = 0.226 ± 0.013, 51KO = 0.176 ± 0.008). However, a significant decrease 
in adrenal gland weights was revealed in 51KO animals compared to WT mice under control 
and stress conditions (tests with contrasts in ANOVA, p < 0.05) (Fig. 1D). 
For thymus weight, ANOVA revealed a condition (F1, 41 = 67.769, p < 0.0001) and a genotype 
effect (F1, 41 = 53.140, p < 0.0001). Chronic stress resulted in a significant decrease in thymus 
weight in both WT and knockout animals (Mean ± SEM: control: WT = 1.545 ± 0.054, 51KO 
= 1.184 ± 0.058; defeat: WT = 1.131 ± 0.059, 51KO = 0.680 ± 0.067). In addition, thymus 
weight was significantly lower in 51KO mice compared to WT animals under control and 
stress conditions (tests with contrasts in ANOVA, p < 0.05) (Fig. 1E).  
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Figure 1: Physiological phenotype of 51KO and WT mice. (A) Body weight before the start of the CSDS. 
(B) Body weight gain over the course of the experiment. (C) Progression of fur quality during the stress 
procedure. (D) Adrenal and (E) thymus weight at the end of the stress exposure. Data are represented as 
mean ± SEM. * significantly different from the control condition of the same genotype, p < 0.05; # 
significantly different from the WT of the same condition, p < 0.05. 
 
Neuroendocrine analysis 
Basal levels of corticosterone were assessed in blood plasma during the circadian nadir in 
the morning. Furthermore, response and recovery blood samples were taken 15 min and 90 
min after the onset of the FST. ANOVA showed a genotype effect for basal corticosterone 
levels (F1, 38 = 7.619, p < 0.01) as well as a genotype by condition interaction (F1, 38 = 9.800, 
p < 0.01). Analyzing the simple effects i.e. condition differences for each genotype and 
genotype differences for each condition we found that chronic stress led to increased 
corticosterone levels in WT animals compared to their control littermates. In contrast, 
stressed 51KO mice revealed lower basal levels of corticosterone compared to control 51KO 
animals. Furthermore, significantly lower corticosterone levels were seen in stressed 51KO 
mice compared to stressed WT mice (tests with contrasts in ANOVA, p < 0.05) (Fig. 2A). 
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Corticosterone response levels (15 min after the FST) indicated a genotype effect (F1, 
39 = 4.428, p < 0.05), a condition effect (F1, 39 = 10.777, p < 0.005) and a genotype by condition 
interaction (F1, 39 = 4.489, p < 0.05). In WT animals, chronic stress resulted in significantly 
higher corticosterone levels compared to non-stressed controls. This effect of chronic stress 
exposure was not observed in 51KO mice, leading to a reduced stress response, with 
significantly lower corticosterone levels in stressed 51KO mice compared to stressed WT 
animals (tests with contrasts in ANOVA, p < 0.05) (Fig. 2B).  
For corticosterone recovery levels (90 min after the FST), ANOVA revealed a genotype effect 
(F1, 37 = 11.072, p < 0.005). WT animals of both conditions showed no difference in recovery 
levels. In 51KO mice, CSDS resulted in higher corticosterone values 90 min after the FST. 
However, 51KO mice displayed an increased ability for negative feedback regulation with 
significantly lower corticosterone levels under control and stress conditions compared to 
WT animals (tests with contrasts in ANOVA, p < 0.05) (Fig. 2C). 
 
Figure 2: Neuroendocrine profile of 51KO and WT animals. (A) Basal morning corticosterone levels at 
the end of the chronic stress procedure. (B) Corticosterone response 15 min after the FST. (C) 
Corticosterone recovery 90 min after the onset of the FST. Data are represented as mean ± SEM. * 
significantly different from the control condition of the same genotype, p < 0.05; # significantly different 
from the WT of the same condition, p < 0.05. 
 
Behavioral analysis 
Three tests were performed in order to investigate exploration, anxiety and stress-coping 
behavior (OF, EPM, FST). 
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Open-field test 
The OF was used to quantify behavioral responses such as locomotor activity and explorative 
behavior. We subdivided the 15 min test interval in three segments of 5 min each. ANOVA 
of repeated measures revealed a time x condition interaction (F2, 40 = 14.867, p < 0.0001) 
concerning the general locomotor activity. In WT animals, CSDS resulted in a significant 
decrease of the total distance traveled compared to their control littermates in segment two 
and segment three (segment 2: F1, 22 = 17.12, p < 0.0001; segment 3: F 1, 22 = 5.46, p < 0.05). 
Under control conditions, 51KO mice showed a significant increase in the distance traveled 
compared to WT animals for segment two (F1, 22 = 8.21, p < 0.01). Furthermore, a significant 
decrease of locomotor activity in stressed 51KO animals compared to control 51KO mice 
was revealed in all three segments (segment 1: F1, 22 = 6.93, p < 0.05; segment 2: F 1, 22 = 
35.71, p < 0.0001; segment 3: F1, 22 = 20.27, p < 0.0001) (Fig. 3A).  
For the time spent immobile, ANOVA with repeated measures illustrated a time x condition 
interaction (F2, 40 = 8.770, p < 0.005). Since genotype did not reveal a main or interaction 
effect we pooled the data of the two genotypes for the following simple effect analysis. The 
time immobile was significantly higher in all three segments of stressed mice compared to 
non-stressed animals (segment 1: F1, 43 = 5.92, p < 0.05; segment 2: F 1, 43 = 61.38, p < 0.0001; 
segment 3: F1, 43 = 26.38, p < 0.0001). There was no difference between the two genotypes 
(Fig. 3B). 
Elevated plus-maze test 
The EPM was used to investigate anxiety-related behavior. For the time spent in the open 
arms, there was no significant effect of condition or genotype (Fig. 3C). The total distance 
traveled revealed a condition effect (F1, 37 = 23.026, p < 0.0001). Irrespective of genotype 
chronically stressed animals showed significantly lower locomotor activity compared to 
their respective control group (tests with contrasts in ANOVA, p < 0.05) (Fig. 3D). 
Forced swim test 
We examined the animals’ stress coping behavior using the FST. Regarding the time spent 
struggling, ANOVA revealed only a significant condition effect. Irrespective of genotype 
chronically stressed mice spent significantly less time struggling compared to mice under 
control conditions (F1, 42 = 8.912, p < 0.01) (Fig. 3E).  
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For the time swimming, only a genotype effect was revealed. Stressed 51KO animals spent 
more time swimming compared to stressed WT mice (F1, 42 = 4.788, p < 0.05) (Fig. 3F). 
Concerning the parameter time floating, ANOVA did not reveal any significant effects (Fig. 
3G). 
 
Figure 3: Behavioral profile of 51KO and WT mice. (A) Total distance traveled in the OF. (B) Time spent 
immobile in the OF. (C) Time spent in the open arms of the EPM. (D) Total distance traveled in the EPM. 
(E) Time spent struggling in the FST. (F) Time spent swimming in the FST. (G) Time spent floating in the 
FST. Data are represented as mean ± SEM. * significantly different from the control condition of the same 
genotype, p < 0.05; # significantly different from the WT of the same condition, p < 0.05; + significant 
condition effect, p < 0.01. 
 
Gene expression analysis 
We performed in-situ hybridization in the hippocampus and PVN in order to examine 
expression patterns of genes involved in the major regulation and mediation of the HPA axis. 
For CRH mRNA expression in the PVN, ANOVA showed a condition effect. Chronically 
stressed animals showed higher CRH expression levels than their respective controls of the 
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same genotype (F1, 38 = 12.886, p < 0.005) (Fig. 4A and B). No significant changes in mRNA 
expression could be shown for AVP (Fig. 4C and D) and GR in the PVN and MR and GR in the 
hippocampus (data not shown).  
 
Figure 4: Gene expression in the PVN of 51KO and WT animals. (A) CRH mRNA expression in the PVN. 
(B) Representative CRH mRNA autoradiograms in the PVN. (C) AVP mRNA expression in the PVN. (D) 
Representative AVP mRNA dark field photomicrographs in the PVN. Data are represented as mean ± SEM. 
* significantly different from the control condition of the same genotype, p < 0.05. 
  
Research articles 
39 
Discussion 
Chronic stress represents a key risk factor for developing many psychiatric diseases (de Kloet 
et al., 2005a; de Kloet et al., 2005b; Bale, 2006), and the CSDS paradigm has been frequently 
used to modulate depression in rodents (Nestler and Hyman, 2010). However, susceptibility 
to stress-related disorders like depression is determined by a combined effect of 
(epi-)genetic predispositions and environmental influences (Caspi and Moffitt, 2006; 
Krishnan and Nestler, 2008; El Hage et al., 2009). By using mice with a conventional deletion 
of the FKBP5 gene, we were able to provide evidence that the co-chaperone FKBP5 
significantly influences the animals’ stress response under basal and chronic stress 
conditions.  
The chronic social defeat stress paradigm resulted in a number of robust physiological 
alterations in WT and 51KO animals, such as adrenal gland enlargement and thymus 
atrophy, which have repeatedly been demonstrated before (Klein et al., 1992; Karst and 
Joëls, 2003; Keeney et al., 2006; Schmidt et al., 2007; van den Brandt et al., 2007). However, 
we found significantly lower adrenal gland weights in 51KO mice compared to WT animals 
under both conditions. Therefore, we cannot exclude an aberrant impairment of organ 
development due to the genetic deletion of the gene. Nonetheless, the decrease in adrenal 
weight may also implicate a reduced HPA axis activity and an improved negative feedback 
regulation under stress and even under control conditions. FKBP5 has previously been 
shown to decrease GR sensitivity in cellular model systems (Wochnik et al., 2005; Westberry 
et al., 2006). Our findings support the hypothesis that FKBP5 reduces GR responsiveness 
also in physiological settings relevant for psychiatric diseases. Our data of lower thymus 
weights in 51KO mice compared to WT animals under both conditions may partly provide 
further evidence for this line of reasoning, as studies of adrenolectomized mice with a 
thymus-specific inducible GR transgene reported a decrease in thymocyte number after 
induced GR overexpression, which could be prevented by the application of a GR antagonist 
(Pazirandeh et al., 2005). In addition, transgenic rats, overexpressing a mutant GR in the 
thymus with increased ligand affinity caused massive thymocyte apoptosis at physiological 
hormone concentrations, which was reversible by adrenalectomy (van den Brandt et al., 
2007). However, the observed lower thymus weights in 51KO mice may very well be a 
combination of an impaired organ development, chronic stress and increased GR sensitivity.  
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In addition, all chronically stressed mice showed a significant decrease in fur quality 
regardless of genotype. The degradation of the fur state can be ascribed to an impairment 
of an animal’s grooming behavior, which has been associated with a depression-like 
phenotype (Ducottet et al., 2003; Mineur et al., 2003; Cryan and Holmes, 2005; Denmark et 
al., 2010). Changes in body weight upon chronic stress are well documented, but rather 
contradictory and still not fully understood. In mice, detailed studies indicate an increase in 
body weight depending on the kind of stressor and the animals’ social status (Bartolomucci 
et al., 2009; Wagner et al., 2011). Our findings are in line with these studies, revealing a 
significant increase in body weight progression in all chronically defeated animals. 
Therefore, both body weight progression during CSDS as well as fur state deterioration may 
be GR-independent phenomena. However, 51KO mice were lighter at the beginning of the 
stress procedure, possibly due to the enhanced GR sensitivity, as elevated levels of GCs are 
observed in most strains of genetically obese mice and adrenalectomy and glucocorticoid 
antagonists tend to attenuate obesity (Friedman and Halaas, 1998). Taken together, the 
chronic social defeat stress paradigm led to a number of physiological changes, including 
lower thymus weight and fur quality as well as higher adrenal weight and body weight gain. 
Furthermore, differences in 51KO mice compared to WT animals, such as lower thymus and 
adrenal weights as well as the initially lower body weight are in line with the predicted 
higher GR activity in those mice. 
Circulating GCs are another robust indicator of stress and HPA axis activity. It has repeatedly 
been shown that chronic stress results in elevated circulating GCs and in a dysregulation of 
the HPA axis regulatory feedback (Sapolsky, 1992; Bartolomucci et al., 2005; Keeney et al., 
2006; Schmidt et al., 2007). In line with these studies we found significantly elevated basal 
corticosterone levels in stressed WT animals compared to controls of the same genotype. In 
contrast, we detected significantly lower basal corticosterone levels in 51KO mice compared 
to WT animals under chronic stress conditions. Moreover, it has been shown, that rodents 
exposed to chronic stress exhibit an enhanced HPA axis response to a novel, acute stimulus 
(Akana et al., 1992; Koolhaas et al., 1997; Bhatnagar and Dallman, 1998). Indeed, we were 
able to detect a significantly higher corticosterone response 15 min after the FST for 
chronically stressed WT mice compared to controls of the same genotype. However, this 
chronic stress effect was not detected in 51KO mice. Corticosterone levels, measured 90 
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min after the FST were significantly higher in chronically stressed 51KO mice compared to 
controls of the same genotype, indicating that chronic stress still impairs the recovery in 
51KO mice. However, both groups of 51KO mice still had significantly lower corticosterone 
levels compared to WT animals of the respective condition, implicating an enhanced 
recovery. Thus, our neuroendocrine data suggest an enhanced negative feedback within the 
HPA axis of 51KO mice and consequently a lower vulnerability to stress in this parameter, 
which is likely mediated by the enhanced GR sensitivity. 
Chronic stress also affects the behavioral phenotype of animals, leading to higher anxiety-
related behavior and diminished locomotor activity (Choleris et al., 2001; Berton and 
Nestler, 2006; Schmidt et al., 2007; Wagner et al., 2011). In the current study, CSDS resulted 
in lower locomotor activity in a novel environment (OF / EPM). The data of the EPM in terms 
of open arm time are not conclusive and may be compromised by the differences in 
locomotor activity. However, in contrast to the neuroendocrine and physiological data, we 
did not detect differences for anxiety-related behavior in 51KO mice. In the OF the 
magnitude of the stress effect compared to baseline was even greater in 51KO mice 
compared to WT animals. It is therefore likely that locomotion and anxiety-related behavior 
as assessed in the current study is largely independent of the FKBP5 modulation of GR 
signaling. 
In order to determine potential differences in stress coping, 51KO mice and WT animals 
were subjected to a FST. It has been shown that chronic stress increases immobility and 
antidepressant sensitivity in mice subjected to the FST (Karolewicz and Paul, 2001). In line 
with this study, we could show a diminished active stress-coping behavior in chronically 
stressed mice compared to control animals. Interestingly, chronic stress led to a significant 
increase in time swimming in 51KO mice compared to WT mice. In contrast, there were no 
significant genotype differences in the other two core parameters of the FST. However, our 
data is in line with findings from Touma and colleagues, who observed a more active stress-
coping behavior in 51KO mice 24 h following restraint stress (Touma et al., 2011). 
Chronic stress has previously been shown to affect gene expression of central HPA axis 
related genes, such as MR and GR in the hippocampus as well as CRH and AVP in the PVN 
(Makino et al., 1995; Albeck et al., 1997; Herman and Spencer, 1998; Bartolomucci et al., 
2003; Figueiredo et al., 2003; Keeney et al., 2006; Schmidt et al., 2007; Lachize et al., 2009). 
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In the current study we observed an increase of CRH expression in the PVN after chronic 
stress, which is in line with previous reports. The lack of AVP, MR and GR regulation may be 
ascribed to the length, nature or intensity of the applied stress protocol. However, gene 
expression regulation was not affected by the lack of FKBP5, which may point at 
compensatory mechanisms. 
A limitation of the current study may be the general involvement of FKBP5 in the maturation 
of other steroid receptors (Pratt and Toft, 2003). Therefore, the observed effects may not 
exclusively be due to increased GR binding, but might partially be a combination of various 
other receptor types. Furthermore, we used mice with a conventional knockout of FKBP5, 
thus potential and yet unidentified compensatory mechanisms or adaptive processes in 
51KO mice cannot be excluded. A spatial and temporal restriction of FKBP5 expression using 
conditional knockouts might reveal a clearer picture of the involvement of this gene in stress 
related disorders and may be a useful tool to provide further insight of the utility of FKBP5 
as a therapeutic target. Nevertheless, our data clearly show the importance of FKBP5 as a 
mediator of the stress response and its involvement in the development of stress related 
disorders. 
In summary, we demonstrate that animals with a conventional FKBP5 deletion are less 
responsive to the adverse effects of chronic stress with regards to physiological and 
neuroendocrine parameters. 51KO mice displayed a diminished physiological and 
neuroendocrine response to chronic social defeat stress, evidenced by lower adrenal 
weights as well as lower basal corticosterone levels, an attenuated response to a novel acute 
stimulus and an enhanced recovery, as well as more active stress coping. In contrast, no 
protective effects were observed for locomotor activity and anxiety-related behavior or 
central gene expression. Thus, the current data support the hypothesis that 51KO mice are 
less affected by chronic social stress on a number of parameters, due to an enhanced 
sensitivity of the GR. Pharmacological inhibition of FKBP5 might thus constitute a novel 
therapeutic approach to ameliorate the neuroendocrine alterations observed in patients 
with stress-related psychiatric disorders. 
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Supplementary data 
Generation of 51KO mice 
Bacterial artificial chromosome (BAC) clones containing genomic regions for FKBP5 were 
isolated by PCR screening the 129SvJ mouse BAC library (Genome Systems, St. Louis, MO). 
Restriction fragments were subcloned into pBluescript (pBS; Stratagene, La Jolla, CA) or 
pZero (Invitrogen, Carlsbad, CA) for further analysis and sequencing. PCR products amplified 
from the BAC clones were used to construct a targeting vector in pPGKneo (kindly provided 
by James Lee, Mayo Clinic Scottsdale). As shown in supplemental Fig. 1, the targeting vector 
contained a beta-galactosidase expression and neomycin resistance cassette flanked 
upstream by a 3 kb PCR product containing parts of intron A and the first 12 amino acids of 
FKBP5 and downstream by a 2.4 kb PCR product containing parts of intron B, exon 3 and 
parts of intron C. Homologous recombination using the final construct resulted in removal 
of most of exon 2 from FKBP5. Sequences for PCR primers or hybridization probe used in 
these studies are available upon request. ES cells isolated from 129SvJ mouse were cultured 
in Knockout DMEM (Invitrogen) supplemented with 10% FBS, penicillin/streptomycin, 
essential amino acids, ESGRO (103 U/ml; Chemicon, Temecula, CA) with irradiated 
embryonic fibroblast feeder cells. ES cells were electroporated at 0.2 kV, 950μF (Gene Pulser 
II; Bio-Rad, Hercules, CA) with linearized targeting vectors and selected with G418 
(300μg/ml). DNA from G418-resistant clones was isolated for Southern blot analysis. A DNA 
probe was used to distinguish PstI restriction fragments from wildtype (~7.5kb) and mutant 
(~10kb) alleles. Appropriate homologous recombination in ES cell clones was confirmed by 
PCR using primers complementary to sequences within the neomycin cassette and to 3’ 
FKBP5 sequences downstream from the recombination site. ES cell clones containing a 
mutant FKBP5 allele were injected into C57BL/6 blastocysts and implanted into 
pseudopregnant 129SvJ females. Chimeric offspring were identified by coat patterns and 
mated to C57BL/6 mice. 
 
Western blot 
Cortex were homogenized in ice-cold lysis buffer (50mM Tris, 150 mM NaCl, 1 mM EDTA, 
1% Triton 100, protease inhibitor cocktail, Sigma, Deisenhofen, Germany) and centrifuged 
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(30 min, 12.000 rpm, 4°C) to eliminate cell debris. Protein concentrations were determined 
using a detergent compatible protein assay kit (Bio-Rad, Hercules, CA, USA). Samples 
containing 100 µg of protein per lane were loaded on 10% sodium dodecyl sulphate-
polyacrylamide gels and transferred onto nitrocellulose membranes (Invitrogen, Karlsruhe, 
Germany). The membranes were blocked with 5 % milk in TBS containing 0.1% Tween 20 
(TBST-T) for 3h at room temperature and incubated with goat-anti-FKBP51 (1:500, 5% milk 
in TBS-T, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or goat anti-actin (1:1000, 1% Milk 
in TBS-T, Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies overnight at 4°C. 
Subsequently, membranes were washed 3x 10min in TBS-T. Following incubation with 
horseradish peroxidase-conjugated rabbit anti-goat (1:500, 5% Milk in TBS-T, overnight at 
4°C, DAKO, Glostrup, Denmark) or donkey anti-goat (1:2000, 1% milk in TBST-T for 2h at 
room temperature, Santa Cruz Biotechnology, Santa Cruz, CA, USA) secondary antibodies, 
membranes were washed 3x10min in TBS-T and bands were visualized using an enhanced 
chemiluminescene system according to the manufacturer’s protocol (Amersham 
Biosciences, Freiburg, Germany).  
 
Fluorescence immunohistochemistry 
Perfused brains were sectioned at -18°C in a cryostat at 30 µm in the coronal plane through 
the level of the dorsal hippocampus. Immunohistochemistry was performed on free-floating 
sections. After several washes (3x10min) with 0.1 M PB containing 0.3% Triton X-100 (PB-T), 
sections were treated with 1% donkey serum in PB-T for 1h to block nonspecific sites. 
Subsequently, sections were incubated overnight at 4°C with rabbit anti-FKBP51 (1:250, 
Abcam, Cambridge, UK) in PB-T containing 1% donkey serum and washed in PB-T (3x10min). 
Sections were incubated in donkey anti-rabbit Alexa Fluor 488 (1:500; Invirtogen, 
Darmstadt, Germany) in 1% donkey serum in PB-T for 3h. After washing (3x10min) with PB, 
sections were transferred onto slides with Vectashield mounting medium containing 4′,6-
diamidino-2-phenylindole (Vector laboratories, Burlingame, CA, USA).  
The fluorescent images (1600 × 1600 pixels) of area CA3 were obtained with an Olympus 
IX81 confocal microscope (Olympus, Tokyo, Japan) at 20× magnification using the Kalman 
filter and sequential scanning mode under identical settings for laser power, photomultiplier 
gain and offset. Images were imported into the NIH ImageJ software, converted to 8-bit 
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grayscale and thresholded uniformly. For visualization of FKBP51, sections from wild type 
and 51KO mice were incubated and developed in the same wells to ascertain identical 
conditions.  
 
Figure S1: A, Targeting strategy. Mouse fkbp5 is ~100 kb in size. Exon 2, the first coding exon, is replaced 
by an in-frame bgal/neo cassette, which permits monitoring fkbp5 expression from the native 5' 
promoter. The 10 coding exons in the wildtype (wt) allele are depicted as solid boxes; the final exon of 
the mutant (mut) allele contains both coding and noncoding (open box) sequences. The gal/neomycin 
resistance cassette ( gal/neo, green) is indicated as are restriction enzyme sites for HindIII (H), KpnI (K), 
PstI (P), SacI (S), and EcoRV (EV). The bar near the 5‘ end of either allele indicates the probe used for 
Southern blots (51βgeo2). Short, bold arrows on the 3‘ half indicate PCR primers used for genotyping. B, 
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Western blot analysis of cortex cytosol confirmed the absence of FKBP51 protein in homozygous mutant 
tissue. C, Representative confocal images of hippocampal area CA3 immunostained for DAPI and FKBP51. 
51KO mice do not express FKBP51. Scale bar = 100 µm. 
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Abstract 
Psychiatric disorders such as depressive disorders and posttraumatic stress disorder are a 
major disease burden worldwide and have a higher incidence in women than in men. 
However, the underlying mechanism responsible for the sex-dependent differences is not 
fully understood. Besides environmental factors such as traumatic life events or chronic 
stress, genetic variants contribute to the development of such diseases. For instance, 
variations in the gene encoding the FK506 binding protein 51 (FKBP51) have been repeatedly 
associated with mood and anxiety. FKBP51 is a negative regulator of the glucocorticoid 
receptor and thereby of the hypothalamic–pituitary–adrenal axis that also interacts with 
other steroid hormone receptors such as the progesterone and androgen receptors. Thus, 
the predisposition of women to psychiatric disorders and the interaction of female 
hormones with FKBP51 and the glucocorticoid receptor implicate a possible difference in 
the regulation of the hypothalamic–pituitary–adrenal axis in female FKBP51 knockout 
(51KO) mice. Therefore, we investigated neuroendocrine, behavioral and physiological 
alterations relevant to mood disorders in female 51KO mice. Female 51KOs and wild type 
littermates were subjected to various behavioral tests, including the open field, elevated 
plus maze and forced swim test. The neuroendocrine profile was investigated under basal 
conditions and in response to an acute stressor. Furthermore, we analysed the mRNA 
expression levels of the glucocorticoid receptor and corticotrophin release hormone in 
different brain regions. Overall, female 51KO mice did not display any overt behavioral 
phenotype under basal conditions, but showed a reduced basal hypothalamic–pituitary–
adrenal axis activity, a blunted response to, and an enhanced recovery from, acute stress. 
These characteristics strongly overlap with previous studies in male 51KO mice indicating 
that FKBP51 shapes the behavioral and neuroendocrine phenotype independent of the sex 
of the individual. 
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Introduction 
Anxiety and mood related disorders such as major depressive disorder (MDD), are a major 
burden for society (Solhaug et al., 2012) affecting more than 1 billion people worldwide 
(Wittchen et al., 2011). Women are more susceptible to develop these disorders than men, 
which may relate to sex-dependent gene x environment interactions (Breslau, 2002; 
Solomon and Herman, 2009; Bangasser, 2013).  
Besides the contribution of sex-specific factors, stress is a major environmental risk factor 
for depression, whose effects in mammals are mainly mediated by the hypothalamus–
pituitary–adrenal (HPA) axis (Holsboer, 2000; de Kloet et al., 2005a). The secretion of 
glucocorticoids, the main end product of the HPA axis, is regulated by the activation of the 
mineralocorticoid receptor and glucocorticoid receptor (GR) in different brain regions, 
including the hypothalamus, pituitary and hippocampus (De Kloet et al., 2009). An 
impairment of this negative feedback loop results in an aberrant stress response and is 
associated with the development of MDD and anxiety disorders (van Rossum et al., 2006; 
Heim and Nemeroff, 2009; Tatro et al., 2009a; Bangasser, 2013; Menke et al., 2013).  
The co-chaperone FK506 binding protein 51 (FKBP51; encoded by the gene fkbp5) acts as an 
inhibitor of GR activity, determines GR binding affinity to glucocorticoids and thus 
determines the negative feedback sensitivity of the HPA axis (Pratt et al., 2006; Cheung-
Flynn et al., 2007; Tatro et al., 2009a). Moreover, translocation of the GR into the nucleus 
induces activation of an intracellular ultra-short feedback loop by directly enhancing fkbp5 
gene transcription, thus ultimately inhibiting GR activity (Hubler and Scammell, 2004; 
Binder, 2009; Storer et al., 2011). FKBP51 also acts as an inhibitor of other steroid hormone 
receptors, such as the progesterone and androgen receptors (Hubler and Scammell, 2004; 
Febbo et al., 2005), thereby potentially linking the stress effects to gonadal hormone 
signalling.  
The involvement of FKBP51 in stress related disorders was first indicated by studies 
illustrating an association between multiple genetic variants of fkbp5 and the risk of MDD 
and PTSD development in humans (Koenen et al., 2005; Binder et al., 2008; Kirchheiner et 
al., 2008; Binder, 2009). This relationship was further investigated in animal models to 
determine the mechanistic role of FKBP51 in HPA axis functioning. In both rats and mice, 
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mRNA expression and protein levels of FKBP51 in GR-rich brain regions can be inducedby 
administration of the glucocorticoid agonist dexamethasone, corticosterone (CORT) or by 
subjecting animals to stress paradigms namely restraint, food deprivation or chronic mild 
stress (Lee et al., 2010; Scharf et al., 2011; Yang et al., 2012; Guidotti et al., 2013). Depletion 
of FKBP51 in males did not reveal robust behavioral differences under basal conditions 
(Touma et al., 2011). However, the lack of FKBP51 in stressed mice led to enhanced stress-
coping behavior and a less vulnerable neuroendocrine state (Touma et al., 2011; Chapter 1). 
To date, only male rodents have been investigated in relation to FKBP51 while the potential 
influence of gonadal hormones like oestrogens has been largely ignored.  
Beyond regulatory function of FKBP51 on GR hormone affinity, FKBP51 lowers ligand affinity 
of other gonadal steroid receptors such as the progesterone receptor and androgen 
receptor (Hubler et al., 2003; Hubler and Scammell, 2004; Febbo et al., 2005). Thus, FKBP51 
functions not only as a regulator of glucocorticoid-induced effects, but also as a negative 
feedback regulator for progesterone and androgens in the brain. This implicates a possible 
sex-specific regulation of the HPA axis and behavior in respect to FKBP51 (Bourke et al., 
2013), which has not been investigated yet in previous studies on FKBP51 mediated HPA 
axis activity. Moreover, the exclusion of female hormones in previous studies of FKBP51 in 
mice is unfortunate as the susceptibly to develop psychiatric disorders is mediated in a sex-
dependent gene x environment fashion (Kendler et al., 2002).  
The predisposition of women to psychiatric disorders and the interaction of female 
hormones such as progesterone or oestradiol with both FKBP51 and GR, implicate a possible 
differential regulation of the HPA axis in female 51KO mice. Therefore, the aim of this study 
was to characterize female 51KO and wild type (WT) littermates under basal conditions, with 
regard to possible behavioral, neuroendocrine and physiological alterations relevant to 
mood disorders. In this regard, we subjected female 51KO and WT littermates to a series of 
behavioral tests, examining exploratory, cognitive, anxiety-related and stress-coping 
behavior. Furthermore, measurements of CORT and ACTH circulating levels, physiological 
parameters and gene expression levels were taken to assess the neuroendocrine profile and 
physiological differences in these animals.  
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Materials and Methods  
Animals  
Female wild type Fkbp51+/+ (WT) and knockout Fkbp51-/- (51KO) mice of 3 to 4 months of 
age were used for the experiment. The 51KO mouse line was previously generated 
(Tranguch et al., 2005) and described (Chapter 1). Females were pair housed under standard 
housing conditions two weeks prior to the start of the experiment. Standard housing 
consisted of sufficient saw-dust bedding, cage enrichment, ad libitum access to food and 
water, a 12h day-night cycle (lights on at 8:00 am) and constant temperature (23± 2 °C) 
conditions.  
All animal experiments were performed in accordance to European Communities Council 
Directive 2010/63/EEC. All efforts were made to minimize animal suffering during the 
experiments. The protocols were approved by the committee for the Care and Use of 
Laboratory Animals of the Government of Upper Bavaria, Germany.  
 
Experimental design  
Female 51KO mice (n=14) and WT littermate controls (n=14) were subjected to a battery of 
behavioral tests, conducted on 5 consecutive days in the following order: open field (OF), 
elevated plus maze (EPM), dark light box (DaLi), Y-maze and forced swim test (FST). 
Additionally, the FST served as acute stressor for a stress response test in order to determine 
CORT levels. The animals were sacrificed by decapitation 2 days after the FST. Trunk blood, 
brain, thymus and adrenal glands were collected for further analysis.  
 
Determination of estrous cycle phase  
Determination of the estrous cycle phase of the females was performed by gentle flushing 
of the vaginal opening with 20 mL 7% standard saline solution, in order to collect vaginal 
cells. Samples containing the cells were transferred to a dry glass slide and coverslipped. The 
samples were viewed shortly after collection of the sample under the microscope at 400x 
magnification. Determination of the cycle phase was based on the presence and absence of 
leukocytes and appearance of epithelial cells, according to standard characteristics as 
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described previously (Goldman et al., 2007). Ultimately, females were classified to be in 
estrous or non-estrous.  
Behavioral assessment  
Behavioral tests were carried out between 08:00 am and 12:00 pm in the same room where 
the animals were housed. All behavioral tests have been described and validated previously 
(Touma et al., 2011; Wang et al., 2011b; Chapter 1). They were performed using an 
automated video-tracking system (Anymaze 4.20, Stoelting, IL, USA). Collection of vaginal 
cells for determination of estrous cycle phase was performed daily after finalizing the 
behavioral test.  
Open field (OF)  
On day 1, general locomotor activity and exploratory behavior was assessed in the OF for 15 
min. Briefly, the apparatus consisted of an empty, enclosed, square arena (50 x 50 x 50 cm) 
made of grey polyvinylchloride (PVC), virtually divided into two areas, an inner zone (25 x 
25 cm) and an outer zone. The arena was evenly and weakly illuminated (< 10 lux). 
Parameters of interest included total distance travelled and inner zone time.  
Elevated plus maze (EPM)  
On the second day, anxiety-related behavior was investigated using the EPM. The animal 
was placed in an elevated (50 cm) plus-shaped platform made of grey PVC, with two 
opposing open arms (30 x 5 x 0.5 cm) and two opposing enclosed arms (30 x 5 x 15 cm), 
which are connected by a central area (5 x 5 cm). Illumination was less than 10 lux in the 
enclosed arms and 25 lux in the open arms. Animals were placed in the center zone facing 
one of both closed arms at the beginning of a 10 minute trial. Parameters of interest 
included the distance travelled and relative open arm time.  
Dark light box (DaLi)  
The DaLi test is an additional setup to measure anxiety-related behavior and was performed 
on day 3. Briefly, the apparatus consisted of a rectangular box with two compartments, the 
dark compartment (15 cm x 20 cm x 25 cm, lit with <10 lux) and the larger, more aversive 
and brightly lit compartment (30 cm x 20 cm x 25 cm, lit with approximately 700 lux), 
connected by a 4 cm long tunnel. Animals were placed in a corner of the dark compartment 
Research articles 
53 
at the beginning of the test. Exploration of dark and lit compartment was allowed during a 
10 minute period. The mice were considered to have entered the lit compartment after 
entering the zone with the hind paws. Behavior of the animal was scored manually. 
Parameters of interest were latency to first lit compartment entry, number of entries and 
time spent in the lit compartment.  
Y-maze  
On day 4, hippocampal-dependent spatial memory was investigated in the Y-maze. The grey 
PVC apparatus consists of a platform of three identical arms, 30 cm long, 10 cm wide, and 
sides 15 cm high, connected by a center zone. The angle between each arm is 120°. The 
inner walls of each arm are marked with distinct, easy recognizable visual cues, using white 
adhesive tape. The illumination was 15 lux in all three arms. The test comprises two trials, 
the acquisition and retrieval trial. During the acquisition trail, one arm was blocked with a 
grey PVC board. The board is removed during the retrieval trail and this arm is further 
referred to as the novel arm. At the start of trial one, the mouse is placed into the central 
zone facing of one of both accessible arms and is allowed to explore the apparatus for a 
duration of 10 minutes. After 30 minutes inter-trial time spent in their home cage, the 
animals were reintroduced to the apparatus by placing them in the same starting position. 
In this retrieval phase, the mouse was allowed to explore all three arms for 5 minutes. Spatial 
memory performance was assessed by analysis of the distance travelled in the novel arm 
compared to distance travelled in the other arms as well as the number of entries into the 
novel arm.  
Forced swim test (FST)  
On the fifth day, analysis of escape-orientated behavior and stress coping was investigated 
during the six minute FST trial. The animals were placed in a two litre glass beaker (diameter: 
13 cm, height: 24 cm) filled with tap water (21° C) to a height of 15 cm, so that the mouse 
could not touch the bottom of the beaker with its hind paws or tail. After the test trial, the 
animals were dried with a towel and put back into their home cage. Scoring of animal 
behavior was performed by an experienced observer who was blind to the genotype of the 
animals, and who classified the following behavioral patterns: floating, swimming and 
struggling.  
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Sample processing  
Females were sacrificed in the beginning of the light phase (between 08.00 and 10.00 am), 
2 days after the last behavioral test (FST). After quick body weight measurement and 
anaesthesia by isoflurane, the animals were sacrificed by decapitation. Collection of vaginal 
cells was performed after sacrifice of the animal to minimize the time handling the animal 
prior to sacrifice. Brains were removed, snap-frozen in isobutene at -40 °C and stored till 
further use at -80 °C for in situ hybridization. Thymus and adrenal glands were removed, 
dissected from fat and weighted. Trunk blood was collected in 1.5 ml EDTA-coated tubes 
(Kabe Labortechnik, Germany) for basal CORT and ACTH level determination. All blood 
samples were kept on ice until centrifugation for 15 minutes at 8000 rpm and at 4 °C. Blood 
plasma was transferred to new tubes; 100 μl blood plasma for ACTH analysis and 10 μl blood 
plasma for CORT analysis, stored at -20 °C until further usage.  
 
Investigation of endocrine profile  
The FST was used as an acute stressor in order to determine the stress response by 
measuring CORT blood plasma concentrations. After the FST, all mice were placed into their 
home cage to recover from the acute stressor. Blood samples for the stress response were 
collected by a tail cut 30 minutes (stress response) and 90 minutes (stress recovery) after 
the onset of the FST (Fluttert et al., 2000). Blood was collected in 1.5 ml EDTA-coated tubes 
(Kabe Labortechnik, Germany) and processed as described above.  
CORT and ACTH concentrations were determined by radioimmunoassay using a 
Corticosterone double antibody 125I RIA kit (sensitivity: 12.5 ng/ml, MP Biomedicals Inc) 
and Adrenocorticotropic double antibody hormone 125I RIA kit (sensitivity: 10 pg/ml, MP 
Biomedicals Inc) and were used following the manufacturers’ instructions. Radioactivity of 
the pellet was measured with a gamma counter (Packard Cobra II Auto Gamma; Perkin-
Elmer). Final CORT and ACTH levels were derived from the standard curve.  
 
In-situ hybridization  
Brain tissue was sectioned at -20 °C in a cryostate microtome at 18 μm in the coronal plane. 
Sections were thaw mounted on Super Frost Plus slides, air dried at a 28 °C warming plate 
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and stored at -20 °C. Hippocampal sections were further divided in dorsal (bregma > -2.70 
mm) and ventral (bregma < -2.70 mm). Expression levels of the GR and corticotrophin 
release hormone (CRH) genes were investigated by in-situ hybridization of different brain 
regions, dorsal hippocampus, ventral hippocampus and paraventricular nucleus (PVN) of the 
hypothalamus, with 35S UTP labelled ribonucleotide probes as previously described 
(Schmidt et al., 2007). Briefly, sections were fixed in 4% para- formaldehyde and acetylated 
in 0.25% acetic anhydride in 0.1 M triethanolamine/ HCl. Subsequently, brain sections were 
dehydrated in increasing concentrations of ethanol and treated with 100% chloroform. The 
antisense cRNA probes were transcribed from a linearized plasmid. Tissue sections were 
saturated with 100 ml of hybridization buffer containing approximately 3-5 million cpm 35S 
labeled riboprobe. Brain sections were coverslipped and incubated overnight at 55 °C. The 
following day, the sections were rinsed in 2 x SSC solution containing 20 mg/l RNAse A and 
washed in increasingly stringent SSC solutions at room temperature. Finally, sections were 
washed in 0.1 x SSC for 1 h at 65 °C and dehydrated through increasing concentrations of 
ethanol. The slides were exposed to Kodak Biomax MR films (Eastman Kodak Co., Rochester, 
NY) and developed. Autoradiographs were digitized, and expression was determined by 
optical densitometry utilizing the freely available NIH ImageJ software. The mean of four 
bilateral measurements (PVN) or two unilateral measurements (hippocampal subregions) 
was calculated for each animal, subtracting the background signal of a nearby structure not 
expressing the gene of interest from the measurements.  
 
Statistical analysis  
Data graphs are presenting the means ± standard error of the mean. Analysis was performed 
using the commercially available software SPSS 17.0. Significance was accepted with P < 
0.05. All data were tested for outliers using the Grubbs’ test (GraphPad software). If the 
equality of variance was violated in Levene’s test (P < 0.05), the modified t-values were used 
for parametric measurements. Body weight, thymus, adrenal glands and gene expression 
data were analyzed with the unpaired Student’s t-test (independent factor genotype). The 
non-parametric Mann-Whitney test was applied in case of non-normality of these datasets. 
The cycle phase (estrous or non-estrous) was assessed after each behavioral test to correct 
for the estrous cycle phase dependent effects on behavioral parameters and 
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neuroendocrine levels. Behavioral and neuroendocrine data were analyzed using the 
analysis of covariance (ANCOVA) model with genotype as independent factor and the 
estrous cycle as covariate. Data of Y-maze novel arm entries were analysed after natural 
logarithmic transformation to meet the assumption of normality for statistical analysis. 
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Results  
Physiological parameters of female 51KO mice  
Body weight measurements were taken before sacrifice and used for normalization of the 
organ weights. Student’s t-test analysis detected that body weight of female 51KOs was 
significant lower than of their WT litter mates (t26 = 3.026, P = 0.006, fig 1A). In addition, 
both relative adrenal glands weight (Student’s t-test: t25 = 7.025, p < 0.001, fig 1B) and 
relative thymus weight (Mann-Whitney: U = 10.00, p < 0.001, fig 1C) were reduced in the 
female 51KO mice in comparison to the WT females.  
 
Figure 1: Physiological parameters of the female 51KO mice and WT littermates. (A) Bodyweight in 
51KOs is reduced. (B) The thymus and (C) adrenal glands weights are reduced in 51KOs. * P < 0.05. 
 
Neuroendocrine profile  
The endocrine profile of the females was investigated by analysis of the CORT blood plasma 
levels after an acute stressor and CORT and ACTH blood plasma levels under basal 
conditions.  
Measurements under basal conditions were made using trunk blood at sacrifice. The ACTH 
levels in blood plasma did not differ between female WT and 51KO mice under basal 
conditions (ANCOVA: F1 = 2.583, P = 0.121, fig 2A). ANCOVA indicated lower CORT levels 
under basal conditions in female 51KOs (F1 =6.472, P = 0.018, fig 2B). Upon stress, as 
induced by the FST, ANCOVA indicated an effect of genotype (F1 = 35.514, P < 0.001). The 
CORT response levels of female WTs were elevated in comparison to the female 51KOs       
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(fig 2C). In addition, ANCOVA revealed that CORT levels of female 51KOs were lower than of 
female WTs 90 minutes after the onset of the FST (F1 = 5.392, P = 0.029, fig 2D).  
 
Figure 2: The neuroendocrine profile of female mice under basal conditions and after an acute stressor 
(FST). (A) ACTH levels under basal conditions are similar in the females. CORT levels in 51KOs are lower 
(B) under basal conditions, (C) 30 minutes after the onset of the FST (response) and (D) 90 minutes after 
the onset of the FST (recovery). * P < 0.05. 
 
Behavioral characterization of female 51KO mice  
Female WT and 51KO mice were subjected to a series of 5 behavioral tests (OF, EPM, DaLi, 
Y-maze, FST) to investigate locomotion, anxiety and stress-coping behavior as well as 
cognitive function.  
Female 51KO and WT mice behaved similar in respect to exploratory behavior during the 
test. ANCOVA did not reveal an effect of genotype on locomotion (F1 = 0.238, P = 0.629, fig 
3A) or on the time spent in the inner zone of the arena (F1 = 0.440, P = 0.513, fig 3B).  
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During the EPM, analysis of anxiety-related behavior using ANCOVA revealed no effects of 
genotype. No differences were present in the distance travelled in the EPM (F1 = 0.001, P = 
0.979887, fig 3C) or the relative time spent in the open arm (F1 = 0.448, P = 0.510, fig 3D).  
Animals were tested in the DaLi as an additional measurement of anxiety-related behavior. 
ANCOVA revealed no differences in the time spent in the lit compartment by 51KO mice (F1 
= 2.993, P = 0.097, fig 3E) or in the number of entries to the lit compartment between 51KO 
and WT (F1 = 1.207, P = 0.283, fig 3F).  
Cognitive functioning of the animals was tested in the hippocampal dependent spatial 
memory related Y-maze. Female WT and 51KO mice did not perform differently on any of 
the parameters. ANCOVA revealed no genotype effect on the number of entries to (F1 = 
0.048, P = 0.829, fig 3G) or the distance travelled in the novel arm (F1 = 0.024, P = 0.879, fig 
3H). Both the distance travelled in the novel arm and the number of entries of the novel arm 
exceeded the chance level of 33% in all animals (fig 3H,I).  
The female mice were subjected to the FST to assess stress-coping behavior. Analysis 
showed an increase in the swimming time in female 51KOs (F1 = 7.466, P = 0.012), but 
revealed no genotype effects on the time spent struggling (F1 = 0.018, P = 0.893) or floating 
(F1 = 0.981, P = 0.331, fig 3I). In addition, ANCOVA of the latency till the first floating moment 
revealed no effect of genotype (F1 = 0.670, P = 0.411, fig 3J).  
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Figure 3: Behavioral profile of female 51KO and WT. Overall, female 51KOs and WTs performed similar 
in all presented behavioral tests. Open field: (A) Total distance travelled and (B) time in inner zone. 
Elevated plus maze: (C) Total distance travelled and (D) percentage of the relative time in the open arm. 
Dark light box: (E) Time in the lit compartment and (F) number of entries to the lit compartment. Y-maze: 
(G) Percentage of novel arm entries of total arm entries and (H) the percentage of distance travelled in 
the novel arm. The striped lines in the graphs of the Y-maze represent the 33% change level of the novel 
arm measurements. Forced swim test: (I) Time spent struggling, swimming or floating and (J) latency till 
the first observed floating episode. * P < 0.05.  
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Gene expression  
Expression of GR mRNA in the hippocampus is similar in female 51KOs and WTs. Student’s 
t-test analysis revealed no effect of genotype in the different subregions of the dorsal 
hippocampus (CA1: t26= -0.617, P = 0.542, CA3: t26 = -1.045, P = 0.306, DG: t26 = -0.466, P 
= 0.645, fig 4A,B) or the ventral hippocampus (CA1: t26 = -0.034, P = 0.973, CA3: t21,257 = -
0.487, P = 0.631, DG: t26 = -0.064, P = 0.949, fig 4C,D).  
Student’s t-test analysis of GR mRNA expression in the PVN showed no genotype effect (t21 
= 0.636, P = 0.532, fig 4E,F), but revealed an increased level of CRH mRNA expression in the 
PVN of female 51KOs (t18 = -2.529, P = 0.021, fig 4G,H).  
 
Figure 4. GR and CRH mRNA expression in the hippocampus and PVN. The hippocampus is split in 
different subregions of (A) the dorsal and (B) the ventral area for analysis of GR mRNA expression. (C) GR 
mRNA expression is similar in the PVN between genotype groups. (D) CRH expression in the PVN is 
elevated in the female 51KOs. Representative autoradiograph images are always depicted on the right 
side of the respective figure panel. * P < 0.05.  
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Discussion  
In this study, we investigated the effects of FKBP51 deletion in female mice on behavioral, 
physiological and neuroendocrine parameters. Overall, female 51KO mice presented a 
reduced basal HPA axis activity as well as a blunted response to, and an enhanced recovery 
from, an acute stressor. Nevertheless, 51KO female behavior was not affected by the lack 
of FKBP51 under basal conditions. The physiological and endocrine profile of the female 
51KOs differs from WT mice and is similar to that of male 51KO mice described previously.  
 
Physiological alterations in female 51KO mice  
Similar to male 51KO mice, several physiological alterations, including reduced thymus and 
adrenal gland weights, are observed in female 51KOs compared to WT animals. Considering 
FKBP51 is known to reduce GR sensitivity in cellular models (Wochnik et al., 2005; Westberry 
et al., 2006; Albu et al., 2013), an enhanced GR sensitivity most likely explains the thymus 
involution in female 51KO mice. Indeed, a study on mutant GR overexpressing rats shows 
an increased affinity for glucocorticoids in the thymus, resulting in strong thymocyte 
apoptosis, which can be reversed by adrenalectomy (van den Brandt et al., 2007). Along this 
line of reasoning, a report of adrenolectomized mice with a thymus-specific inducible GR 
transgene, showed a reduction in thymocyte number after induced GR overexpression, 
which could again be inhibited by a GR antagonist (Pazirandeh et al., 2005). Chronic stress 
and HPA axis hyperactivity have been consistently associated with adrenal gland 
enlargement (Wagner et al., 2011; Wagner et al., 2012; Chapter 1) with considerable 
consequences for brain structure and function (Lucassen et al., 2014). However, we found 
that female 51KO mice showed rather decreased adrenal gland weight compared to WTs 
even under basal conditions. This may implicate attenuated HPA axis activity and enhanced 
negative feedback regulation in absence of FKBP51.  
Next to the alterations in organ weights, body weight of the female 51KOs was also reduced, 
as it was in the males. Studies of obesity risk in psychiatric disorders relate enhanced 
glucocorticoid levels to the level of obesity (Rebuffé-Scrive et al., 1992; Mustillo et al., 2003). 
Hence, reduced circulating CORT levels and lower female 51KO body weight may point to 
the reversed situation, possibly as a result of the hypothesized GR sensitivity. The specific 
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underlying biomechanism of the association between body weight and glucocorticoid levels 
is not identified to-date, and requires future research (Touma et al., 2011).  
 
FKBP51 depletion shapes levels of circulating CORT  
The present profile of basal and stress-induced CORT secretion in female 51KO mice 
supports the hypothesis of an enhanced GR sensitivity. This could result from the depleted 
FKBP51 mediated inhibition of hormone binding to the GR. Under basal condition, as well 
as shortly after an acute stressor and during the recovery of this stressor, female 51KOs 
show reduced circulating CORT, thereby exhibiting a highly similar phenotype to male 51KO 
mice. However, ACTH levels do not show a significant modulation in female 51KOs at the 
present time point. It cannot be ruled out that over the course of the circadian rhythm (e.g. 
at the onset of the dark period) differences in ACTH secretion might be apparent. Overall, 
the neuroendocrine profile of the female 51KO mice is modulated in a similar manner as the 
previously described male 51KOs (Touma et al., 2011; Chapter 1). Beyond its role on GR and 
thus HPA axis activation, it is known that FKBP51 inhibits gonadal hormone receptors in the 
brain (Hubler et al., 2003; Hubler and Scammell, 2004; Febbo et al., 2005; Bourke et al., 
2013), suggesting that FKBP51 may have distinct effects in male and female mice. However, 
the presented neuroendocrine profiles of female and male 51KOs strongly overlap and no 
genotype x estrous cycle interaction was observed.  
 
Expression levels of GR and CRH  
Next to the circulating glucocorticoids, expression of GR is a key factor affecting HPA axis 
feedback and regulation. GR mRNA levels in the PVN of the hypothalamus and in different 
subregions of the hippocampus were similar in female 51KOs and WT animals. Interestingly, 
the observed increase in CRH mRNA in the female 51KOs, might be due to a reduced GR-
mediated negative feedback on CRH expression as a consequence of the lower circulating 
CORT levels in these animals. In male 51KOs, no differences of CRH mRNA in the PVN are 
described (Chapter 1), indicating a sex-specific difference in HPA axis regulation at the level 
of the PVN in 51KO animals. Overall, possible compensatory mechanisms in the 51KO 
females might involve other components of the HPA axis or steroid hormones. At least in 
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human brain, sex specific differences in GR protein expression in depression are present 
(Wang et al., 2012a).  
 
FKBP51 deletion in female mice does not affect behavior under basal conditions  
In order to determine the behavioral profile of female mice depleted of FKBP51, mice were 
subjected to a battery of behavioral tests. The behavioral phenotype of female 51KO mice 
appears to be unaffected by the depletion of the FKPB51 under basal conditions. Female 
51KOs perform adequate and similar to WT littermates, in all performed behavioral tests. 
The increase in swimming time during the FST is the only difference between 51KOs and 
WTs. This type of behavior is considered to be neutral, whereas no differences were 
observed in the determinative types of behavior during this test (i.e. attempting to escape 
and despair-like types of behavior). Overall the behavior of female 51KOs is in line with 
previous studies in male 51KOs that also did not display behavioral alterations under basal 
conditions. Yet, FKPB51 deletion led to marked alterations in males that were challenged by 
chronic stress (Touma et al., 2011; Chapter 1). Whether this is the case for female mice as 
well remains to be elucidated.  
In accordance to the regulation of CORT and ACTH in female 51KOs, no behavioral 
differences under basal conditions or in stress-coping behavior during the FST were 
observed nor could they be subscribed to the effects of gonadal hormones in female 51KOs 
and WTs. Although FKBP51 interacts with steroid hormones besides CORT (Hubler et al., 
2003; Hubler and Scammell, 2004; Febbo et al., 2005; Bourke et al., 2013), no interaction of 
FKBP51 with the estrous cycle was present in the current study. Future investigation is 
needed to reveal whether this is only the case under basal conditions. Studies of chronic 
stress models in female mice at least illustrate regulatory effects of oestrogens and 
androgens on HPA axis activity and behavior (Walf and Frye, 2006; McCormick and 
Mathews, 2007; Weiser and Handa, 2009). Therefore, even though no interaction of FKBP51 
in female 51KOs is indicated in the present study, it is possible that mediating effects of 
female gonadal hormones in absence of FKBP51 are present under other conditions, namely 
after exposure to chronic stress.  
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Abstract 
Aversive life events represent one of the main risk factors for the development of many 
psychiatric diseases, but the interplay between environmental factors and genetic 
predispositions is still poorly understood. One major finding in many depressed patients is 
an impaired regulation of the hypothalamic-pituitary-adrenal (HPA) axis. The negative 
feedback loop of the HPA axis is mediated via the glucocorticoid receptor (GR) and the 
mineralocorticoid receptor. The co-chaperones FK506-binding protein 51 (FKBP51) and 
FK506-binding protein 52 (FKBP52) are components of the heat shock protein 90-receptor-
heterocomplex and are functionally divergent regulators of both receptors. Here, we 
characterized heterozygous Fkbp52 knockout (Fkbp52+/-) mice under basal or chronic social 
defeat stress (CSDS) conditions with regards to physiological, neuroendocrine, behavioral 
and mRNA expression alterations. Fkbp52+/- mice displayed symptoms of increased stress 
sensitivity in a subset of behavioral and neuroendocrine parameters. These included 
increased anxiety-related behavior in the elevated plus-maze and an enhanced 
neuroendocrine response to a forced swim test (FST), possibly mediated by reduced GR 
sensitivity. At the same time, Fkbp52+/- mice also demonstrated signs of stress resilience in 
other behavioral and neuroendocrine aspects, such as reduced basal corticosterone levels 
and more active stress-coping behavior in the FST following CSDS. These contrasting results 
are in line with previous reports showing that FKBP52 is not involved in all branches of GR 
signaling, but rather acts in a gene-specific manner to regulate GR transcriptional activation.  
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Introduction 
Susceptibility to psychiatric disorders such as major depression is determined by the 
relationship between genetic predisposition and environmental factors including negative 
life events and chronic stress (Hammen, 2005; El Hage et al., 2009; Gillespie et al., 2009; 
Hyde et al., 2011). However, the molecular mechanisms underlying individual vulnerability 
or resilience to chronic stress are still poorly understood.  
The hypothalamus-pituitary-adrenal (HPA) axis represents one of the major stress-systems 
in mammals, which ultimately leads to the release of glucocorticoids (GCs) from the adrenal 
cortex. GCs are then acting on numerous organ systems, including the brain, to modulate 
metabolism and behavior. In parallel, GCs activate a negative feedback circuit via 
glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) at different levels of the 
HPA axis, thereby terminating the stress response (De Kloet et al., 1998; Ulrich-Lai and 
Herman, 2009). 
GRs and MRs are ligand-dependent transcription factors (De Kloet and Reul, 1987). The 
process of receptor folding, maturation, activation, trafficking and subsequent receptor 
action on gene transcription is regulated by a multiprotein complex that assembles around 
the molecular chaperone heat shock protein 90 (hsp90) (Pratt et al., 2006; Grad and Picard, 
2007). The FK506-binding protein 51 (FKBP51, encoded by the FKBP5 gene) and FK506-
binding protein 52 (FKBP52, encoded by the FKBP4 gene) are components of the chaperone-
receptor heterocomplex and differentially regulate the GR or MR at two levels: hormone 
binding and nuclear translocation. FKBP51 has been shown to decrease ligand binding 
sensitivity of the receptor and efficiency of nuclear translocation (Denny et al., 2000; 
Scammell et al., 2001; Wochnik et al., 2005; Westberry et al., 2006). Upon ligand binding, 
FKBP51 is replaced by FKBP52, which in turn binds to dynein. This promotes the 
translocation of the receptor-complex into the nucleus and enhances subsequent DNA-
binding (Davies et al., 2002; Wochnik et al., 2005; Gallo et al., 2007; Galigniana et al., 2010; 
Schülke et al., 2010). For a detailed illustration and description of the mechanism see review 
of Binder 2009. 
In numerous clinical studies, single nucleotide polymorphisms of FKBP51 have repeatedly 
been associated with stress-related diseases such as posttraumatic stress disorder and 
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major depression (Yehuda et al., 2009; Zobel et al., 2010; Zou et al., 2010; Mehta et al., 
2011). In addition, we could recently show that Fkbp51 knockout (51KO) mice were less 
affected by chronic social defeat stress (CSDS), in a subset of neuroendocrine and behavioral 
parameters (Chapter 1). Furthermore, 51KO mice displayed enhanced active stress coping 
behavior following an acute severe stress exposure which was independently also shown in 
aged 51KO mice, likely due to a more sensitive GR (O'Leary, III et al., 2011; Touma et al., 
2011). 
In contrast, most studies with Fkbp52 knockout (Fkbp52-/-) mice focused on developmental 
and molecular aspects. In this regard it is important to know that Fkbp52-/- mice show an 
increased embryonic lethality, while the Mendelian ratio of heterozygous Fkbp52 (Fkbp52+/-
) mice is normal (Cheung-Flynn et al., 2005; Tranguch et al., 2005; Warrier et al., 2010). 
Nonetheless, several studies revealed an androgen, progesterone, and glucocorticoid 
insensitivity in Fkbp52-/- mice (Cheung-Flynn et al., 2005; Tranguch et al., 2005; Yang et al., 
2006; Yong et al., 2007; Warrier et al., 2010). Furthermore, it has been shown that female 
Fkbp52-/- mice are infertile as a result of embryonic implantation and decidualization failure 
caused by uterine defects and progesterone insensitivity (Tranguch et al., 2005; Yang et al., 
2006; Tranguch et al., 2007). Male Fkbp52-/- mice display several defects in reproductive 
tissues such as ambiguous external genitalia and dysgenic prostate consistent with partial 
androgen insensitivity (Cheung-Flynn et al., 2005; Yong et al., 2007). In addition, Fkbp52+/- 
mice showed a susceptibility to high-fat diet induced hepatic steatosis, due to a state of 
glucocorticoid resistance arising from liver-specific loss of GR activity (Warrier et al., 2010). 
All these findings suggest that FKBP52 plays an important role in steroid receptor function. 
However, a comprehensive behavioral, endocrine and neurogenetic characterization 
combined with challenging conditions such as chronic stress is still lacking. To fill this gap, 
we investigated the function of FKBP52 and its potential role in the development of stress-
related disorders. We characterized heterozygous Fkbp52 knockout mice under basal and 
chronic stress conditions. Mice were then analyzed for alterations in physiological, 
neuroendocrine, behavioral and mRNA expression parameters. We hypothesized that 
Fkbp52+/- mice would display a higher stress sensitivity due to a partial glucocorticoid 
insensitivity. 
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Materials and Methods 
Animals and housing conditions 
The Fkbp52 knockout mouse line was previously generated as described by Cheung-Flynn et 
al., (2005) and were kept on a mixed 129SvJ x C57BL/6 background. Due to the low viability 
of null embryos, we used Fkbp52+/- mice in this study, obtained from heterozygous breeding 
pairs. Genotypes were verified by PCR of tail DNA. Only male mice were used for the 
experiment. Animals were 12 weeks old at the start of the experiment. Mice were singly 
housed two weeks prior to the experiment. Maintenance and experiments were performed 
under a 12 h light, 12 h dark cycle (lights on at 0800 h) and constant temperature (23 ± 2 °C) 
conditions. Food and water were provided ad libitum. 
Male CD1 mice (12 - 16 weeks old) serving as residents were allowed to habituate to the 
social defeat cage for two weeks before the onset of the experiments. Male juvenile Balb/c 
mice (5 weeks old) serving as social targets in the sociability test were housed in groups of 
4. The experiments were performed in accordance with the European Communities Council 
Directive 2010/63/EU. All efforts were made to minimize animal suffering during the 
experiments. The protocols were approved by the committee for the Care and Use of 
Laboratory Animals of the Government of Upper Bavaria, Germany.  
 
Chronic social defeat paradigm 
The CSDS paradigm was conducted as described previously (Wagner et al., 2011; Wang et 
al., 2011a; Chapter 1). Briefly, the experimental mice were introduced into the home cage 
(45 cm x 25 cm) of a dominant resident mouse and defeated shortly after. After the defeat 
was achieved, the animals were separated by a wire mesh, preventing physical but allowing 
sensory contact for 24 h. Each day, stressed animals were defeated by another unfamiliar, 
dominant resident mouse, in order to exclude a repeated encounter throughout the 
experiment. Experimental mice were always defeated by resident males during the entire 
experimental period. Control mice were housed in their home cages during the course of 
the experiment. All mice were handled daily; body weight and fur quality were assessed 
every 3-4 days prior to the social defeat. 
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The fur state was rated by an experienced investigator as previously described (Mineur et 
al., 2003). Briefly, ratings were classified according to a 4-point scale, where 1 represents a 
perfect, clean fur, while 4 stands for disheveled, scruffy fur, often including traces of wounds 
and scurf. Scores of 2 and 3 demonstrate intermediate fur states, respectively. 
 
Experimental design 
24 wild-type (WT) and 24 Fkbp52+/- mice were divided into four groups (WT control, 
Fkbp52+/-control, WT stress and Fkbp52+/- stress) of 12 animals each and subjected to the 
CSDS paradigm for 21 days. The daily defeat was performed between 1200 h and 1600 h; 
varying starting times reduced the predictability of the stressor and therefore minimized a 
potential habituation effect. All behavioral tests were conducted during the third week of 
the stress paradigm. In case of serious injury or death, mice were excluded from the 
experiment. 
 
Behavioral analysis 
Behavioral tests were carried out between 0830 h and 1230 h in the same room in which 
the mice were housed. All tests were performed using an automated video-tracking system 
(Anymaze 4.20, Stoelting, IL; USA).  
Sociability test 
On day 15 of the stress paradigm, the sociability test was performed as previously described 
(Moy et al., 2004; Sankoorikal et al., 2006; O'Tuathaigh et al., 2008), with slight 
modifications. The test was employed to assess the preference between a social target 
(unfamiliar juvenile Balb/c mouse) and a non-social object (a toy mouse). The apparatus, a 
three chamber box (50 x 25), contained one center and two outer compartments (left and 
right chamber 19 x 25 x 40 cm; center chamber 12 x 25 x 40 cm). Two small openings with 
doors served as access points from the center chamber to the others. The apparatus was 
filled with bedding and evenly illuminated with 3-5 Lux. The test consisted of two separate 
trials. In the initial habituation trial, the animals were allowed to freely explore the 
apparatus on two consecutive days for 10 min. Only the empty wire cages were present in 
the chambers at this time. On the third day of testing, the sociability trial took place. This 
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time an unfamiliar male juvenile BALB/c mouse was introduced into one of the chambers, 
enclosed in the wire cage, while a toy mouse was placed in the opposite chamber (alteration 
occurred after 3 consecutive trials). The test mouse was placed in the middle chamber for 5 
min with both trap doors being shut. Afterwards, the doors were opened and the test animal 
was allowed to explore the rest of the apparatus for an additional 10 min. An experienced 
observer scored the time the mouse spent in the zone with the social target and the time 
spent in the zone with the non-social object. The discrimination index in % was calculated 
as follows:  
[Time in zone with social target (s) / (Time in zone with social target (s) + Time in zone with 
non-social object (s))]*100.  
Elevated plus-maze 
The elevated plus-maze (EPM) was conducted on day 16 of the stress procedure. The device 
consisted of a plus-shaped platform with two opposing open arms (length: 30 cm x width: 5 
cm x height: 0.5 cm) and two opposing enclosed arms (length: 30 cm x width: 5 cm x height: 
15 cm), made of gray polyvinyl chloride (PVC), which were connected by a central area (5 
cm x 5 cm). The whole device was elevated 50 cm above the floor. The illumination was 25 
Lux in the open arms and less than 10 Lux in the closed arms. Testing duration was 5 min 
and all mice were placed into the center zone facing one of the enclosed arms at the start 
of the test. The time spent in the open arms compared to the total arm time as well as the 
number of open arm entries were analyzed. 
Open-field test 
On day 17 of the stress paradigm, the open-field test (OF) was performed. Testing was 
carried out in an empty open-field arena (50 cm x 50 cm x 50 cm) made of gray PVC, which 
was evenly illuminated with 15 Lux. Testing time was 15 min, split into 3 segments, 5 min 
each. Parameters of interest were the total distance traveled as well as the inner zone time 
(inner zone size 25 cm x 25 cm). 
Forced swim test 
The forced swim test (FST) was performed on day 19 of the CSDS procedure. Each mouse 
was put into the a 2 l glass beaker (diameter: 13 cm, height: 24 cm) filled with tap water (21 
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± 1 °C) to a height of 15 cm, so that the mouse could not touch the bottom with its hind 
paws or tail. Testing duration was 6 min. The parameters time floating, time swimming, time 
struggling and latency to 1st floating were scored by an experienced observer, blind to 
genotype or condition of the animals. 
 
Acute stress response 
The FST was performed on day 19 and served as an acute challenge in order to determine 
the stress response by measuring corticosterone plasma concentrations. Blood samples 
were taken by tail cut 15 min (stress response) and 90 min (stress recovery) after the onset 
of the FST (Fluttert et al., 2000). Samples were collected in 1.5 ml EDTA-coated 
microcentrifuge tubes (Kabe Labortechnik, Germany). All blood samples were kept on ice 
and later centrifuged at 8000 rpm at 4 °C for 15 min. Plasma was transferred to new, labeled 
microcentrifuge tubes and stored at -20 °C until further processing.  
 
Sampling procedure 
All animals were sacrificed 24 h after the last defeat in the circadian nadir by decapitation 
following quick anaesthesia by isoflurane. Trunk blood was collected in labeled 1.5 ml EDTA-
coated microcentrifuge tubes (Kabe Labortechnik, Germany) for basal corticosterone levels. 
All blood samples were kept on ice until centrifugation at 4 °C and 8000 rpm for 15 min. 
After centrifugation, the blood plasma was transferred to a new, labeled 1.5 ml 
microcentrifuge tube. All plasma samples were stored at -20 °C until the determination of 
corticosterone by radioimmunoassay (MP Biomedicals Inc; sensitivity 6.25 ng/ml). Brains 
were removed, snap-frozen in isopentane at -40 °C, and stored at -80 °C for in-situ 
hybridization. Adrenal and thymus glands were removed, dissected from fat and weighed. 
 
In-Situ hybridization 
Frozen brains were sectioned at -20 °C in a cryostat microtome at 18 µm at the level of the 
paraventricular nucleus (PVN) and the dorsal hippocampus, thaw mounted on Super Frost 
Plus slides, dried and stored at -80 °C. In-situ hybridization using 35S UTP labeled 
ribonucleotide probes (Corticotropin-releasing hormone (CRH), vasopressin (AVP), GR, MR, 
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androgen receptor (AR), FKBP51, FKBP52) was performed as described previously (Schmidt 
et al., 2007). Briefly, sections were fixed in 4% paraformaldehyde and acetylated in 0.25% 
acetic anhydride in 0.1 M triethanolamine/HCl. Subsequently, brain sections were 
dehydrated in increasing concentrations of ethanol. The antisense cRNA probes were 
transcribed from a linearized plasmid. Tissue sections were saturated with 100 μl of 
hybridization buffer containing approximately 3-5 × 106 cpm 35S labeled riboprobe. Brain 
sections were coverslipped and incubated overnight (14 h) at 55 ºC. The following day, the 
sections were rinsed in 2 × SSC (standard saline citrate), treated with RNAse A (20 mg/l) and 
washed in increasingly stringent SSC solutions at room temperature. Finally, sections were 
washed in 0.1 × SSC for 1h at 65 ºC and dehydrated through increasing concentrations of 
ethanol. The slides were exposed to Kodak Biomax MR films (Eastman Kodak Co., Rochester, 
NY) and developed. Autoradiographs were digitized, and expression was determined by 
optical densitometry utilizing the freely available NIH ImageJ software 
(http://rsbweb.nih.gov/ij/). We performed two measurements (left and right for the 
hippocampus and PVN) for each brain slice and assessed two brain slices per animal. The 
data was analyzed blindly, always subtracting the background signal of a nearby structure 
not expressing the gene of interest.  
For AVP, slides were dipped in Kodak NTB2 emulsion (Eastman Kodak Co., Rochester, NY) 
and exposed at 4 °C for 8 h. Slides were developed and examined with a light microscope 
with both bright and dark field condensers. Expression of AVP mRNA in the parvocellular 
part of the PVN was determined by optical densitometry as described above. 
 
Statistical analysis 
All results are shown as mean ± SEM and were analyzed by the software SPSS 16.0. Values 
outside the 95 % confidence interval were defined as outliers and excluded from the 
analysis. For body weight and fur status progression as well as for the time-dependent 
behavioral parameters assessed in the open field test, 3-factorial analysis of variance 
(ANOVA) with repeated measures was performed. Thereby, genotype and condition were 
two between-subjects factors and time a within-subjects factor. Two factorial multivariate 
ANOVAs were employed for thymus, adrenal gland weight, neuroendocrine, and other 
behavioral variables as well as for gene expression contrasts. Whenever significant main (p 
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< 0.05) or interaction (p < 0.1) effects were found in the ANOVAs, univariate F-tests or tests 
with contrasts followed for specifying and locating simple effects. As a nominal level of 
significance p < 0.05 was accepted and corrected according to Bonferroni (univariate F-tests, 
test of simple effects or contrasts).  
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Results 
Verification of reduced Fkbp52 expression in Fkbp52+/- mice 
As expected, we observed an overall reduction of Fkbp52 mRNA expression with in-situ 
hybridization which was specifically quantified in the hippocampus. Statistical analysis 
showed significantly lower Fkbp52 mRNA expressions in the hippocampus for Fkbp52+/- mice 
compared to WT animals under control (CA1: T21 = 9.710, p < 0.0001; CA3: T21 = 9.461, p < 
0.0001; DG: T21 = 10.341, p < 0.0001) (Fig. 1A and B) as well as under stress conditions (CA1: 
T22 = 6.942, p < 0.0001; CA3: T22 = 7.607, p < 0.0001; DG: T22 = 7.953, p < 0.0001). There were 
no CSDS-dependent effects on Fkbp52 mRNA expression either in WT or in Fkbp52+/-mice 
(data for stress condition not illustrated). 
 
Figure 1: FK506-binding protein 52 (Fkbp52) mRNA expression. (A) Representative in-situ hybridization 
images show Fkbp52 mRNA expression in the hippocampus of wild type (WT) and Fkbp52+/- mice under 
control (ctrl) conditions. (B) Heterozygous deletion of Fkbp52 reduces hippocampal Fkbp52 mRNA 
expression (NWT Ctrl = 11, NFkbp52+/- Ctrl = 12). Data are represented as mean + SEM. # significantly different 
from the WT, p < 0.05. 
 
Physiological parameters 
CSDS evoked robust physiological changes in both WT and Fkbp52+/- animals. A significant 
increase in body weight was observed in all stressed animals independent of genotype 
(ANOVA with repeated measures: time x condition interaction; F6, 47 = 10.505, p < 0.001). 
Body weight of stressed WT mice at days 8, 18 and 21 was significantly increased compared 
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to their littermate controls (tests with contrasts in ANOVA, p < 0.01). Similarly, a significant 
body weight increase was also identified in stressed Fkbp52+/- mice at days 4, 11, 15, 18 and 
21 compared to their respective controls (Fig. 2A). 
A significant decrease in the animal’s fur state was observed in all stressed animals 
independent of genotype (ANOVA with repeated measures: time x condition interaction; F6, 
47 = 19.918, p < 0.0001). Fur quality of stressed Fkbp52+/- mice was significantly reduced in 
comparison to Fkbp52+/- controls from day 4 to day 21 and from day 8 to day 21 in stressed 
WT mice compared to their controls (tests with contrasts in ANOVA, p < 0.05) (Fig. 2B).  
Organ weights were measured on the day of sacrifice. Adrenal gland weights were 
significantly increased in chronically stressed WT and Fkbp52+/- mice (ANOVA: condition 
effect F1, 45 = 63.586, p < 0.0001) (Fig. 2C). Further, we observed a significant reduction in 
thymus weights in both WT and Fkbp52+/- stressed animals (ANOVA, condition: F1, 46 = 
94.535, p < 0.0001) (Fig. 2D). 
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Figure 2: Physiological phenotype evoked by chronic social defeat stress (CSDS). (A) Body weight gain 
over the course of the experiment (NWT Ctrl = 11, NFkbp52+/- Ctrl = 12, NWT Stress = 12, NFkbp52+/- Stress = 12). (B) Fur 
state progression during the stress exposure (NWT Ctrl = 11, NFkbp52+/- Ctrl = 12, NWT Stress = 12, NFkbp52+/- Stress = 
12). 1 represents a perfect, clean fur, 2 and 3 stand for intermediate fur states, 4 demonstrates a 
disheveled, scruffy fur. (C) Adrenal (NWT Ctrl = 10, NFkbp52+/- Ctrl = 12, NWT Stress = 12, NFkbp52+/- Stress = 11) and (D) 
thymus weight (NWT Ctrl = 11, NFkbp52+/- Ctrl = 12, NWT Stress = 11, NFkbp52+/- Stress = 12) at the end of CSDS. Data 
are represented as mean ± SEM. α significant condition effect in WT animals, p < 0.05; + significant 
condition effect in Fkbp52+/- mice, p < 0.05; * significantly different from the control condition of the 
same genotype, p < 0.05. 
 
Neuroendocrine analysis 
Basal levels of corticosterone were measured in blood plasma at circadian nadir. Moreover, 
response and recovery blood samples were collected 15 min and 90 min after the onset of 
the FST. ANOVA identified a genotype x condition interaction (F1, 45 = 9.214, p < 0.01) for 
basal corticosterone levels. Analyzing condition differences for each genotype and genotype 
differences for each condition, we found that chronic stress led to increased corticosterone 
levels in WT mice compared to WT controls. Moreover, significantly lower corticosterone 
levels were seen in stressed Fkbp52+/- mice compared to stressed WT animals (tests with 
contrasts in ANOVA, p < 0.05) (Fig. 3A). 
A condition (F1, 45 = 23.887, p < 0.0001) and a genotype (F1, 45 = 5.619, p < 0.05) effect were 
identified for corticosterone response values (15 min after the FST). Fkbp52+/- mice had 
significantly higher corticosterone levels compared to WT mice under control conditions. 
Furthermore, chronic stress led to a significant increase in corticosterone levels in WT and 
in Fkbp52+/- mice compared to non-stressed controls (Fig 3 B). 
Regarding corticosterone recovery levels (90 min after the FST), ANOVA revealed a condition 
effect (F1, 44 = 21.777, p < 0.0001) and a marginal genotype effect (F1, 44 = 3.626, p = 0.064), 
but not a significant interaction. Both chronically stressed groups had significantly lower 
corticosterone levels 90 min after the FST compared to their control groups. However, 
chronically stressed Fkbp52+/- mice showed significantly higher corticosterone levels 
compared to stressed WT animals (Fig. 3C). 
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Figure 3: Corticosterone profile of Fkbp52+/- and WT mice. (A) Basal morning corticosterone levels at the 
end of the stress exposure (NWT Ctrl = 10, NFkbp52+/- Ctrl = 12, NWT Stress = 12, NFkbp52+/- Stress = 11). (B) 
Corticosterone response 15 min after the forced swim test (FST) (NWT Ctrl = 11, NFkbp52+/- Ctrl = 12, NWT Stress = 
11, NFkbp52+/- Stress = 11). (C) Corticosterone recovery 90 min after the onset of the FST (NWT Ctrl = 11, NFkbp52+/- 
Ctrl = 12, NWT Stress = 10, NFkbp52+/- Stress = 11). Data are represented as mean + SEM. * significantly different 
from the control condition of the same genotype, p < 0.05; # significantly different from the WT of the 
same condition, p < 0.05. 
 
Behavioral analysis 
Four tests were conducted in order to investigate social preference, anxiety, exploration and 
stress-coping behavior (Sociability, EPM, OF, FST). 
Sociability test 
The sociability test was performed to assess the social preference between an unfamiliar 
juvenile Balb/c mouse and a non-social object. The time spent in the zone with the social 
target revealed a condition effect (F1, 45 = 7.495, p < 0.01). Chronically stressed Fkbp52+/- 
mice spent significantly less time in the zone with the social target compared to their control 
group of the same genotype (Fig. 4A), while this effect was not significant in WT controls.  
Elevated plus-maze test 
The EPM was used to investigate anxiety-related behavior. Animals which fell off the open 
arms were excluded from the analysis (2 WT Ctrl and 2 Fkbp52+/- Ctrl mice). For the time 
spent in the open arms, ANOVA identified a genotype x condition interaction (F1, 39 = 3.352, 
p = 0.076). Under control conditions, Fkbp52+/- mice spent significantly less time in the open 
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arms compared to WT mice. Furthermore, chronic stress resulted in a significant decrease 
in open arm time in stressed WT mice compared to WT controls (tests with contrasts in 
ANOVA, p < 0.05) (Fig. 4B, left panel). 
For the open arm entries, ANOVA revealed a condition effect (F1, 39 = 9.483, p < 0.01). Chronic 
stress led to significantly less open arm entries in stressed WT mice compared to their 
controls of the same genotype (Fig. 4B, right panel).  
 
Figure 4: Behavioral profile of Fkbp52+/- and WT mice (part 1). (A) Sociability test. Time in the zone with 
social target (left panel) (NWT Ctrl = 11, NFkbp52+/- Ctrl = 11, NWT Stress = 11, NFkbp52+/- Stress = 12) and representative 
track plots of Fkbp52+/- and WT mice in the sociability apparatus (right panel). (B) Elevated plus-maze. 
Time spent in the open arms (left panel) and open arm entries (right panel) (NWT Ctrl = 8, NFkbp52+/- Ctrl = 9, 
NWT Stress = 12, NFkbp52+/- Stress = 10). Data are represented as mean + SEM. * significantly different from the 
control condition of the same genotype, p < 0.05. # significantly different from the WT of the same 
condition, p < 0.05. 
 
Research articles 
80 
Open-field test 
The open-field test was used to assess behavioral responses such as locomotor activity and 
explorative behavior. The 15 min test interval was subdivided in three segments of 5 min 
each. For the total distance traveled, ANOVA with repeated measures revealed a time effect 
(F2, 47 = 109.260, p < 0.0001) and a time x condition interaction (F2, 47 = 12.176, p < 0.0001). 
Post hoc analysis with contrast tests showed a significant decrease of locomotor activity in 
chronically stressed WT mice compared to WT controls in segment 3. A significant decrease 
of locomotor activity in stressed Fkbp52+/- mice compared to Fkbp52+/- controls could be 
shown in all 3 segments (tests with contrasts in ANOVA, p < 0.05) (Fig. 5A, left panel). 
Regarding the time spent immobile, ANOVA with repeated measures demonstrated a time 
effect (F2, 47 = 30.309, p < 0.0001) and a condition effect (F1, 47 = 22.987, p < 0.0001). Chronic 
stress resulted in a significantly higher immobility in both groups compared to their 
respective controls of the same genotype in all three segments (tests with contrasts in 
ANOVA, p < 0.05) (Fig. 5A, middle panel). 
For time in the inner zone, ANOVA with repeated measures indicated a condition effect (F1, 
47 = 13,429, p < 0.001). Chronically stressed Fkbp52+/- mice spent significantly less time in 
the inner zone compared to Fkbp52+/- controls in all three segments. This effect did not 
reach significance in WT animals (Fig. 5A, right panel). 
Forced swim test 
We investigated the animals’ stress coping behavior using the FST. For the time spent 
struggling, ANOVA identified a genotype x condition interaction (F1, 46 = 3.742, p = 0.06). 
Chronic stress led to a significant decrease in time struggling in WT mice compared to WT 
control animals (tests with contrasts in ANOVA, p < 0.05). This effect was not observed in 
Fkbp52+/- mice (Fig. 5B, left panel). 
Concerning the parameter time floating, ANOVA showed a condition effect (F1, 46 = 22.844, 
p < 0.0001). Chronically stressed WT and Fkbp52+/- mice spent significantly more time 
floating compared to their respective control group of the same genotype (tests with 
contrasts in ANOVA, p < 0.05) (Fig. 5B, middle panel). 
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For the latency to 1st floating, ANOVA found a significant genotype x condition interaction 
(F1, 46 = 8.559, p < 0.01). Chronic stress lead to a significant decrease in the latency to 1st 
floating in WT mice compared to WT control animals. This effect was not seen in Fkbp52+/- 
mice. In contrast, chronically stressed Fkbp52+/- animals had a significantly increased latency 
to 1st floating compared to WT mice of the same condition (tests with contrasts in ANOVA, 
p < 0.05) (Fig. 5B, right panel). 
 
Figure 5: Behavioral profile of Fkbp52+/- and WT mice (part 2). (A) Open field. Total distance traveled 
(left panel), time immobile (middle panel) and time in the inner zone (right panel) (NWT Ctrl = 11, NFkbp52+/- 
Ctrl = 12, NWT Stress = 12, NFkbp52+/- Stress = 12). (B) FST. Time spent struggling (left panel), time spent floating 
(middle panel) and latency to 1st floating (right panel) (NWT Ctrl = 11, NFkbp52+/- Ctrl = 12, NWT Stress = 12, NFkbp52+/- 
Stress = 11). Data are represented as mean ± SEM. α significant condition effect in WT animals, p < 0.05; + 
significant condition effect in Fkbp52+/- mice, p < 0.05; * significantly different from the control condition 
of the same genotype, p < 0.05. # significantly different from the WT of the same condition, p < 0.05. 
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Gene expression analysis 
We conducted in-situ hybridization in order to investigate expression patterns in the 
hippocampus and PVN of genes involved in the major regulation and mediation of the HPA 
axis. Expression of CRH mRNA in the PVN was significantly increased in chronically stressed 
WT mice compared to their respective controls of the same genotype (ANOVA condition 
effect: F1, 44 = 6.330, p < 0.05). This effect was not observed in Fkbp52+/- mice (Fig. 6A). 
A significant effect in hippocampal MR mRNA expression was shown by ANOVA. In the CA1, 
CA3 and the dentate gyrus (DG) region, condition effects were found (CA1: F1, 44 = 6.637; 
CA3: F1, 44 = 9.437; DG: F1, 44 = 4.865, p < 0.05). In Fkbp52+/- mice, chronic stress led to 
significantly higher MR mRNA expression levels in all three hippocampal regions compared 
to Fkbp52+/- control animals (tests with contrasts in ANOVA, p < 0.05). This effect was not 
observed in WT mice (Fig. 6B). No significant condition or genotype changes in mRNA 
expression could be shown for GR, AR and FKBP51 in the hippocampus and GR, AVP and 
FKBP51 in the PVN (data not shown). 
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Figure 6: Gene expression in the paraventricular nucleus (PVN) and hippocampus of Fkbp52+/- and WT 
mice. (A) Corticotropin-releasing hormone (CRH) mRNA expression in the PVN (left panel) (NWT Ctrl = 10, 
NFkbp52+/- Ctrl = 11, NWT Stress = 11, NFkbp52+/- Stress = 12). Representative in situ hybridization images in the PVN 
(right panel). (B) Mineralocorticoid receptor (MR) mRNA expression in the hippocampus (CA1, CA3 and 
dentate gyrus (DG)) (NWT Ctrl = 11, NFkbp52+/- Ctrl = 11, NWT Stress = 10, NFkbp52+/- Stress = 12). Representative in situ 
hybridization images in the hippocampus (lower right panel). Data are represented as mean + SEM. * 
significantly different from the control condition of the same genotype, p < 0.05. 
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Discussion 
By characterizing Fkbp52+/- mice generated in the Cox/Smith lab, we were able to provide 
evidence that the co-chaperone FKBP52 significantly alters the animal’s phenotype on 
behavioral and neuroendocrine levels under basal and chronic stress conditions. 
Intriguingly, these animals show a higher stress vulnerability in some parameters, while at 
the same time being less affected by the stress procedure in other parameters tested. 
Loss of one functional Fkbp52 led to a significant decrease of Fkbp52 expression. 
Independent of genotype, CSDS led to robust physiological changes, such as higher adrenal 
gland and reduced thymus weights, implicating an increased HPA axis activity which has 
repeatedly been reported before (Karst and Joëls, 2003; Keeney et al., 2006; Schmidt et al., 
2007; Wagner et al., 2011; Wang et al., 2011a; Chapter 1). Moreover, exposure to chronic 
stress caused a reduction in fur quality for both genotypes, which can be ascribed to an 
impaired grooming behavior, and has been associated with a depression-like phenotype 
(Ducottet et al., 2003; Mineur et al., 2003; Cryan and Holmes, 2005; Denmark et al., 2010). 
Alterations in body weight following chronic stress are frequently documented, but 
nonetheless a rather inconsistent finding. The outcome mainly depends on the type of 
stressor, its intensity, diet, as well as the paradigm duration, mouse strain and social status 
of the animal (Bartolomucci et al., 2009; Finger et al., 2011). In line with previous reports 
concerning body weight change in this CSDS paradigm, stressed mice gained more body 
weight than controls (Wagner et al., 2011; Wang et al., 2011a; Chapter 1). Taken together, 
the exposure to CSDS led to a number of profound physiological alterations, independent of 
genotype. 
One of the most robust characteristics found in many depressed patients is an HPA axis 
overdrive (Holsboer, 2000). In mice, HPA axis hyperactivity caused by chronic stress has 
repeatedly been shown to increase circulating corticosterone (Bartolomucci et al., 2005; 
Keeney et al., 2006; Schmidt et al., 2010a; Schmidt et al., 2010b; Komatsu et al., 2011). 
Therefore, we assessed plasma corticosterone levels under control and chronic stress 
conditions. Basal corticosterone levels in control mice did not differ between genotypes, 
which has been reported previously (Warrier et al., 2010). And while CSDS led to increased 
basal circulating GCs in WT animals, Fkbp52+/- mice showed an attenuated response to 
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chronic stress, reflected by a lack of increased basal corticosterone levels. This finding is 
counterintuitive considering the reported glucocorticoid insensitivity in the Fkbp52 
knockout mouse line generated by Yang et al., 2006. However, the increased hippocampal 
MR mRNA expression levels observed in chronically stressed Fkbp52+/- mice may account for 
a potential explanation for the blunted basal corticosterone levels to CSDS, due to a subtle 
shift in MR/GR balance towards increased MR signaling in chronically stressed Fkbp52+/- 
mice. This might be further supported by the fact that forebrain specific MR overexpressing 
female mice exhibit a moderate suppression of corticosterone response to restraint stress 
(Rozeboom et al., 2007), while conventional MR knockout mice show elevated plasma 
corticosterone levels (Gass et al., 2001). 
HPA axis reactivity to an acute challenge was increased after CSDS, independent of 
genotype, which is in line with previous reports (Akana et al., 1992; Koolhaas et al., 1997; 
Bhatnagar and Dallman, 1998). Interestingly, even under control conditions Fkbp52+/- mice 
showed an increased HPA axis response to the acute stress challenge and a blunted recovery 
under chronic stress conditions. In contrast to the data under basal conditions, these 
findings are in line with our initial hypothesis of a higher vulnerability of Fkbp52+/- mice to 
chronic stress. Given the fact that FKBP52 has been shown to be a positive regulator of GR 
function in vitro (Wochnik et al., 2005) and the reported increased susceptibility to high fat 
diet-induced glucocorticoid resistance in Fkbp52+/- mice (Warrier et al., 2010), our findings 
of an increased HPA axis response and an attenuated negative feedback in Fkbp52+/- mice 
following an acute stress challenge might be most likely due to reduced GR sensitivity.  
Numerous acute and chronic stressors have previously been shown to alter the expression 
of central HPA axis related genes, such as CRH, AVP, FKBP51, MR and GR in the PVN and/or 
the hippocampus (Makino et al., 1995; Albeck et al., 1997; Herman and Spencer, 1998; 
Bartolomucci et al., 2003; Figueiredo et al., 2003; Keeney et al., 2006; Schmidt et al., 2007; 
Lachize et al., 2009; Scharf et al., 2011). In line with these reports, CSDS resulted in increased 
CRH mRNA expression in the PVN of WT mice. Interestingly, this was not observed in 
Fkbp52+/- mice. However, the reduced corticosterone levels and the increased hippocampal 
MR mRNA expression in chronically stressed Fkbp52+/- mice, might explain why CRH mRNA 
levels in the PVN were not increased as observed in WT mice following CSDS. The lack of 
AVP, GR and FKBP51 regulation may be ascribed to the nature, duration and intensity of the 
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applied stressor. In addition, the absence of genotype alterations in the analyzed genes may 
be due to compensatory effects. 
It has repeatedly been shown that chronic stress can have a major impact on the behavioral 
phenotype of animals, often resulting in diminished locomotor activity and higher anxiety-
related behavior (Choleris et al., 2001; Berton et al., 2006; Schmidt et al., 2007; Wagner et 
al., 2011; Chapter 1). Similarly, in the current study CSDS led to lower general locomotor 
activity in the OF and increased anxiety-related behavior in the EPM, independent of 
genotype. Interestingly, Fkbp52+/- mice displayed this stress-related phenotype already 
under non-stressed conditions in the EPM, which could possibly be due to reduced 
glucocorticoid sensitivity. In addition, only chronically stressed Fkbp52+/- mice developed a 
deficit in social behavior, resulting in a reduced social preference for an unfamiliar juvenile 
conspecific in the sociability test. A reduction of social preference is often reminiscent of 
core endophenotypes of depression (Nestler and Hyman, 2010; Dedic et al., 2011). Thus, in 
these behavioral parameters Fkbp52+/- mice seem to display a more stress sensitive 
phenotype. On the other hand, chronic stress has also been shown to lower the animals’ 
active stress-coping behavior in the forced swim test (Karolewicz and Paul, 2001; Zhang et 
al., 2012). While we detected this effect in WT animals, this was not observed in Fkbp52+/- 
mice. This finding is of high importance, as it not only suggests a stress-resilience in this test, 
but also mimics the phenotype of Fkbp51 deficient mice in the FST (O'Leary, III et al., 2011; 
Touma et al., 2011). We did not observe a reduction of FKBP51 mRNA in Fkbp52+/- mice in 
the hippocampus and PVN. However, the deletion of FKBP52 may have resulted in a down 
regulation of hormone-induced FKBP51 expression in other brain regions or peripheral 
tissue (Yong et al., 2007), since it has been shown that FKBP51, but not FKBP52, is hormone-
regulated. In addition, the lack of a reduced active stress-coping behavior in Fkbp52+/- mice 
might be related to the observed decrease of basal corticosterone levels and the increased 
MR mRNA expression in chronically stressed Fkbp52+/- mice. However, the causal 
relationship between stress system activity, GR sensitivity and stress-coping behavior is still 
unclear and awaits further investigation. 
The interplay of FKBP52 with other steroid receptors (Gallo et al., 2007; Schülke et al., 2010; 
Sanchez, 2011; Storer et al., 2011) does not allow for a simple explanation of our results. 
The observed effects may not exclusively be due to increased glucocorticoid insensitivity, 
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but could at least be partially the result of a combination of effects on various other receptor 
types. In addition, we used mice with a heterozygous ablation of Fkbp52, allowing for 
counter-regulatory effects. Nevertheless, our approach is more closely related to the natural 
situation of variations in Fkbp52 expression. Furthermore, using a spatial and temporal 
restriction of Fkbp52 expression instead of conventional knockouts may be a useful tool to 
provide further insight of the utility of FKBP52 as a therapeutic target. To our knowledge 
this data demonstrates for the first time the importance of FKBP52 as a mediator of the 
stress response and its close involvement in GR signaling in the context of stress related-
disorders in an in vivo model. 
Taken together, we demonstrate that Fkbp52+/- mice display symptoms of increased stress 
sensitivity in a subset of behavioral and neuroendocrine parameters, probably due to 
reduced GR sensitivity, and stress resilience in another subset of these parameters. This 
seeming discrepancy is in line with previous work showing that FKBP51 can be down-
regulated in certain tissues of Fkbp52+/- mice (Yong et al., 2007), which may then partially 
mimic the phenotype of 51KO mice. Therefore, the observed effect in Fkbp52+/- mice may 
have been a complex mixture, resulting from the deletion of FKBP52 and a potential down-
regulation of FKBP51, especially under conditions where GR activity was enhanced. In 
addition, FKBP52 is not involved in all branches of GR signalling, but instead acts in gene-
specific manner to regulate GR transcriptional activation (Wolf et al., 2009). Therefore, our 
findings clearly underline the potential of FKBP52 for the treatment of diseases that are 
involved in functional steroid receptor signaling pathways. 
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Abstract 
Aversive life events represent one of the main risk factors for the development of numerous 
psychiatric diseases, but the interplay between environmental factors and genetic 
predispositions is still poorly understood. One major finding in many depressed patients is 
an impaired regulation of the hypothalamic-pituitary-adrenal (HPA) axis. The negative 
feedback loop of the HPA axis is mediated via the glucocorticoid receptor (GR) and the 
mineralocorticoid receptor, whose ligand binding sensitivity has been shown to be 
decreased by the FK506-binding protein 51 (FKBP51) . In humans, polymorphisms in the 
FKBP5 gene have been linked to psychiatric diseases. Recently, we could show that FKBP51 
knockout mice (51KO mice) are less vulnerable to three weeks of chronic social defeat stress 
(CSDS). In a follow up study, we now aimed to investigate the ability of 51KO mice to recover 
from CSDS and to examine the effects of chronic paroxetine treatment during the 3-week 
recovery period. Mice were subsequently analyzed with regard to physiological, 
neuroendocrine and behavioral alterations. Our results show an enhanced recovery in 51KO 
mice with respect to physiological, neuroendocrine and behavioral parameters compared 
to wild-type animals. 51KO mice demonstrated lower adrenal weights and corticosterone 
levels, as well as no alteration in social behavior as observed in stressed WT mice in the 
social avoidance test. These results suggest an enhanced negative glucocorticoid feedback 
within the HPA axis of 51KO mice, likely modulated by an increased sensitivity of the GR. 
Moreover, chronic paroxetine treatment did not alter the behavioral phenotype of 51KO 
mice as observed in WT animals in the forced swim test and the social avoidance test. These 
results are in line with clinical studies, showing that patients with increased FKBP51 protein 
levels in lymphocytes, experience increased numbers of depressive episodes, but also 
respond faster to antidepressants.  
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Introduction 
Psychiatric disorders, such as major depression (MD) and post-traumatic stress disorder 
(PTSD) are a significant disease burden worldwide, but the underlying molecular 
mechanisms are still poorly understood (Tennant, 2001; Krishnan and Nestler, 2008; Nestler 
and Hyman, 2010). One of the most robust characteristics in many depressed patients is an 
altered glucocorticoid receptor (GR) signaling, which often leads to a disturbed negative 
feedback loop of the hypothalamic-pituitary-adrenal (HPA) axis and thus to partial 
glucocorticoid resistance (Holsboer, 2000; Pariante and Miller, 2001). In recent years, 
genome-wide association studies identified several HPA axis related genes that are 
contributing to the development of psychiatric diseases (Engineer et al., 2013; Rogers et al., 
2013; Guillaume et al., 2013). 
One interesting candidate gene is the co-chaperone FK506 binding protein 51 (FKBP51), 
which has been shown to alter GR sensitivity. When it is bound to GR via hsp90, the 
receptors affinity for cortisol (in humans), or corticosterone (in rodents), is decreased (Riggs 
et al., 2003). Upon hormone binding, FKB51 is replaced by its close homologue and 
functional opponent FKBP52, which in turn enhances the receptor’s translocation to the 
nucleus and subsequent DNA binding (Davies et al., 2002; Wochnik et al., 2005; Binder, 
2009). Single nucleotide polymorphisms in the FKBP51 gene have repeatedly been 
associated with suicidal behavior, bipolar disorder, MD and PTSD (Binder et al., 2008; Brent 
et al., 2010; Horstmann et al., 2010; Lavebratt et al., 2010; Pérez-Ortiz et al., 2012; Klengel 
et al., 2013). Interestingly, risk allele carriers of FKBP51 have elevated FKBP51 protein levels 
in lymphocytes, an increased recurrence of depressive episodes, but also an enhanced 
selective serotonin reuptake inhibitor (SSRI) treatment response (Binder et al., 2004; 
Lekman et al., 2008; Laje et al., 2009; Zou et al., 2010). 
In addition to the genetic contribution to psychiatric disorders, the environment plays a 
significant role in the development of mood disorders. It is generally accepted, that trauma 
and chronic stress represent key risk factors that are able to trigger (in interaction with a 
genetic predisposition and previous life history) the development of psychiatric diseases 
(McEwen, 2004; de Kloet et al., 2005a; Chrousos, 2009). 
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To further elucidate the complex nature of these disorders, mouse models and stress 
paradigms have proven extremely useful not only regarding the validation of 
neurobiological underpinnings, but also with respect to the identification and improvement 
of therapeutic substances (Nestler and Hyman, 2010). Indeed, we could recently show that 
FKBP51 knockout (51KO) mice are less affected by three weeks of chronic social defeat stress 
(CSDS), especially with regard to neuroendocrine parameters (Chapter 1).  
The genetic link of increased FKBP51 levels, increased numbers of depressive episodes and 
an enhanced antidepressant treatment response in humans, made us question whether we 
would see similar results in the FKBP51 knockout mouse line. We hypothesised that mice 
lacking the FKBP51 gene may show an enhanced recovery from the long lasting effects of 
CSDS and may be less responsive to antidepressant treatment. We therefore analyzed the 
ability of 51KO mice and wild-type littermates to recover from three weeks of CSDS and the 
effects of chronic paroxetine treatment during a 3-week recovery period, thereby closely 
mimicking the clinical treatment situation. 
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Materials and Methods 
Animals 
The Fkbp51 knockout (51KO) mouse line was previously generated (Tranguch et al., 2005) 
and fully backcrossed to C57/Bl6. Genotypes were verified by PCR of tail DNA. Only male 
mice were used for the experiment, obtained from heterozygous breeding pairs. Animals 
were between 10 and 16 weeks old at the start of the experiment. Mice were held under 
standard conditions (12L: 12D light cycle, lights on at 08:00 am, temperature 23±2°C), were 
singly housed and acclimated to the room for one week before the beginning of the 
experiments. Male CD1 mice (16–18 weeks of age) served as resident mice, which were held 
under the conditions described above. They were allowed to habituate to the social defeat 
cage for 2 weeks before the experiment. Food (Altromin 1314, Altromin GmbH, Germany) 
and tap water were available ad libitum.  
All experiments were carried out in the animal facilities of the Max Planck Institute of 
Psychiatry in Munich, Germany. The experiments were carried out in accordance with the 
European Communities' Council Directive 86/609/EEC. All efforts were made to minimize 
animal suffering during the experiments. The protocols were approved by the committee 
for the Care and Use of Laboratory animals of the Government of Upper Bavaria, Germany. 
 
Experimental design  
We analyzed the ability of 51KO mice to recover from CSDS and the effects of chronic 
paroxetine treatment during a 3-week recovery period. Initially, wild-type and 51KO mice 
were split into 2 x 2 groups (control WT, control 51KO, defeat WT, defeat 51KO) and 
subjected to the chronic stress procedure described below. After cessation of the stressor, 
groups were subdivided into vehicle-treated and paroxetine-treated animals, resulting in 8 
groups (n = 7-13 per group). The treatment phase lasted for three weeks. The behavioral 
tests took place during the last week of the paroxetine treatment.  
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Chronic Stress Procedure and Physiological Parameters 
The CSDS paradigm lasted for 21 days and was conducted as described previously (Wagner 
et al., 2011). Briefly, the experimental mice were introduced into the home cage (45 cm x 
25 cm) of a dominant resident mouse and defeated shortly after. When the defeat was 
achieved, the animals were separated by a wire mesh, preventing physical but allowing 
sensory contact for 24 h. Each day, stressed animals were defeated by another unfamiliar, 
dominant resident mouse in order to exclude a repeated encounter throughout the 
experiment. The daily defeat was performed between 1100 and 1600 h; varying starting 
times reduced the predictability of the stressor and therefore minimized a potential 
habituation effect. Experimental mice were always defeated by resident males during the 
entire stress period. Control mice were housed in their home cages during the course of 
experiment. Both stress and control animals were handled daily during the stress procedure; 
body weight for all mice was assessed at the beginning of the experiment, after the cessation 
of the stress period, and on the day of killing. Animals that underwent the stress procedure 
were subsequently single housed in standard cages. 
 
Paroxetine treatment 
Paroxetine (GlaxoSmithKline, Munich, Germany) was administered via drinking water as 
described previously (Wagner et al., 2012). Briefly, the paroxetine solution was diluted in 
tap water to a final concentration of 0.16 mg/ml. With average water consumption of 
5ml/mouse/day, the daily dose of paroxetine was ~20 mg/kg body weight. Fluid intake was 
monitored daily and the variation of fluid intake was found to be <10% over the course of 
experiment. 
 
Behavioral Analysis  
The behavioral tests were carried out between 0830 and 1230 h in the same room in which 
the mice were housed. The testing order was as follows: Open-field (OF), social avoidance 
(SA), forced swim test (FST), and acute stress response. All tests were analyzed using an 
automated videotracking system (Anymaze 4.20, Stoelting, Wood Dale, IL). All animals 
underwent the same testing battery in the same order of tests. To minimize possible 
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carryover effects of the different behavioral tests, the sequence of tests was arranged from 
the least stressful to the most stressful, with a minimum of 24 h between tests (McIlwain et 
al., 2001). 
Open-field test 
The open-field test was performed to investigate locomotion differences. Testing was 
carried out in an empty open-field arena (50 cm x 50 cm x 50 cm) made of gray polyvinyl 
chloride (PVC), which was evenly illuminated with 15 Lux. The low illumination of the open 
field arena was chosen to specifically investigate locomotion behavior and not create an 
aversive center region that may induce anxiety-related behavior. Testing time was 10 min 
and the main parameter of interest was the total distance travelled.  
Social avoidance test 
The social avoidance test was performed as described previously (Golden et al., 2011). 
Briefly, animals were allowed to explore the open field arena for 2.5 min with an empty wire 
mesh cage placed at one side of the apparatus. In a second stage, the animals were 
confronted with an unfamiliar CD1 resident mouse in the wire mesh cage for another 2.5 
min. The ratio between the time in the interaction zone of the no-target trial and the time 
in the interaction zone of the target trial serves as a marker for disturbed social behavior 
associated with depressive disorders. Animals that did not explore the interaction zone at 
all were excluded from the analysis (wt ctrl veh = 1; 51KO ctrl veh = 1; wt ctrl PAR = 2; 51KO 
ctrl PAR = 1; wt stress veh = 1; 51KO stress veh = 1; wt stress PAR = 1). 
Forced swim test 
In the forced swim test, each mouse was put into the a 2 l glass beaker (diameter: 13 cm, 
height: 24 cm) filled with tap water (21 ± 1 °C) to a height of 15 cm, so that the mouse could 
not touch the bottom with its hind paws or tail. Testing duration was 5 min. Time spent 
immobile (floating) and time spent struggling was scored by an experienced observer, blind 
to treatment or condition of the animals. 
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Acute stress response 
The FST also served as an acute stressor in order to determine the stress response by 
measuring corticosterone plasma concentrations. After the FST, all mice were towel-dried 
and placed into their home cage to recover from the acute stressor. Blood samples were 
taken by tail cut (Fluttert et al., 2000) 30 min (stress response) and 90 min (stress recovery) 
after the onset of the FST. Samples were collected in 1.5 ml EDTA-coated microcentrifuge 
tubes (Kabe Labortechnik, Germany). All blood samples were kept on ice and later 
centrifuged at 8000 rpm at 4 °C for 15 min. Plasma was transferred to new, labeled tubes 
and stored at -20 °C until determination of corticosterone by radioimmunoassay (MP 
Biomedicals Inc; sensitivity 12.5 ng/ml). 
 
Sampling Procedure  
24 hours after the last defeat, blood samples were taken by tail cut as described above, in 
order to assess the plasma corticosterone levels immediately after the chronic stress 
paradigm. 3 weeks after the last defeat, thus following 3 weeks of treatment, all animals 
were killed by decapitation following quick anesthesia by isoflurane at the end of the 
experiment. Basal trunk blood samples were processed as described above. Adrenal and 
thymus glands were removed, dissected from fat, and weighed. 
 
Statistical Analysis 
The data presented are shown as means+SEM, analyzed by the commercially available 
software SPSS 16.0. When two groups were compared, the student’s t-test was applied. For 
four or more group comparisons, 2-way or 3-way analysis of variance (ANOVA) was 
performed. If interaction effects (p < 0.05) were observed Tukey post-hoc tests were 
applied. A nominal level of significance p < 0.05 was accepted.  
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Results 
We aimed to investigate the ability of 51KO mice to recover from CSDS and to examine the 
effects of chronic paroxetine treatment during the 3-week recovery period (Figure 1). 
Figure 1: Time course of the experiment. Treatment with paroxetine commences after the stress 
procedure. Body weight was assessed on day 1, day 22 and day 43. Basal corticosterone was measured 
on day 22 and day 43. The behavioral testing (open field, social avoidance, forced swim test) and the 
stress response test (corticosterone samples 30 min and 90 after the FST) is performed in the last week 
of the treatment phase. 
 
Physiology 
51KO mice were significantly leaner compared to wild-type mice before the start of the 
experiment (T84 = 3.458, p < 0.001) (Figure 2A). After 3 weeks of CSDS, all chronically stressed 
animals demonstrated a significant increase in body weight (2-way ANOVA, condition effect: 
F1,81= 4.865, p < 0.05). Independent of condition, 51KO mice were still significantly leaner 
than wild-type animals (2-way ANOVA, genotype effect: F1,81= 17.794, p < 0.001) (Figure 2B). 
On the day of sacrifice (e. g. day 43, after 3 weeks treatment), we found a main genotype 
effect (3-way ANOVA, F1,66 = 30.177, p < 0.001) and a condition x treatment interaction (3-
way ANOVA, F1,66 = 3.296, p = 0.074) for body weight (Figure 2C). In order to isolate 
genotype-dependent stress and treatment effects, we proceeded to normalize the data to 
either non-stressed controls or vehicle treatment. First, we normalized all stressed groups 
by assessing the difference in body weight compared to their corresponding unstressed 
control of the same genotype and treatment. We found a significant treatment effect (2-
way ANOVA, F1,36 = 5.557, p < 0.05), because stress-induced increase of body weight was 
significantly more pronounced in vehicle treated mice than in paroxetine treated mice 
(Figure 2D). To isolate stress effects as well as genotype-dependent treatment effects, we 
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then normalized all paroxetine treated groups by assessing the difference in body weight 
compared to their corresponding vehicle treated control of the same genotype and 
condition. 2-way ANOVA revealed a significant condition (F1,36 = 6.000, p < 0.05) and 
genotype effect (F1,36 = 4.458, p < 0.05). Paroxetine-induced body weight increase was 
significantly enhanced in mice under basal conditions compared to stressed animals. In 
addition, 51KO mice were significantly less affected by paroxetine-induced body weight 
increase compared to wild-type mice (Figure 2E). For adrenal gland size, 3-Way ANOVA 
revealed a main genotype effect (F1,69 = 51.909, p < 0.001), a main condition effect (F1,69 = 
60.813, p < 0.001), a genotype x condition interaction (F1,69 = 51.909, p < 0.05) and a 
genotype x treatment interaction (F1,69 = 4.838, p < 0.05) (Figure 2F). To analyze simple 
treatment effects and genotype-dependent stress effects, we normalized all stressed groups 
by assessing the difference in adrenal gland weight compared to their corresponding 
unstressed control of the same genotype and treatment. Stress-induced increase of adrenal 
gland weight was significantly less pronounced in paroxetine-treated mice compared to 
vehicle treated animals (2-way ANOVA, F1, 38 = 4.407, p < 0.05). In addition, 51KO mice were 
significantly less affected by stress-induced adrenal gland enlargement compared to wild-
type mice (2-way ANOVA, F1, 38 = 12.609, p < 0.001) (Figure 2G). To isolate stress effects and 
genotype-dependent treatment effects, we normalized all paroxetine treated groups by 
assessing the difference in adrenal weight compared to their corresponding vehicle treated 
control of the same genotype and condition. 2-way ANOVA revealed a condition effect (F1, 
36 = 8.620, p < 0.01) and a genotype effect (F1, 36 = 22.198, p < 0.001) (Figure 2H). Paroxetine 
treatment induced adrenal gland enlargement in wild-type mice under control conditions, 
but not under defeat conditions (Figure 2H). The lack of paroxetine-induced enlargement of 
the adrenals in defeated wild-type mice, might however be a ceiling effect, due to the strong 
stress-induced adrenal gland increase (Figure 2G). In contrast to the wild-types, adrenal 
gland weight of 51KO mice under control conditions was not affected by paroxetine. 
However, under stress conditions paroxetine treatment led to a decrease in adrenal gland 
size (Figure 2H). For the thymus weight, stressed animals showed significantly reduced 
thymus gland size, with 51KO mice having a decreased overall thymus gland weight (3-Way 
ANOVA: main condition effect: F1,70 = 6.546, p < 0.05; main genotype effect: F1,70 = 63.415, 
p < 0.001) (Figure 2I). We did not find any genotype-dependent treatment or stress effects 
(data not shown). 
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Figure 2: FKBP51 shapes the physiological effects of stress and paroxetine. Whenever we found an 
interaction effect (p < 0.1) in the 3-way ANOVA, we additionally isolated genotype-dependent stress and 
treatment effects, by normalizing the data to either non-stressed controls or vehicle treatment. A, Body 
weight was significantly reduced in 51KO mice before the start of the first defeat. B, CSDS induced a 
significant increase of body weight. 51KO showed still significantly reduced body weight, independent of 
condition. C-E, Stress-induced body weight increase was still present after 3 weeks of recovery. 
Paroxetine-induced increase of body weight was most pronounced under control conditions. 51KO mice 
were less affected by paroxetine-induced body weight increase. F-H, 51KO mice showed overall reduced 
adrenal gland size compared to wild-type mice. Adrenal gland weight was significantly increased in 
stressed animals. The stress effect was less pronounced in 51KO mice compared to wild-type animals. 
Paroxetine led to adrenal gland enlargement in WT and reduced size in 51KO mice. I, Thymus size was 
significantly reduced following CSDS. 51KO mice demonstrated significantly lower thymus weight than 
wild-type mice. # main genotype effect, * main condition effect, $ main treatment effect, a genotype x 
treatment interaction, b genotype x condition interaction, c condition x treatment interaction; for #, *, $, 
a, b: p < 0.05; for c p < 0.1; data are expressed as mean + SEM. 
 
Neuroendocrinology 
Directly after the cessation of the stressor on day 22, 2-way ANOVA revealed a condition 
effect (F1,76 = 16.226, p < 0.001), a genotype effect (F1,76 = 6.465, p < 0.05) and a genotype x 
condition interaction (F1,76 = 4.519, p < 0.05) for basal corticosterone levels. Tukey post-hoc 
tests showed that corticosterone levels were significantly increased in stressed wild-type 
mice compared to control wild-type mice (p < 0.05). This stress effect was not observed in 
51KO, instead they showed significantly reduced corticosterone levels compared wild-type 
mice under defeat conditions (p < 0.05) (Figure 3A). On day 43, 51KO mice showed an overall 
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reduction of basal corticosterone levels compared to wild-type animals (3-way ANOVA: main 
genotype effect: F1,68 = 18.256, p < 0.001). 3-way ANOVA also revealed a genotype x 
treatment interaction (F1,68 = 2.991, p = 0.088) (Figure 3B). To isolate simple treatment 
effects and genotype-dependent stress effects, we normalized all stressed groups by 
assessing the difference in corticosterone compared to their corresponding unstressed 
control of the same genotype and treatment. 2-way ANOVA only revealed a significant 
genotype effect (F1, 35 = 7.407, p < 0.01); corticosterone levels in 51KO were not affected by 
the previous stress period as observed in wild-type mice (Figure 3C). To isolate stress effects 
and genotype-dependent treatment effects, we normalized all paroxetine treated groups by 
assessing the difference in corticosterone compared to their corresponding vehicle treated 
control of the same genotype and condition. Paroxetine treatment reduced corticosterone 
levels especially in 51KO mice, independent of condition (2-way ANOVA, genotype effect, 
F1, 36 = 4.924, p < 0.05) (Figure 3D). In response to a novel acute stressor, lack of FKBP51 
largely decreased the corticosterone response, independent of condition or treatment (3-
Way ANOVA: main genotype effect: F1,71 = 85.594, p < 0.001) (Figure 3E). At 90 min after the 
acute stressor, all defeated animals recovered faster from the acute challenge (3-Way 
ANOVA: main condition effect: F1,73 = 10.703, p < 0.01). In addition, 51KO mice 
demonstrated significantly lower corticosterone recovery levels than wild-type animals (3-
Way ANOVA: genotype effect: F1,73 = 67.998, p < 0.001) (Figure 3F). 
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Figure 3: FKBP51 shapes the neuroendocrine effects of stress. Whenever we found an interaction effect 
(p < 0.1) in the 3-way ANOVA, we additionally isolated genotype-dependent stress and treatment effects, 
by normalizing the data to either non-stressed controls or vehicle treatment. A, CSDS resulted in 
significantly increased basal corticosterone levels in wild-type, but not in 51KO mice. B, Basal 
corticosterone levels assessed three weeks after the stressor were significantly lower in 51KO mice. C, 
Basal corticosterone levels of 51KO mice were less affected by the long lasting effects of CSDS. D, 
Paroxetine decreased basal corticosterone especially in 51KO mice. E and F, Circulating corticosterone 
was significantly decreased in 51KO mice in response to an acute stressor as well as after a 90 min 
recovery period. # main genotype effect, a genotype x treatment interaction, b genotype x condition 
interaction, § Tukey post-hoc; for #, b, §: p<0.05; for a, p < 0.1; data are expressed as mean + SEM.  
 
Behavior 
In the third week of the treatment phase, general locomotion in the open field did not differ 
between genotype, condition or treatment groups (Figure 4A). In the social avoidance test, 
3-Way ANOVA revealed a main treatment effect (F1,66 = 6.084, p < 0.05), a genotype x 
condition interaction (F1,66 = 4.271, p < 0.05) and a genotype x treatment interaction (F1,66 = 
3.221, p = 0.077) (Figure 4B). To isolate treatment effects and genotype-dependent stress 
effects, we normalized all stressed groups by assessing the difference in the social 
interaction ratio compared to their corresponding unstressed control of the same genotype 
and treatment. We found that CSDS significantly reduced social behavior in wild-type, but 
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not in 51KO mice (2-way ANOVA, F1,33 = 10.677, p < 0.01) (Figure 4C). To isolate stress effects 
and genotype-dependent treatment effects, we normalized all paroxetine treated groups by 
assessing the difference in the social interaction ratio compared to their corresponding 
vehicle treated control of the same genotype and condition. Paroxetine significantly 
enhanced social behavior in wild-type, but not in 51KO mice, both in CSDS-exposed and 
control animals (2-way ANOVA, F1,31 = 5.663 , p< 0.05) (Figure 4D). In the forced swim test, 
we observed a genotype x treatment interaction for the parameters struggling and floating 
(3-Way ANOVA; struggling: F1,72 = 3.777, p = 0.056; floating: F1,72 = 4.784, p < 0.05) (Figure 
4E and F). To isolate stress effects and genotype-dependent treatment effects, we 
normalized all paroxetine treated groups by assessing the difference in struggling and 
floating compared to their corresponding vehicle treated control of the same genotype and 
condition. In both parameters, 51KO mice were significantly less affected by paroxetine 
treatment compared to wild-type mice, independent of condition (2-way ANOVA, genotype 
effect, struggling: F1,35 = 5.105, p < 0.05, floating: F1,35 = 11.740, p < 0.01) (Figure 4G and H). 
The parameter swimming did not differ between genotype, condition or treatment groups 
(data not shown). 
Figure 4: FKBP51 shapes the behavioral effects of stress and paroxetine. Whenever we found an 
interaction effect (p < 0.1) in the 3-way ANOVA, we additionally isolated genotype-dependent stress and 
treatment effects, by normalizing the data to either non-stressed controls or vehicle treatment. A, 
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General locomotion in the open field did not differ, independent of genotype, condition or treatment of 
the mice. B - D, Stressed 51KO mice demonstrated no alteration in social behavior, as observed in stressed 
WT mice in the social avoidance test. Paroxetine treatment could enhance social behavior in wild-type, 
but not in 51KO mice. E-H, Paroxetine treatment significantly increased the time struggling and decreased 
the time floating of wild-type mice in the forced swim test. 51KO mice were significantly less affected by 
paroxetine-induced FST behavior. # main genotype effect, $ main treatment effect, a genotype x 
treatment interaction, b genotype x condition interaction; for #, $: p<0.05; for a, b: p < 0.1; data are 
expressed as mean + SEM.  
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Discussion 
In this study, we show that FKBP51 critically impacts the long lasting effects of chronic stress 
as well as paroxetine responsiveness in mice. CSDS resulted in robust physiological, 
neuroendocrine and behavioral alterations in wild-type mice that were still detectable after 
a 3 weeks recovery period. These stress effects included increased body weight and adrenal 
gland size, as well as increased social withdrawal. Interestingly, these long lasting alterations 
were less pronounced in 51KO mice. Treatment with the commonly used SSRI paroxetine 
could ameliorate the stress-induced phenotype in wild-type mice, especially with regard to 
social behavior. Moreover, chronic paroxetine treatment evoked substantial changes in 
physiology and forced swim test behavior even under control conditions. However, 51KO 
mice were less responsive to paroxetine treatment with regard to physiological and 
behavioral parameters, independent of condition. 
In order to confirm the stress effects of the paradigm, we assessed a couple of physiological 
and neuroendocrine parameters immediately after the cessation of the stressor. CSDS 
resulted in significantly increased body weight at day 22, which has previously been 
reported for this stress paradigm (Wagner et al., 2011; Chapter 1 and 3). In addition, 
elevated circulating glucocorticoids are a robust indicator of chronic stress and an impaired 
negative feedback regulation of the HPA axis. Thus, we measured basal corticosterone 24 
hrs after the last defeat. In line with previous reports, CSDS evoked significantly elevated 
corticosterone levels in wild-type mice compared to control mice of the same genotype, 
confirming the effectiveness of stress paradigm (Wagner et al., 2011; Wagner et al., 2012; 
Chapter 3). As previously shown, we also detected significantly lower corticosterone levels 
in 51KO mice compared to wild-type mice under CSDS conditions (Chapter 1). 
We were especially interested in the long lasting effects of chronic stress and the influences 
of a subsequent paroxetine treatment. Stress-induced physiological alterations were still 
detectable after the three weeks recovery period especially in WT mice. Body weight at day 
43 was still increased in stressed mice compared to controls in vehicle-treated groups. 
Paroxetine treatment led to significantly increased body weight in wild-type mice, especially 
under control conditions, which is in line with previous findings (Wagner et al., 2012). 
Interestingly, 51KO mice were not affected by the paroxetine-induced body weight gain. 
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Adrenal glands were enlarged in all groups of stressed animals, implicating an increased HPA 
axis activity, which has repeatedly been reported before (Karst and Joëls, 2003; Keeney et 
al., 2006; Wang et al., 2011a; Wagner et al., 2012). However, the stress-induced adrenal 
gland enlargement was significantly lower in 51KO mice than in wild-type animals. This 
points to a less vulnerable phenotype of 51KO mice, which is most-likely meditated by a 
reduced HPA axis activity and an improved negative feedback regulation, due to an 
increased GR sensitivity (Wochnik et al., 2005; Tatro et al., 2009b; Chapter 1). This is in line 
with our previous report that 51KO mice were already less affected by the immediate effects 
of CSDS, reflected in a stress-resistant HPA system (Chapter 1). Interestingly, SSRI treatment 
shaped adrenal gland size in an opposing manner in both genotypes. While paroxetine 
increased adrenal gland weight in wild-type mice, it led to a decrease in 51KO mice, 
highlighting the impact of FKBP51 on paroxetine actions. Thymus weight was significantly 
decreased in 51KO mice compared to wild-type animals, independent of condition or 
treatment, which is in line with previous findings of this mouse line, possibly mediated by 
an enhanced GR sensitivity (Chapter 1). 
Basal corticosterone on day 43, as well as response and recovery levels after the FST, were 
mainly shaped by FKBP51, independent of condition or treatment. 51KO always 
demonstrated significantly lower corticosterone values compared to wild-types of the same 
condition and treatment group. This is in line with previous reports, implicating FKBP51 as 
regulator of neuroendocrine stress physiology (Touma et al., 2011; Albu et al., 2013; Chapter 
1).  
Disturbed exploratory and social behavior are phenotypes that have repeatedly been 
observed during or immediately after the CSDS period (Berton et al., 2006; Golden et al., 
2011; Wagner et al., 2011; Chapter 3). Regarding the long-lasting effects of our CSDS model, 
general locomotion, as assessed in the open field test, returned to basal levels, independent 
of genotype or treatment. However, even after the three weeks recovery period, social 
behavior was still severely affected, as stressed, vehicle-treated wild-type mice showed 
significantly increased social withdrawal compared to vehicle-treated WTs under control 
condition. This long-lasting stress effect was not observed in 51KO mice, which may 
implicate an enhanced recovery from CSDS, especially because the behavioral phenotype of 
wild-type and 51KO mice was equally affected by the immediate effects of CSDS in our 
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previous study (Chapter 1). Paroxetine treatment reversed social avoidance behavior in 
stressed wild-type mice and further enhanced their social activity under control conditions, 
which is in line with previous findings (Berton et al., 2006). In contrast, 51KO mice did not 
respond to the SSRI treatment with regard to social behavior. Along these lines, paroxetine 
evoked the classical antidepressant effects in the forced swim test of increased activity and 
lower immobility time in wild-type mice (Sillaber et al., 2008; Ghasemi et al., 2009; Wagner 
et al., 2012; Gai et al., 2014), while 51KO mice were significantly less responsive to the 
antidepressant treatment in the FST. 
Intriguingly, our current findings on the one hand further underline the importance of 
FKBP51 in GR-dependent stress physiology, due to the resilient phenotype of 51KO mice. On 
the other hand we demonstrate that antidepressant actions are largely absent in this mouse 
line. Thus, stress resilience and lack of antidepressant response in these mice may point to 
different molecular pathways of FKBP51. Indeed, recent studies identified FKBP51 in various 
cellular processes besides its regulatory function of the GR (Pei et al., 2009; Blair et al., 2013). 
Therefore, it is likely that FKBP51 is also implicated in GR-independent functions, which may 
overlap with antidepressant pathways. 
In summary, we could provide evidence that FKBP51 critically shapes the long lasting effects 
from chronic stress, as well as antidepressant actions. 51KO mice were less affected from 
CSDS after a three weeks recovery period on the physiological, neuroendocrine and 
behavioral level, which is possibly due to an enhanced GR sensitivity. We could previously 
show that 51KO were already less vulnerable to the immediate effects of CSDS. Therefore, 
our current findings are likely the result of a less vulnerable phenotype of 51KO mice 
immediately after the stress period together with an enhanced recovery from CSDS during 
the subsequent three weeks. The other major outcome of this study demonstrated that 
FKBP51 is necessary for the physiological and behavioral effects of the commonly used SSRI 
paroxetine. Our results strikingly mirror findings of human genetic studies, linking FKBP51 
levels to the recurrence of depressive episodes as well as to antidepressant response rate 
(Binder et al., 2004; Lekman et al., 2008; Laje et al., 2009; Zou et al., 2010). Future studies 
are necessary to further investigate and understand the underlying molecular mechanisms. 
In conjunction with previous studies, our findings highlight the important role of FKPB51 in 
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the development of stress-associated psychiatric disorders and its potential as a drug target 
for future treatment options.  
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Abstract  
Background  
FK506 binding protein 51 (FKBP51) is an Hsp90 co-chaperone and regulator of the 
glucocorticoid receptor, and consequently of the stress hormone axis and stress physiology. 
Clinical studies suggested a genetic link between the co-chaperone FKBP51 and 
antidepressant response in mood disorders; however the underlying mechanisms remained 
elusive. 
Methods and Findings  
We first show that antidepressant action on behavior is abolished in FKBP51 KO mice. 
Searching for novel molecular actions of FKBP51 linked to antidepressant effects we found 
that autophagic markers, such as the autophagy initiator Beclin1, were increased following 
antidepressant treatment in brains from wild type but not FKBP51 KO animals. Further 
cellular and biochemical assays revealed that FKBP51 binds to Beclin1, changes decisive 
protein interactions and phosphorylation of Beclin1, and triggers autophagic pathways. In 
addition, we demonstrate that antidepressants enhance the FKBP51-Beclin1 complex 
formation and affect autophagic pathways in dependency of FKBP51. Since autophagic 
pathways have been linked to synaptic function, we also treated hippocampal slices with 
antidepressants and found that they enhanced hippocampal synaptic transmission in wild 
type, but not FKBP51 KO mice. Finally, in human blood cells of healthy subjects, FKBP51 
levels correlate with the potential of antidepressants to induce autophagic pathways. 
Importantly, the clinical antidepressant response of patients with depression (sample size 
n=43) could be predicted by the antidepressant response of autophagic markers in patient-
derived peripheral blood lymphocytes cultivated and treated ex vivo, as well as by the 
lymphocyte expression levels of FKBP51 and Beclin1 at admission. 
Conclusions  
These findings provide the first evidence for the molecular mechanism of FKBP51 in priming 
autophagic pathways; this process is linked to synaptic function and is required for full 
antidepressant potency. These newly dicoverd functions of FKBP51 also provide novel 
predictive markers for treatment outcome, further illustrating their high physiological and 
clinical relevance.  
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Introduction 
Depression is a devastating mental disorder affecting an estimated 350 million people 
worldwide (Kessler et al., 2009). While currently available antidepressants (ADs) show an 
overall favorable benefit/risk balance, less than 50% of patients achieve sustained remission 
following treatment, indicating a large inter-individual variability in treatment efficacy and 
response (Geddes and Miklowitz, 2013). The poor effectiveness of ADs is at least partially 
due to the fact that the mechanism of action of these drugs, which is responsible for their 
clinical potency, is still largely unknown. As a consequence, it is currently also not possible 
to predict treatment success in individual patients, constraining physicians and patients to 
lengthy trial and error procedures with uncertain success. 
FK506 binding protein 51 (FKBP51) is a regulator of the glucocorticoid receptor, and 
consequently of the stress hormone axis and stress physiology (Wochnik et al., 2005; 
Attwood et al., 2011; Touma et al., 2011; Klengel et al., 2013; Chapter 1). Human genetic 
studies suggested a link of FKBP51 to the AD response rate (Binder et al., 2004; Lekman et 
al., 2008; Laje et al., 2009; Zou et al., 2010). Despite the intimate connection of stress 
physiology to pathophysiology and treatment of depression (Holsboer, 2000; de Kloet et al., 
2005a), the mechanistic role of FKBP51 for AD response has not been elucidated.  
Putative convergent molecular pathways addressed by both FKBP51 and ADs might explain 
and substantiate the suggested impact of FKBP51 on AD response; the modulation of these 
pathways by FKBP51 could influence their reactivity to ADs. We analyzed whether these 
pathways involve autophagic events based on reports stating that some ADs alter at least 
the initial processes of autophagy (Rossi et al., 2009; Zschocke et al., 2011). Given that 
FKBP51 can act via the central chaperone Hsp90, which controls several kinases including 
autophagy regulators like Akt and Beclin1 (Taipale et al., 2010), the intracellular autophagic 
events appeared more likely to be co-regulated by FKBP51 than the membrane targets of 
ADs.  
Autophagy is a conserved cellular degradation process ensuring continuous removal of 
damaged macromolecules, and thus, functional integrity of cells and tissues (Mizushima and 
Komatsu, 2011). The predominant form of autophagy involves a step-wise formation of an 
autophagosome engulfing damaged cytosolic proteins or organelles, and subsequent fusion 
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with a lysosome yield to the autolysosome. This process is orchestrated by a series of 
autophagy-related genes (Atg) and is regulated by complex pathways, which are partly 
under control of the kinase mTOR (Nakatogawa et al., 2009). Based on multitude of involved 
factors, autophagy is commonly assessed by the determination of several autophagy 
executers. These include, among others, the initiators Beclin1 and Vps34 (class III 
phosphatidylinositol-3-kinase), Atg12 and lipidation of LC3B-I (yielding LC3B-II) involved in 
autophagosome membrane expansion and vesicle formation, and the association of LC3B-II 
with mature autophagosomes. Very recently, the mTOR-independent regulation of 
autophagy was reported: Akt-dependent phosphorylation of Beclin1 shifts Beclin1’s action 
from autophagy to apoptosis (Wang et al., 2012b). As guardian of cellular homeostasis, 
autophagy has been established as a pivotal process in a range of (patho-) physiological 
conditions including infectious diseases, cancer, diabetes, and more recently 
neurotransmission and neurodegeneration (Levine and Kroemer, 2008; Cai et al., 2010; 
Harris and Rubinsztein, 2012; Welberg, 2012). Indirect evidence has been provided for a 
potential role of autophagy in depression; some ADs change the autophagic flux and the 
expression of autophagy markers (Zschocke et al., 2011; Chen et al., 2012). Moreover, the 
induction of autophagy by the mTOR inhibitor rapamycin was reported to exert AD-like 
effects in mice (Cleary et al., 2008).  
In this study, we examined the FKBP51-dependency of molecular actions of ADs on signaling 
pathways. We revealed a novel function of FKBP51 in directing autophagic processes. 
FKBP51 is required for the behavioral effects of ADs in mice, for the AD effects on autophagic 
pathways in cells and mice, and for the AD effects on synaptic function in brain slices. In 
humans, treatment response in patients could be predicted by the expression of FKBP51 
and Beclin1 in lymphocytes, and in particular by the response of autophagic markers to AD 
treatment of lymphocytes cultivated ex vivo.  
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Methods 
Detailed information on experimental procedures is provided in supplementary Materials 
and Methods. 
 
Animal treatments and behavioral experiments  
The Fkbp51-/- mouse line was previously generated (Touma et al., 2011) and fully 
backcrossed to C57/Bl6. Male mice (age 10-16 weeks) were injected intraperitoneally with 
a single dose of either PAR (10 mg kg-1) or saline vehicle. 45 min later, a subgroup of mice 
(WT vehicle, n=10; Fkbp51-/- vehicle, n=9; WT PAR, n=10; Fkbp51-/- PAR, n = 10; WT) was 
sacrificed. Hippocampus and prefrontal cortex were extracted. Another subgroup (WT 
vehicle, n=8; Fkbp51-/- vehicle, n=8; WT PAR, n=9; Fkbp51-/- PAR, n=7) was subjected to a 
forced swim test (6 min test duration) 45 min after the injection.  
 
Electrophysiology  
Brain slices were obtained from 11-18 week-old male FKBP51+/+ and FKBP51-/- mice. 
Preparation and staining of slices with the voltage-sensitive dye Di-4-ANEPPS as well as VSDI 
and data analysis were performed essentially as described (von Wolff et al., 2011; Refojo et 
al., 2011). Four acquisitions subsequently recorded at intervals of 5 s were averaged. 
Neuronal activity was evoked by square pulse electrical stimuli (200 µs pulse width) 
delivered via a custom-made monopolar tungsten electrode to the Schaffer collateral-
commissural pathway (Stepan et al., 2012). The circular ROI was placed into the CA1 stratum 
radiatum near the stimulation electrode. The ROI also covered a part of the adjacent CA1 
stratum pyramidale (Fig. 3). The intensity of voltage stimulation was adjusted to produce 
FDSs with peak amplitudes of ~30% of the highest attainable value. 
 
Analysis of GFP-LC3 in astrocytes 
2x106 cells were transfected with 2 ng GFP-LC3 expressing plasmid or the respective cloning 
vector using the Amaxa Nucleofactor. Cells were grown for 48 h and analyzed by 
fluorescence microscopy. At least 20 cells were counted. 
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Human samples  
Protein-protein correlations were determined in extracts from PBMCs from 21 healthy male 
subjects (25.8±2.7 yrs). 14 of these subjects received 1.5 mg DEX and protein changes in 
PBMCs were determined 6 h later. FKBP51-dependent AD effects were evaluated in 
cultivated PBMCs from another 20 healthy male subjects (age 34.8±6.9 yrs).  
43 consecutive participants (25 females, 18 males; age: 49.7 ± 14.5 yrs) of the Munich 
Antidepressant Response Signature (MARS) project were selected for protein expression 
analyses and PBMC cultivation and treatment. MARS is an open-label prospective clinical 
study conducted at the hospital of the Max Planck Institute of Psychiatry Munich and 
collaborating hospitals in South Bavaria and Switzerland to evaluate typical depression 
courses under standard antidepressant (AD) treatment (Hennings et al., 2009). Patients 
were diagnosed according to DSM-IV criteria (American Psychiatric Association, 2000). 
Patients suffered from major depression, recurrent depression or from a depressive episode 
within a bipolar disorder (n=6). Depression severity was assessed by using the 21-item 
Hamilton Depression rating scale (HDRS) (Overall and Rhoades, 1982) with an average 
baseline score of 24.3 (SD 5.5), indicating severe depression. Patients received 
antidepressant treatment in a naturalistic study setting (Hennings et al., 2009). AD 
treatment outcome was evaluated as percent change in the HDRS scores between baseline 
and after six weeks of treatment. Fasting venous blood samples for extraction of PBMCs 
were drawn from patients between 8 and 9 a.m. within 5 days after admission.  
 
Ethics statement 
The animal experiments were carried out in accordance with the European Communities' 
Council Directive 2010/63/EU. All efforts were made to minimize animal suffering during the 
experiments; all experiments were based on the 3R principles: reduction, refinement, 
replacement. The protocols were approved by the committee for the Care and Use of 
Laboratory animals of the Government of Upper Bavaria, Germany (license number 55.2-1-
54-2532-48-11). 
Approval for the MARS project was received by the ethics committee in charge (submission 
number 318/00, ethics committee of the Medical Faculty at the Ludwig Maximilians 
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University Munich, Germany), and participants gave oral and written consent before study 
inclusion. 
 
Statistical analysis 
When two groups were compared, the student’s t-test was applied. For three or more group 
comparisons, one-way or two-way analysis of variance (ANOVA) was performed, followed 
by Tukey’s post-hoc test, as appropriate. All ANOVA F and p-values are reported in table S1; 
significant results of the contrast tests are indicated by asterisks in the graphs. Protein-
protein associations were analyzed using Pearson correlations. In the clinical sample, 
associations between human protein expression and antidepressant treatment outcome as 
well as protein-protein interactions were evaluated with Pearson correlations after 
correction for the effects of age and gender (partial correlation). p < 0.05 was considered 
significant. 
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Results 
FKBP51 dependent effects of paroxetine on behavior in FKBP51 knockout mice and 
identification of FKBP51- directed pathways of autophagy. 
To assess whether FKBP51 modulates AD response in mice, we treated Fkbp51+/+ and 
Fkbp51-/- mice with the antidepressant paroxetine (PAR). We employed a well-established 
test for AD action; Fkbp51-/--mice were subjected to the forced swim test to monitor the 
animals’ response to an acute PAR injection (10 mgkg-1). PAR-treated Fkbp51+/+ mice spent 
less time floating (immobility) compared to vehicle-treated Fkbp51+/+ mice, thus exhibiting 
the expected response to ADs. In contrast, the effect of PAR was significantly less 
pronounced in Fkbp51-/- mice (Fig. 1A). Similarly, PAR treatment led to an increase in the 
time spent struggling in Fkbp51+/+ mice. This effect of PAR was significantly attenuated in 
Fkbp51-/- mice (Fig. 1A).  
To evaluate molecular effects of ADs that may depend on FKBP51 and parallel the behavioral 
phenotype, we analyzed autophagy markers in protein extracts from the hippocampus and 
prefrontal cortex after PAR injection (10 mgkg-1). In Fkbp51+/+ mice, PAR treatment 
increased the levels of Beclin1, Atg12, and Vps34, increased the ratio of LC3B-II/I, and 
evoked dephosphorylation of the kinase Akt (phosphorylation at S473 in Akt1 represents 
the activated form, subsequently referred to as “pAktS473”). In contrast, Fkbp51-/- mice 
showed no alterations in protein levels of autophagy markers and pAktS473 in either brain 
region after PAR treatment (Figs. 1B,C, S1).  
The results in FKBP51-/- mice suggest a role of FKBP51 in autophagic events, which we further 
evaluated using biochemical and cell biological methods. Because FKBP51 has been 
reported to interact with Akt (Pei et al., 2009), which in turn regulates Beclin1 (Wang et al., 
2012b), we initially tested whether FKBP51 interacts with Beclin1. FLAG-tagged FKBP51 was 
expressed in HEK cells to assess its interaction with the autophagy initiator Beclin1 by co-
immunoprecipitation. FKBP51 displayed binding to Beclin1 (Fig. 1D), in addition to the 
previously reported interaction with Akt and the phosphatase PHLPP (Pei et al., 2009). 
A direct effect of Akt on Beclin1 has been discovered as an important mechanism blocking 
autophagy (Wang et al., 2012b). Thus, we next tested whether FKBP51 affects the 
interaction between Akt and Beclin1. Increasing the levels of FKBP51 led to higher overall 
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levels of Beclin1 (Figs. 1D, S2) and to higher amounts of Akt co-precipitating with Beclin1 
(normalized to precipitated Beclin1, Figs. 1E, S2A). In addition, FKBP51 lowered the amounts 
of pAktS473 interacting with Beclin1 (Figs. 1E, S2A). Furthermore, FKBP51 increased the levels 
of autophagy promoting dephosphorylated Beclin1 (Figs. 1E, S2B). The overall level of 
pAktT308 (conferring basal activity) was unchanged upon expression of FKBP51, while the 
pAktS473 levels were reduced (Fig. S2B). This is in line with previous findings and has been 
explained by the recruitment of the phosphatase PHLPP to Akt (Pei et al., 2009). Together, 
the findings support the model that FKBP51 acts two-fold on Beclin1: first by increasing the 
overall Beclin1 levels, and second by recruiting the inactive (dephosphorylated by PHLPP) 
form of AktS473 to Beclin1 (cf. Fig. 7).  
To evaluate whether FKBP51’s effects on Beclin1 go along with alterations of other 
autophagy markers, we compared Fkbp51-/- and wild-type (Fkbp51+/+) mouse embryonic 
fibroblasts (MEFs). MEFs lacking FKBP51 displayed reduced levels of Beclin1 and decreased 
levels of two other autophagy proteins, LC3B-II/I and Atg12 (Figs. 1F, S3A). Consistent with 
the reduced levels of pAktS473 observed in HEK cells upon ectopic expression of FKBP51 (Fig. 
S2B), deletion of FKBP51 in MEF cells resulted in higher levels of pAktS473 (Fig. S3A). These 
effects of FKBP51 gene deletion were attenuated by ectopic expression of FKBP51 in Fkbp51-
/--MEFs (Figs. 1F, S3A). Together, the data corroborate a stimulatory role of FKBP51 on 
autophagic pathways.  
Given that FKBP51 acts on a variety of intracellular proteins, we used Akt1/2-/- MEFs to test 
whether FKBP51’s impact on pAktS473 was required for its influence on autophagic markers. 
In wild-type Akt1/2 MEFs, transfection of FKBP51 increased the levels of the autophagy 
markers Beclin1 and LC3B-II/I (Fig. S3B). These effects of FKBP51 were not observed in 
Akt1/2-/--MEFs, but were restored after re-introducing Akt1 and Akt2 into Akt1/2-/--MEFs by 
transient transfection (Fig. S3B). Thus, the impact of FKBP51 on autophagy markers requires 
Akt1 and/or Akt2 (cf. also Fig. 7). 
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Figure 1. FKBP51 is required for the effects of PAR on behavior and directs autophagic pathways. A, 
FKBP51-/- and FKBP51+/+ mice were treated with PAR (10 mgkg-1) or vehicle and subjected to the forced 
swim test (n=7-9 per group). Graphs show the times of immobility and struggling. B, C, FKBP51-/- and 
FKBP51+/+ mice were treated with PAR (10 mgkg-1) or vehicle and sacrificed 45 mins later. Protein levels 
were determined in extracts of the hippocampus and the prefrontal cortex from 9-10 animals in technical 
triplicates. *p<0.05; **p<0.01; ***p<0.001. Statistical parameters in Table S1. D, HEK cells were 
transfected with a FLAG-tagged FKBP51 expressing plasmid and lysed 3 d later. After precipitation of 
protein complexes using a Flag-antibody, (co)precipitated proteins were visualized by Western blotting. 
E, quantification of pBeclin1 and Beclin1-Akt/pAktS473 interaction after Beclin1-immunoprecipitation from 
HEK cells transfected with FKBP51/52 (details in Fig. S2). F, effects of FKBP51 expression in FKBP51+/+-
MEFs, FKBP51-/--MEFs, and FKBP51-/--MEFs transfected with FKBP51 on endogenous Beclin1-, LC3B-II/I-, 
and Atg12-levels. Graphs show the relative mean expression +SEM (n=4). *p<0.05; **p<0.01; 
***p<0.001, see also Fig. S3, Table S1. 
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Cellular effects of ADs on autophagic markers depend on FKBP51 
To determine potential effects of ADs on the FKBP51-directed autophagic events 
characterized above, we tested whether PAR, amitriptyline (AMI), or fluoxetine (FLX) (all at 
10 µM, the concentration that proved sufficient for induction of autophagy markers 
(Zschocke et al., 2011)) impacted on FKBP51 heterocomplexes in HEK cells. Treatment with 
PAR increased the amount of Akt and Beclin1 co-precipitating with FKBP51 (Fig. 2A, S4A). 
Similar effects were observed with AMI, while FLX showed no effect (Fig. S4A).  
Both a decrease and an increase of pAktS473 induced by ADs have been reported to date 
(Jeon et al., 2011; Huang et al., 2013). Treatment of rat primary astrocytes with PAR, AMI, 
or FLX decreased the levels of pAktS473 (Figs. 2B, S4B,C). This AD effect was significantly 
stronger when FKBP51 was transfected into astrocytes.  
The importance of FKBP51 for AD effects on components of the autophagy pathway was 
further evaluated in Fkbp51-/-- and Akt1/2-/--MEFs. PAR, AMI, and FLX reduced pAktS473 in 
Fkbp51+/+-, but not in FKBP51-/--MEFs; ectopic expression of FKBP51 in Fkbp51-/--MEFs 
restored the effect of ADs on pAktS473 (Figs. 2C, S4D,E). The autophagy marker LC3B-II/I was 
elevated upon AD treatment in Fkbp51+/+-MEF cells (Figs. 2D, S4D, S5A), as reported 
previously for astrocytes (Zschocke et al., 2011). This AD effect was blunted in Fkbp51-/--
MEFs, and restored when FKBP51 was ectopically expressed in these cells. In Akt1/2-/--MEFs, 
AD exposure did not induce changes in the ratio of LC3B-II/I (Figs. S5B,C). When Akt1 and 
Akt2 were re-introduced by ectopic expression, the effects of ADs re-emerged.  
The shift of LC3B from cytosolic to autophagosomal compartments is also a major hallmark 
of autophagy. The influence of FKBP51 on the capability of ADs to change the distribution 
of recombinant GFP-LC3B was monitored in primary cortical astrocytes. Ectopically 
expressed FKBP51 enhanced AD-induced clustering of GFP-LC3B (Figs. 2E,F, S5D,E). In the 
absence of ADs, FKBP51 triggered the formation of GFP-LC3B positive puncta to a lesser 
extent. Further, FKBP51 enhanced the ability of ADs to induce conversion from LC3B-I to 
LC3B-II and to elevate Beclin1 and Atg12 levels in astrocytes (Figs. 2G-I, S4B, S5F-H). 
Collectively, these data support the conclusion that the cellular AD effects on autophagy 
pathways depend on FKBP51. 
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Figure 2. FKBP51 enhances cellular effects of ADs. A, the interaction of FKBP51 with Beclin1 and Akt in 
HEK cells in the presence or absence of PAR (10 µM) was analyzed by co-immunoprecipitation. B, primary 
rat cortical astrocytes were transfected with vector-control or FKBP51, treated with PAR (10 µM) for 48 h, 
and the pAktS473/Akt ratio was determined. Bars represent the mean +SEM (n=3). C, D, FKBP51+/+-, 
FKBP51-/--, and FKBP51-/--MEFs transfected with FKBP51 were treated with PAR (10 µM) for 48 h; 
pAktS473/Akt (C) and LC3B-II/I (D) ratios were determined. Bars represent the mean +SEM (n=3). Protein 
levels in untreated FKBP51+/+-MEFs were set to 1. E, primary astrocytes were cotransfected with GFP-
LC3B together with vector-control or FKBP51, and treated with PAR (10 µM) for 48 h. The number of GFP-
LC3B positive puncta/cell was determined in 15-25 randomly selected cells for each condition. F, 
representative fluorescence images of E. G-I, primary astrocytes were transfected with vector-control or 
FKBP51, and treated as in B; Beclin1, LC3B-II/I and Atg12 levels were determined. Bars represent the 
mean +SEM (n=3). *p<0.05; **p<0.01; ***p<0.001. Statistical parameters in Table S1. 
 
FKBP51 shapes the effects of ADs on synaptic function 
Irrespective of the question whether AD-induced increase of autophagic markers in all cases 
indicates enhanced protein turnover (Rossi et al., 2009; Zschocke et al., 2011), autophagic 
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pathways have been linked to synaptic function. Since the latter is more obviously linked to 
behavior (Luo et al., 2008) and diseases such as depression, we also tested whether FKBP51 
changes the effect of PAR on neuronal function. Hippocampal CA3-CA1 synapses were 
electrically stimulated in brain slices from Fkbp51+/+ and Fkbp51-/- mice, and CA1 neuronal 
activity was monitored by means of voltage-sensitive dye imaging (VSDI) (Refojo et al., 2011; 
von Wolff et al., 2011; Stepan et al., 2012). This approach was chosen for two reasons. First, 
the CA1 area is an important output subfield of the hippocampus, which has been implicated 
in the pathophysiology of depression and in AD action (Airan et al., 2007; Duman and 
Aghajanian, 2012). Second, we considered potential heterogeneity of the PAR effect at CA3-
CA1 synapses; thus, VSDI measurement of neuronal activity in a larger portion of CA1 
appeared more relevant than the typically more restricted electrode recording techniques. 
In slices from Fkbp51+/+-mice, bath application with PAR (10 µM) enhanced the ‘region of 
interest’ (ROI)-extracted fast, depolarization-mediated imaging signals (FDSs), which reflect 
excitatory postsynaptic potentials as well as neuronal action potentials (von Wolff et al., 
2011; Stepan et al., 2012). This effect was not observed in slices from Fkbp51-/- animals (Fig. 
3A and B). 
 
Figure 3. FKBP51 is required for the effect of PAR on evoked CA1 neuronal activity. A, Left, illustration 
of the position of the stimulation electrode (Stim) and ROI used for the calculation of CA1 neuronal 
population activity. Right, depolarization-mediated VSDI signal recorded 11 ms after the electrical 
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stimulation pulse. Warmer colors represent higher values of the fractional change in fluorescence (F/F) 
and, thus, stronger neuronal activity. B, Left, quantification of PAR’s effects on CA1 FDSs (n=10 slices from 
4 mice for each group). *p=0.032 (paired t-test); n.s., p=0.912 (paired t-test); data are given as mean 
±SEM. Right, representative recording traces illustrating the PAR effects on CA1 FDSs. 
 
Effects of ADs and of dexamethasone in blood cells of healthy individuals depend on 
FKBP51 
We next tested if the link between FKBP51 expression and AD response of autophagy 
markers could be confirmed in human peripheral blood mononuclear cells (PBMCs). PBMCs 
derived from healthy male subjects showed marked variations in basal FKBP51 expression 
(Figs. 4A-C, S6A). The FKBP51 expression level was positively correlated with the expression 
of Beclin1 and Atg12, and negatively correlated with the phosphorylation status of AktS473; 
LC3B-II/I displayed a trend correlation with FKBP51 protein levels (Figs. 4A-C, S6A,B).  
Since FKBP51 is a stress-responsive gene [(Hubler and Scammell, 2004; Klengel et al., 2013) 
and glucocorticoids have been shown to induce autophagy (Laane et al., 2009), FKBP51 
might also link stress to autophagy. We determined the expression of Beclin1 and FKBP51 
in PBMCs from healthy male subjects before and 6 h after administration of the synthetic 
glucocorticoid dexamethasone (DEX, 1.5 mg). There was a significant correlation between 
the induction of FKBP51 and the increase in Beclin1 expression (Figs. S6C,E), and between 
the induction of FKBP51 and the de-phosphorylation of pAktS473 (Figs. S6D,E). In an animal 
model, DEX affected levels of Beclin1, Vps34, and pAktS473 in cortical astrocytes from Fkbp51-
/-, but not from Fkbp51+/+-mice (Fig. S6F,G).  
PBMCs from healthy male subjects were also cultivated ex vivo and treated with AMI, FLX, 
or PAR for 72 h. To more closely mimic the clinically relevant in vivo conditions, drug 
concentrations were chosen according to actual consensus guidelines for therapeutic drug 
monitoring in psychiatry (Hiemke et al., 2011). The extent of de-phosphorylation of pAktS473, 
change of LC3B-II/I ratio, and levels of Beclin1 in response to ADs correlated with the 
expression level of FKBP51 (Figs. 4D-F, S6H,I). Higher expression of FKBP51 was associated 
with AD-induced de-phosphorylation of pAktS473, and lower expression of FKBP51 was 
associated with AD-enhanced pAktS473. With increasing FKBP51 levels, a gradual shift from 
slightly inhibitory to stimulatory effects of ADs on Beclin1 expression was observed. The AD-
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triggered lipidation of LC3B-I was positively correlated with the FKBP51 expression status. 
Atg12 expression was not significantly changed by AMI and FLX, but PAR affected Atg12 
expression in an FKBP51-dependent fashion similarly to Beclin1. Taken together, FKBP51 is 
required for the effects of AD and of DEX on autophagic pathways in humans. 
 
Figure 4. Correlation of FKBP51 with autophagy pathway components and with effects of ADs in human 
PBMCs. A-C, protein levels of FKBP51, Beclin1, pAktS473/Akt, and LC3B-II/I, in PBMCs from healthy male 
subjects (n=21). Each dot represents the levels of FKBP51 and the respective protein in PBMCs from one 
individual subject. Average expression levels were set to 1. D-F, levels of FKBP51, Beclin1, pAktS473, and 
LC3B-II/I in PBMCs from healthy male subjects (n=21), cultivated ex vivo and treated with PAR (0.365 µM, 
48 h). Plots depict protein changes upon treatment with AD compared to vehicle-treated cells in 
correlation to FKBP51. Each dot represents the level of FKBP51 and the expression change of the 
respective protein in PBMCs from one individual.  
 
Clinical improvement of depressive patients is predicted by their levels of Beclin1 
and FKBP51 at hospital admission. 
To further evaluate the clinical relevance of our findings we determined the expression 
levels of Beclin1, FKBP51, and pAktS473 in PBMCs from inpatients with a current depressive 
episode at admission and compared them with the clinical treatment response. The clinical 
response after 6 weeks of treatment showed statistically significant positive correlations 
with the levels of Beclin1 and FKBP51, and a negative correlation with pAktS473 (Figs. 5A-C).  
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Figure 5. Correlation of clinical AD response with the expression of FKBP51 and Beclin1, and with the 
effects of ADs in PBMCs ex vivo. A-C, Beclin1, FKBP51, and pAktS473/Akt levels in PBMCs from inpatients 
with depression (n=43) at admission. Expression values are correlated with the response to AD-treatment 
expressed as percent change in the total score of the 21-items Hamilton Depression Rating scale between 
admission and after 6 weeks of treatment.  
 
Reactivity of Beclin1 and pAkt of patient-derived PBMCs to AD treatment ex vivo 
predicts clinical improvement. 
PBMCs were also collected from inpatients at admission, cultivated and treated with AMI, 
FLX, or PAR ex vivo. We observed a correlation between therapeutic outcome and the 
increase of Beclin1 levels in treated PBMCs for all three ADs (Figs. 6A-C). There was a 
significant negative correlation between therapeutic outcome and the change of pAktS473 
upon treatment with AMI or PAR, (Fig. 6D, E; no correlation for FLX, Fig. S7A). There was a 
trend for the correlation between therapeutic outcome and induction of LC3B-II/I in the case 
of treatment with PAR, but not with AMI or FLX (Figs . 6F, S7B,C). Thus, the levels of FKBP51 
and Beclin1 at admission, as well as the response to AD treatment in PBMCs, correlate with 
therapeutic outcome. 
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Figure 6. Correlation of clinical AD response with the effects of ADs in PBMCs ex vivo. PBMCs from 
depressive inpatients were cultivated ex vivo and treated with PAR (0.365 µM), FLX (1695 nM) or AMI 
(888 nM) for 48 h. The AD induced changes in expression of Beclin1, pAktS473/Akt and LC3BII/I are 
correlated with the clinical response to AD-treatment expressed as percent change in the total score of 
the 21-items Hamilton Depression Rating scale between admission and after 6 weeks of treatment. 
 
  
Research articles 
126 
Discussion 
FKBP51 has originally been selected as a candidate for genetic analyses in depression and 
AD responsiveness (Binder et al., 2004), because it is involved in the regulation of the 
glucocorticoid receptor (Wochnik et al., 2005), and thereby the stress hormone axis 
(Scammell et al., 2001). Our study brings novel FKBP51-directed pathways to the fore (Fig. 
7), and establishes the importance of FKBP51 in AD action at the molecular, cellular, and 
organismic level. It also identifies a molecular mechanism of the previously suggested 
(Binder et al., 2004) positive correlation between FKBP51 expression and AD treatment 
response. 
 
Figure 7. Model of FKBP51‘s impact on Beclin1 and autophagy pathways. FKBP51 interacts with PHLPP, 
Akt, and Beclin1. Since the PHLPP de-phosphorylates Akt (S473 in Akt1), inactive Akt is recruited to 
Beclin1. This results in lower phosphorylation of Beclin1 and thus the induction of autophagic pathways 
(Wang et al., 2012b). Autophagic pathways, and thereby also FKBP51, are linked to synaptic function 
(Hernandez et al., 2012) as a physiological correlate of behavior (Luo et al., 2008). ADs act on the same 
pathways in an FKBP51-dependent manner and change FKBP51 protein interactions; this could form the 
basis for the FKBP51-dependency of AD effects in cells, animals, and humans. 
Research articles 
127 
The impact of FKBP51 on autophagy established in this study significantly expands the range 
of actions of this versatile protein to be considered relevant for AD action. Our protein 
interaction analyses support the model (Fig. 7) that FKBP51 as scaffolding protein recruits 
Akt to Beclin1; since FKBP51 also binds to PHLPP (Pei et al., 2009), inactive Akt is recruited 
to Beclin1. This results in decreased phosphorylation of Beclin1, thereby shifting Beclin1’s 
action to trigger autophagy (Wang et al., 2012b). FKBP51-mediated increase in overall 
Beclin1 levels constitutes a further route by which FKBP51 facilitates autophagy.  
The regulation of FKBP51 by glucocorticoids (Hubler and Scammell, 2004; Klengel et al., 
2013) potentially links all the molecular actions of FKBP51 to stress. Our data provide strong 
evidence that up-regulation of FKBP51 mediates dexamethasone-induced autophagy and 
de-phosphorylation of pAktS473 (Laane et al., 2009). Akt, in turn, has been reported as target 
of AD action before, and both positive and negative changes of pAktS473 levels have been 
found for different ADs in various cellular systems (Basta-Kaim et al., 2005; Jeon et al., 2011; 
Bhuiyan et al., 2011; Huang et al., 2013). Treatment duration and other factors may account 
for the divergent results; based on our findings, we propose that the FKBP51 expression 
status determines whether and how ADs alter pAktS473. In general, pAktS473 is under 
multifactorial control (Manning and Cantley, 2007) that could be the basis for both inhibitory 
and FKBP51-dependent stimulatory actions of ADs. 
In light of the still largely unknown molecular mechanism by which ADs act, our results 
highlight intracellular molecular mechanism of AD effects that complement the known 
actions on mono-aminergic neurotransmitter systems (Berton and Nestler, 2006). 
Previously, a link has been discovered from autophagy to neurotransmission (Hernandez et 
al., 2012), and from neuronal circuit dynamics in the hippocampus to behavior in an animal 
model of depression (Airan et al., 2007). Thus, it is plausible that the FKBP51-governed 
autophagy pathways underlie the here described FKBP51 dependency of PAR’s effect on 
neuronal activity and on behavior, and the FKBP51-dependency of clinical AD response.  
While genetic studies of complex diseases, including studies on respective drug actions, 
have significantly benefitted from the advanced technologies of genome-wide genotyping, 
the necessity of complementary approaches such as molecular pathways and network 
analyses to move from genomic localization to mechanistic insight has come into focus only 
recently (Barabasi et al., 2011). Overall, our finding of FKBP51-dependent effects of ADs on 
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intracellular pathways and consequently brain function and behavior strengthens the 
relevance of the genetic association of FKBP51 with AD response and provides substantial 
information for more targeted genetic studies. In addition, our results suggest considering 
autophagy initiating mechanisms as a pharmacological target to improve treatment of 
depression, as discussed for other diseases (Harris and Rubinsztein, 2012). Finally, our data 
provide a direct basis for including the current protein expression status of FKBP51 and 
Beclin1 as well as the response of autophagic factors to AD treatment of ex vivo cultivated 
lymphocytes as novel biomarkers predicting antidepressant efficacy in depressed patients.  
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Supplemental Materials and Methods  
 
Suppl. Fig. 1. The effect of paroxetine in mice depends on FKBP51. FKBP51-/-- and FKBP51+/+-mice were 
treated with PAR (10 mgkg-1) or vehicle and sacrificed 45 mins later. Protein levels were determined in 
extracts of the hippocampus and the prefrontal cortex from 9-10 animals in technical triplicates. A, 
*p<0.05; ***p<0.001. Statistical parameters in supplemental Table 1. B, representative Western blots, 
also to figure 1B,C of the main text.  
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Suppl. Fig. 2. Functional interaction of FKBP51 with Beclin1, Akt and PHLPP. HEK cells were transiently 
transfected with vector control or a plasmid expressing FKBP51. A, representative Western blots of 
Beclin1 immunoprecipitations from transfected cells and analysis of pBeclin1S234,S295 and co-precipitating 
pAktS473/Akt are displayed (corresponding to Fig. 1E). The antibodies directed against phosphorylated 
Beclin only worked after immunoprecipitation (Wang et al., 2012b). The table summarizes the results of 
3 independent co-immunoprecipitations with 3 technical replicates of the respective Western blots. In 
the case of Akt and pAktS473, numbers indicate relative intensities of interaction with Beclin1 (intensity of 
vector control was set to 1), including p-values of interaction differences. In the case of pBeclin1S234,S295, 
numbers indicate the fold change in the presence or absence of ectopic FKBP51 (vector control set to 1), 
including p-values. B, representative Western blots indicating the change of total Beclin1, pAktS473 and 
pAktT308 upon expression of FKBP51. FKBP51 was detected by an antibody directed against its FLAG tag. 
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Numbers indicate the the effect of FKBP51 expression on the levels of Beclin1 and on the phosphorylation 
status of AktS473 and AktT308, and reflect the results of 3 independent experiments with 3 technical 
replicates of the respective Western blots.  
 
 
Suppl. Fig. 3. Effect of FKBP51 on autophagic markers in cells deficient of endogenous FKBP51 or Akt1/2. 
A, the impact of the FKBP51 expression status on the levels of Beclin1, Atg12, LC3B-II/I, and pAktS473 was 
assessed by Western blot analysis in Fkbp51+/+ MEFs, Fkbp51-/- MEFs, and Fkbp51-/- MEFs transfected 
with an FKBP51 expressing plasmid. Graphs show the relative mean expression +SEM of 3 different 
experiments; expression in Fkbp51+/+ MEFs was set to 1. Western examples of Beclin1, Atg12 and LC3B-
II/I correspond to Figure 1F of the main text. B, cellular effects of FKBP51 require Akt1 or Akt2. The 
expression of Beclin1 and LC3B-II/I was evaluated in Akt1/2+/+ MEFs, Akt1/2-/- MEFs and in Akt1/2-/- MEFs 
transfected with Akt1 and Akt2 expressing plasmids. Representative Western examples are shown. 
Graphs display pairwise comparisons of cells cotransfected with vector or FKBP51 expressing plasmid and 
represent the relative mean expression + SEM of 3 different experiments; expression in Akt1/2+/+, vector-
transfected MEFs was set to 1. **p<0.01; ***p<0.001. See supplemental Table 1 for all statistical 
parameters.  
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Suppl. Fig. 4. Convergent effects of FKBP51 and antidepressants in cells on protein interactions and 
pAkt. A, the interaction of FKBP51 with Beclin1 and Akt was analyzed by Western blotting after 
coimmunoprecipitation from HEK cells cultivated in the presence or absence of AMI or FLX (10 µM each). 
Table indicates changes of protein interaction relative to vehicle treatment. B, C, cortical astrocytes were 
transfected with an FKBP51 expression or control plasmid and treated as in A and levels of pAktS473/Akt 
were determined by Western blotting (representative blot in B). Bars represent the mean +SEM of 3 
independent experiments performed in triplicate. Protein levels in wild-type, untreated cells were set to 
1. D and E, Fkbp51+/+, Fkbp51-/- and Fkbp51-/- MEFs transfected with an FKBP51 expressing plasmid were 
treated AMI, FLX or PAR (10 µM each) for 48 h, and the pAktS473/Akt (E) ratios were determined by 
Western blot (representative blot in D, also referring to Figs. 2C,D, S5A). Bars represent the mean +SEM 
of 3 independent experiments performed in triplicate. Protein levels in Fkbp51+/+, untreated cells were 
set to 1. *p<0.05. See supplemental Table 1 for all statistical parameters. 
Research articles 
133 
 
Suppl. Fig. 5. Convergent effects of FKBP51 and antidepressants in cells on LC3B-II/I, Beclin1 and Atg12. 
A, Fkbp51+/+, Fkbp51-/- and Fkbp51-/- MEFs transfected with an FKBP51 expressing plasmid were treated 
with AMI, FLX or PAR (10 µM each) for 48 h, and LC3B-II/I ratios were determined by Western blot 
(representative blot in Figure S4D). Bars represent the mean +SEM of 3 independent experiments 
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performed in triplicate. Protein levels in untreated Fkbp51+/+ cells were set to 1. B, C, Akt1/2+/+ MEFs, 
Akt1/2-/- MEFs and in Akt1/2-/- MEFs transfected with Akt1 and Akt2 expressing plasmids were treated 
with AMI, FLX or PAR (10 µM each) for 48 h. The ratio of LC3B-II/I was determined by Western blot 
(representative example in B). Bars represent the mean +SEM of 3 independent experiments performed 
in triplicate. LC3B-II/I in the respective untreated cells was set to 1 (dotted line). D, E, primary rat cortical 
astrocytes were transfected with a vector expressing GFP-LC3B, in combination with an FKBP51 
expressing vector or cloning vector, and treated with AMI or FLX (10 µM each) for 48 h. The number of 
GFP-LC3B positive puncta was determined per cell (D). 15-25 randomly selected cells were evaluated for 
each condition (Representative fluorescence images in E). F-H, cortical astrocytes were transfected with 
an FKBP51 expression or control plasmid, treated as in A, and levels of Beclin1 (F), LC3B-II/I (G) and Atg12 
(H) were determined by Western blotting (representative blot in Fig. S4B). Bars represent the mean +SEM 
of 3 independent experiments performed in triplicate. Protein levels in wild-type, untreated cells were 
set to 1. *p<0.05; **p<0.01; ***p<0.001. See Supplemental Data Table 1 for all statistical parameters. 
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Suppl. Fig. 6. FKBP51-dependendency of autophagy pathway components in human PBMCs and of the 
effects of dexamethasone and antidepressants in primary astrocyte and in human PBMCs. A, protein 
extracts from PBMCs of healthy volunteers were analyzed for expression of FKBP51 and components of 
the autophagy pathway. Representative Western blot corresponding to Figure 4A-C and Figure S6B. B, 
correlation of protein levels of Atg12 and FKBP51 in PBMCs from healthy male subjects (n=21). Each dot 
represents the levels of Atg12 and FKBP51 in PBMCs from one individual subject. Average expression 
levels were set to 1. C-E, PBMCs were collected from healthy volunteers (n=14) before and 6 h after the 
intake of 1.5 mg dexamethasone (DEX) and proteins were analyzed. Representative Western blot is 
shown in E. F, G, primary astrocytes from FKBP51+/+ and FKBP51-/- mice were treated with vehicle or DEX 
(10 µM for 6 h) and protein levels were determined by Western blot (representative example in G). H, 
representative Western of extracts from AD-treated PBMCs (corresponding to Figure 4D-F of the main 
text and table in I). I, summary of the correlations of the effects of ADs on autophagic markers with the 
expression of FKBP51 in PBMCs from healthy subjects (n=21).  
 
 
Suppl. Fig. 7. Correlation of Clinical response to antidepressant treatment with response to 
antidepressant treatment of PBMCs ex vivo. PBMCs from depressive inpatients were cultivated and 
treated with FLX (1695 nM) or AMI (888 nM) for 48 h. The AD induced changes in expression of 
pAktS473/Akt and LC3II/I are correlated with the clinical response to AD-treatment expressed as percent 
change in the total score of the 21-items Hamilton Depression Rating scale between admission and after 
6 weeks of treatment.  
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Suppl. Table 1. Details of the results of the statistical analyses. NS, non significant.  
 
 
Cell lines 
Human embryonic kidney cells (HEK-293, ATCC CRL-1573) and mouse embryonic fibroblasts 
(MEFs) were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) 
supplemented with 10% FCS and 100 units/ml penicillin and streptomycin, respectively. 
FKBP51-/- and Akt1/2-/- MEFs (kind gift of Nissim Hay, University of Illinois, Chicago, Illinois) 
have been described before (Skeen et al., 2006; Touma et al., 2011).  
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Primary cultures of murine astrocytes 
Enriched astroglial cultures were prepared from postnatal day 1 rat pups (Sprague-Dawley, 
Charles River, Sulzfeld, Germany) and handled as described (Franke et al., 1998; Perisic et 
al., 2010).  
 
FKBP51 Rescue in MEF Fkbp51-/- cells 
Afore detached MEF cells (2 x 106) were re-suspended in 100 µl transfection buffer (50 mM 
HEPES pH 7.3, 90 mM NaCl, 5 mM KCl, 0.15 mM CaCl2) (Schumann Burkard et al., 2011). A 
maximal amount of 5 µg plasmid DNA was added to the cell suspension, and electroporation 
was carried out using the Amaxa Nucleofactor system (program # T-020). Cells were re-
plated at a density of 105/cm2 and further processed for Western blot analysis.  
 
Analysis of GFP-LC3 in astrocytes 
2x106 cells were transfected with 2 ng GFP-LC3 expressing plasmid or the respective cloning 
vector using Amaxa Nucleofactor system as described above. Cells were grown for 48 h and 
analyzed by fluorescence microscopy. At least 20 cells were counted. 
 
Plasmids 
Plasmids expressing FKBP51-FLAG, Akt1, Akt2, and LC3B have been described (Brunet et al., 
1999; Wochnik et al., 2005; Brognard et al., 2007; Kim et al., 2010). 
 
Co-Immunoprecipitation (CoIP) 
CoIPs of Flag-tagged FKBP51/52 and Flag-tagged FKBP51 endogenous Akt with were 
performed in HEK293 cells. 5×106 cells were electroporated with 5 µg of the respective 
expression plasmids using a GenePulser (Bio-Rad, USA) at 350 V/700 µF in 400 µl of 
electroporation buffer (50 mM K2HPO4/KH2PO4, 20 mM KAc, pH 7.35, 25 mM MgSO4). After 
three days of cultivation in DMEM/10% FCS, cells were lysed in CoIP-buffer containing 20 
mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Igepal complemented with protease 
inhibitor cocktail (Sigma, P2714). This was followed by incubation on an overhead shaker for 
Research articles 
138 
20 min at 4 °C. The lysate was cleared by centrifugation, the protein concentration was 
determined, and 1.2 mg of lysate was incubated with 2.5 µg FLAG antibody overnight at 4 
°C. 20 µl of BSA-blocked Protein G Dynabeads (Invitrogen, 100-03D) were added to the 
lysate–antibody mix followed by 3 h incubation at 4 °C. The beads were washed 3 times with 
PBS and protein-antibody complexes were eluted with 100 µl of 1× FLAG-peptide solution 
(Sigma, 100–200 µg ml-1, F3290) in CoIP buffer for 30 min at 4 °C. 5–15 µg of the cell lysates 
or 2.5 µl of the immunoprecipitates were separated by SDS-PAGE. 
 
Western Blot analysis 
Protein extracts were obtained by lysing cells in 62.5 mM Tris, 2% SDS and 10% sucrose, 
supplemented with protease (Sigma , P2714) and phosphatase (Roche, 04906837001) 
inhibitor cocktail. Samples were sonicated and heated at 95 ºC for 5 min. Proteins were 
separated by SDS-PAGE and electro-transferred onto nitrocellulose membranes. Blots were 
placed in Tris-buffered saline, supplemented with 0.05% Tween (Sigma, P2287) and 5% non-
fat milk for 1 h at room temperature and then incubated with primary antibody (diluted in 
TBS/0.05% Tween) overnight at 4 ºC. The following primary antibodies were used: Beclin1 
(1:1000, Cell Signaling, #3495), pBeclin1 (S234 and S295, both 1:1000, Phosphosolutions 
#p117-234 and #p117-295), Atg12 (1:1000, Cell Signaling #2010), LC3B-I/II (1:1000, Cell 
Signaling, #2775), FLAG (1:7000, Rockland, 600-401-383), PI3K Class III (Vps34, 1:1000, Cell 
Signaling, #4263), FKBP51 (1:1000, Bethyl, A301-430A), Akt (1:1000, Cell Signaling, #4691), 
pAkt (1:1000, Ser473, T308, 1:1000, Cell Signaling, #4058, #9275), Actin (1:5000, Santa Cruz 
Biotechnologies, sc-1616). 
Subsequently, blots were washed and probed with the respective horseradish peroxidase- 
or fluorophore-conjugated secondary antibody for 1 h at room temperature. The immuno-
reactive bands were visualized either using ECL detection reagent (Millipore, Billerica, MA, 
USA, WBKL0500) or directly by excitation of the respective fluorophore. Determination of 
the band intensities were performed with BioRad, ChemiDoc MP, or X-ray-films 
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Preparation of human PBMCs 
Blood of healthy male volunteers and of depressed patients was collected via venipuncture, 
diluted with PBS and carefully loaded on Biocoll solution (1BioChrom AG, L6113) and 
centrifuged at 800 x g for 20 min (brakeless running down). PBMCs were enriched by 
selecting the interphase of the Biocoll gradient. PBMCs of the interphase were washed two 
times with ice-cold PBS. PBMCs were re-suspended in RPMI and plated at 4x105/cm2. After 
recovery for 6 h, cells were treated with either 888 nM (120 ng ml-1) AMI, 1695 nM (500 ng 
ml-1) FLX, 365 nM (120 ng ml-1) PAR. Concentrations had been chosen to match therapeutic 
concentrations in the serum according to the consensus guidelines for therapeutic drug 
monitoring in psychiatry (Hiemke et al., 2011). 
 
 
140 
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3.6. Pharmacological FKBP51 inhibition reduces anxiety-related 
behavior in mice 
 
Jakob Hartmann1, Klaus V. Wagner1, Steffen Gaali1, Alexander Kirschner1, Lianne 
Hoeijmakers1, Sören Westerholz1, Manfred Uhr1, Alon Chen1 Florian Holsboer1, Felix 
Hausch1, Mathias V. Schmidt*1 
 
1Max Planck Institute of Psychiatry, Kraepelinstr. 2-10, 80804 Munich, Germany 
 
 
 
Manuscript in preparation 
  
Research articles 
142 
Abstract 
Psychiatric disorders such as major depression (MD) and posttraumatic stress disorder 
(PTSD) represent one of the largest health burdens worldwide, with still increasing numbers. 
However, a substantial group of patients does not respond to any of the currently used 
pharmacotherapies. Therefore, the need to focus research on personalized medicine and 
the development of conceptually novel drugs is stronger than ever. Single nucleotide 
polymorphisms of the FK506 binding protein 51 (FKBP51) gene have been associated with 
MD, PTSD and suicidal behavior in numerous studies in recent years. In addition it has been 
shown that FKBP51 is involved in stress-vulnerability by reducing the sensitivity of the 
glucocorticoid receptor (GR). Given the intimate relationship of stress and anxiety and the 
robust induction of FKBP51 in the amygdala following stress, we hypothesized that 
amygdala FKBP51 may mediate anxiety-related behaviors. We therefore first mimicked the 
stress effect by specifically overexpressing FKBP51 in the basolateral amygdala (BLA) of mice 
via virus-mediated gene transfer, which resulted in increased anxiety-related behavior. Next 
we show that blockade of an overexpressed functionally fully active FKBP51 variant (with a 
point mutation) in the BLA with a highly selective and specifically designed FKBP51 
antagonist (bump-and-hole approach), was able to reduce the observed anxiogenic 
phenotype. Finally, we blocked wild-type FKBP51 with a potent and highly selective FKBP51 
inhibitor in naïve mice, which led to an anxiolytic phenotype. To our knowledge this is the 
first study assessing a selective FKBP51 antagonist with regard to anxiety in an in vivo 
system, thereby further unraveling the role of FKBP51 as a potential drug target in the 
context of stress-related psychiatric diseases. 
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Introduction 
Psychiatric diseases such as major depression (MD) and posttraumatic stress disorder (PTSD) 
contribute significantly to disease burden worldwide, but their underlying molecular 
mechanisms are still poorly understood (Tennant, 2001; Krishnan and Nestler, 2008; Nestler 
and Hyman, 2010). In addition, a substantial proportion of patients does not benefit from 
prevalent treatment options such as selective serotonin re-uptake inhibitors (SSRIs), 
highlighting the need for personalized medicine (Porcelli et al., 2011).  
In recent years, genome wide association studies identified several genes contributing (in 
interaction with environmental factors) to the development of such disorders. One 
interesting candidate is the gene encoding FK506 binding protein 51 (FKBP51), which has 
been shown to alter glucocorticoid receptor (GR) sensitivity (Riggs et al., 2003; Binder et al., 
2004). When it is bound to the GR via Hsp90, the receptor’s affinity for glucocorticoids is 
reduced and the translocation to the nucleus is less efficient. Interestingly, one major 
characteristic of many depressed patients is an impaired negative feedback loop of the 
hypothalamic-pituitary-adrenal (HPA) axis, including altered GR signaling (Holsboer, 2000; 
Pariante and Miller, 2001).  
Single nucleotide polymorphisms (SNPs) in the Fkbp51 gene have repeatedly been 
associated with various psychiatric diseases such as MD, bipolar disorder (Binder et al., 
2004; Willour et al., 2009; Tatro et al., 2009b; Lavebratt et al., 2010) and PTSD (Binder et al., 
2008; Mehta et al., 2011). In addition, FKBP51 variants have been linked with risk for suicidal 
behavior (Willour et al., 2009; Brent et al., 2010; Roy et al., 2010; Supriyanto et al., 2011). 
Interestingly, alterations in FKBP51 expression in the amygdala have been reported in 
suicide victims (Pérez-Ortiz et al., 2012). The amygdala plays a pivotal role in the 
neurocircuitry of fear and anxiety disorders (LeDoux, 2007; Shin and Liberzon, 2010; Dias et 
al., 2013), and was also shown to modulate the HPA-axis through negative feedback 
mediated by the GR (Gray, 1993; Davis, 1994; McEwen and Sapolsky, 1995). 
Importantly, FKBP51 mRNA expression is strongly upregulated in the amygdala following 
acute stress (Scharf et al., 2011). Furthermore, we could recently show that FKBP51 
knockout mice are less affected by chronic social defeat stress, reflected in a stress-resistant 
HPA system, possibly mediated by an increased GR sensitivity (Chapter 1).  
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Pharmacological inhibition of FKBP51 might thus constitute a novel therapeutic approach 
for the prevention and treatment of stress-related affective disorders. The recent 
development of the first selective and potent FKBP51 antagonists (Gaali and Kirschner et al., 
unpublished data), now offers the unique possibility to test this hypothesis. In the current 
study we therefore aimed to further unravel the role of FKBP51 as a potential drug target in 
the context of stress-related anxiety diseases. First, we mimicked the stress-induced FKBP51 
increase in the basolateral amygdala (BLA) and studied anxiety-related behavior in mice. 
Second, we over-expressed a functionally fully active FKBP51 variant with a point mutation 
(FKBP51F67V) in the BLA, for which a custom-designed antagonist (Ligand1) was recently 
developed (Gaali and Kirschner et al., unpublished data). We then tested, whether this 
antagonist, which does not affect wild-type FKBP51, can ameliorate the phenotype induced 
by FKBP51F67V overexpression. In a third step, we blocked wild-type FKBP51 in naïve mice, 
using a potent and highly selective antagonist (SAFit2) and subsequently studied anxiety-
related behavior. 
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Materials and Methods 
Animals 
For all experiments, male C57Bl/6N mice (Charles River Laboratories, Maastricht, the 
Netherlands) at the age of 12 weeks were used. The mice were held under standard 
conditions (12L: 12D light cycle, lights on at 08:00 AM, temperature 23±2°C) and were single 
housed and acclimated to the room for 2 weeks before the beginning of the experiments. 
Food (Altromin 1324, Altromin GmbH, Germany) and tap water were available ad libitum. 
For all experiments a separate batch of animals was used (n = 8 – 14). All experiments were 
carried out in the animal facilities of the Max Planck Institute of Psychiatry in Munich, 
Germany. The experiments were carried out in accordance with the European Communities' 
Council Directive 2010/63/EU. All efforts were made to minimize animal suffering during the 
experiments. The protocols were approved by the committee for the Care and Use of 
Laboratory animals of the Government of Upper Bavaria, Germany. 
 
Experimental design  
Experiment 1. 
We investigated the effects of a FKBP51 overexpression in the BLA or the dorsal 
hippocampus (dHc) with regard to anxiety-related behavior (n = 11-14 per group). 
Experiment 2. 
We first tested the blood-brain barrier penetration of Ligand1, a FKBP51 antagonist that 
specifically binds to the mutated FKBP51F67V variant, but does not bind to wild-type FKBP51. 
FKBP51F67V preserves the repressing activity of wild type FKBP51 on the GR, but can 
specifically be inhibited by the FKBP51 antagonist Ligand1. Animals received a single 
injection of either 0.1 mg/kg BW, 1.0 mg/kg BW, 10.0 mg/kg BW Ligand1 or vehicle solution 
(n = 4 per group). Next, we tested the ability of Ligand1 to rescue the anxiogenic effects, 
induced by FKBP51F67V overexpression in the BLA (n = 11-13 per group). To confirm the 
specificity and to rule out any potential side effects of the antagonist in the control group, 
we performed an additional control experiment, in which naïve C57Bl/6N mice received a 
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single injection of 10.0 mg/kg BW Ligand1 or vehicle solution and were subsequently tested 
with regard to anxiety-related behavior (n = 8 per group). 
Experiment 3. 
We selectively blocked wild-type FKBP51 with SAFit2 in naïve mice and investigated its 
effects on anxiety-related behavior (n = 8 – 12 per group). 
 
Viral overexpression of FKBP51 
Viral overexpression was performed as described previously (Schmidt et al., 2011). We used 
an adeno-associated bicistronic AAV1/2 vector (GeneDetect). In experiment 1 the vector 
contained a CAG-HA-tagged-FKBP51-WPRE-BGH-polyA expression cassette (containing the 
coding sequence of human Fkbp51 NCBI CCDS ID CCDS4808.1). For experiment 2 the vector 
contained a CAG-HA-tagged-FKBP51-F67V-mutant-WPRE-BGH-polyA expression cassette 
(containing the coding sequence of the human Fkbp51 NCBI CCDS ID CCDS4808.1) with a 
F67V point mutation (Gaali and Kirschner et al., unpublished data). For the control group, 
we used the same vector construct without expression of FKBP51 (CAG-Null/Empty-WPRE-
BGH-polyA). Virus production, amplification, and purification were performed by 
GeneDetect. Mice were anesthetized with isoflurane, and 0.5 µl of either AAV-FKBP51, AAV-
FKBP51F67V or AAV-Empty (titers: 1.3 x 1012 genomic particles/ml (experiment 1), 2.6 x 1012 
genomic particles/ml (experiment 2) were bilaterally injected in the BLA or hippocampus at 
0.06 µl/min by glass capillaries with tip resistance of 2–4MΩ in a stereotactic apparatus. For 
the amygdala the following coordinates were used: 1.0 mm posterior to bregma, 3.5 mm 
lateral from midline, and 3.8 mm below the surface of the skull, targeting the BLA; for the 
hippocampus we used: 1.9 mm posterior to bregma, 1.3 mm lateral from midline, and 
1.3/1.8 mm below the surface of the skull, targeting the CA1 and dentate gyrus (DG) region 
of the dorsal hippocampus. After surgery, mice were treated for 5 d with Metacam via 
drinking water. Behavioral testing started 4 weeks after virus injection. Successful 
overexpression of the FKBP51-forms was verified by in situ hybridization and 
immunofluorescence. Animals that were not infected bilaterally in the dorsal hippocampus 
or BLA were excluded from the analysis. Quantification of the overexpression was achieved 
by in situ hybridization using the riboprobe described below. 
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Behavioral testing 
All behavioral tests were recorded using a videotracking system (Anymaze 4.20; Stoelting). 
The following behavioral tests were performed: open field (OF), elevated plus maze (EPM), 
dark-light box (DaLi). The testing procedures were performed as described below. 
Open field 
The open-field test was performed to investigate general locomotor activity. Testing was 
carried out in an empty open-field arena (50 cm x 50 cm x 50 cm) made of gray polyvinyl 
chloride (PVC), which was evenly illuminated with 15 Lux. The low illumination of the open 
field arena was chosen to specifically investigate locomotion behavior and not create an 
aversive center region that may induce anxiety-related behavior. Testing time was 15 min 
and parameter of interest was the total distance traveled.  
Elevated plus maze 
The EPM was conducted to display changes in anxiety-related behavior. The device 
consisted of a plus-shaped platform with two opposing open arms (30 cm x 5 cm x 0.5 cm) 
and two opposing enclosed arms (30 cm x 5 cm x 15 cm), made of gray PVC, which were 
connected by a central area (5 cm x 5 cm). The whole device was elevated 50 cm above the 
floor. The illumination was 25 Lux in the open arms and less than 10 Lux in the closed arms. 
Testing duration was 10 min in experiment 1 and 3 and 5 min in experiment 2. Mice were 
placed into the center zone facing one of the enclosed arms at the start of the test. The time 
spent in the open arms compared to the total arm time as well as the number of open arm 
entries were analyzed. Animals that fell off the open arm of the apparatus during testing 
were excluded from the analysis. 
Dark-Light box 
The DaLi test was used as another paradigm to measure anxiety-related behavior. The 
apparatus consisted of a rectangular box with two compartments, the dark compartment 
(15 cm x 20 cm x 25 cm), with <10 lux and the light compartment (30 cm x 20 cm x 25 cm), 
lit with 700 lux. Both compartments were connected by a 4 cm long tunnel. At the beginning 
of the test, each mouse was placed in the center of the dark compartment facing the back 
wall of the apparatus. Testing duration was 7 min in experiment 1 and 10 min in experiment 
2 and 3. The time spent in the lit compartment, as well as the number of lit compartment 
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entries, the latency to the first entry to the lit compartment and the distance traveled in the 
lit compartment were analyzed. 
 
Drugs 
The FKBP51 antagonists (Ligand1 and SAFit2) were solubilized in 4% EtOH, 5% Tween80 and 
5% PEG400 in 0.9% saline. In experiment 2, animals received an intraperinal (IP) injection of 
either vehicle (4% EtOH, 5% Tween80 and 5% PEG400 in 0.9% saline) or Ligand1 (0.1 mg/kg 
BW, 1.0 mg/kg BW or 10mg/kg BW) solution 1 hr prior perfusion to assess the blood-brain 
barrier penetration. Mice that underwent surgeries and behavioral analysis in experiment 2 
received an IP injection of vehicle or Ligand1 (10mg/kg BW) on 10 consecutive days. On 
testing days, the injection was applied 1 hr prior to the start of the test. Naïve mice (without 
surgery) received a single IP injection of vehicle or Ligand1 (10mg/kg BW) 1 hr prior to the 
start of the behavioral test. In experiment 3, animals received an IP injection of vehicle or 
SAFit2 (20mg/kg BW) 1hr or 16 hrs prior to the start of the test. 
 
Sampling procedure 
At the day of sacrifice, animals were deeply anesthetized with isoflurane. For animals that 
were used to assess the pharmacokinetics of Ligand1 in experiment 2, blood samples were 
taken by cardiac puncture, kept on ice and later centrifuged at 8000 rpm at 4°C for 15 min. 
Plasma was transferred to new, labeled tubes and stored at -20°C. These mice were perfused 
intracardially with saline; brains were removed and immediately stored at -80°C. The 
concentration of the FKBP51 antagonist in plasma and brain was quantified by LC-MS/MS. 
All other animals of experiment 1 and experiment 2 were perfused intracardially with 4% 
paraformaldehyde. Brains were removed, post-fixed overnight in 4% paraformaldehyde, 
followed by subsequent overnight incubation in 30% sucrose solution at 4 °C, and then 
stored at -80 °C until processing for in situ hybridization and immunohistochemistry. 
 
In Situ hybridization and immunohistochemistry 
For in situ hybridization and immunohistochemistry, frozen brains were coronally sectioned 
in a cryostat microtome at 25 µm and kept at -80°C. In situ hybridization using a 35S UTP-
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labeled ribonucleotide probe for Fkbp51 (Forward primer: 5’-CTTGGACCACGCTATGGTTT; 
Reverse primer: 5’-GGATTGACTGCCAACACCTT) was performed as described previously 
(Schmidt et al., 2007). Immunofluorescence (mouse anti-Ha, 1:1000, Sigma; Donkey anti-
mouse Alexafluor 488, 1:500) was performed on free-floating sections (n =3 per mouse) as 
described previously (Wang et al., 2011a). 
 
Statistical analysis 
The data presented are shown as means +SEM and were analyzed by the commercially 
available software SPSS 17.0 and Sigma Plot 11.0. When two groups were compared, the 
unpaired student’s t-test was applied. If data were not normally distributed the non-
parametric Mann-Whitney test (MW-test) was used. For four group comparisons, two-way 
analysis of variance (ANOVA) was performed, followed by Tukey’s post-hoc test, as 
appropriate. P values of less than 0.05 were considered significant. 
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Results 
FKBP51 overexpression in the basolateral amygdala induces anxiogenic behavior 
We overexpressed FKBP51 in the BLA by viral mediated gene transfer and subsequently 
investigated mice with regard to anxiety-related behavior. The stable FKBP51 
overexpression in the BLA was quantified by in situ hybridization (t-test: 
T26 = 105.000, p < 0.001) and was additionally validated by immunofluorescence  
(Figure 1A-D).  
Mice with a FKBP51 overexpression in the BLA (51OEBLA mice) showed increased anxiety-
related behavior in the EPM, which was reflected in a significantly reduced open arm time 
(t-test: T22 = 2.593, p < 0.05) as well as in significantly decreased open arm entries (t-test: 
T22 = 2.198, p < 0.05) compared to control mice (Figure 1E, F). These findings were further 
supported by an increased latency to enter the aversive lit compartment (t-test: 
T26 = -1.781, p = 0.087) (Figure 1G). This anxiogenic phenotype of 51OEBLA mice was 
independent of general locomotor activity, which did not differ between the groups (Figure 
1H). Furthermore, these effects were BLA specific, as we did not observe any differences in 
anxiety-related behavior in mice with a FKBP51 overexpression in the dHc (Suppl. Figure 1). 
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Figure 1: Overexpression of FKBP51 in the basolateral amygdala (BLA) induces anxiety-related 
behavior. A, Schematic representation of the viral injection into the BLA. B, Representative of 
autoradiographs of viral FKBP51 mRNA expression in the BLA 7 weeks after injection C, Quantification of 
FKBP51 mRNA levels in the BLA. Infection with the viral construct induced a strong increase. D, 
Representative immunohistochemistry of viral FKBP51 expression (Ha-tag Immuno) in the BLA region 7 
weeks after injection. E and F, FKBP51 overexpression in the BLA leads to significantly reduced open arm 
time and open arm entries in the elevated plus maze (EPM). G, 51OEAmy mice show an increased latency 
to enter the lit compartment in the dark light box (DaLi). H, General locomotion as assessed in the open 
field (OF) is not affected by FKBP51 overexpression in the BLA. # p < 0.05, data are expressed as mean + 
SEM. 
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A specific FKBP51 antagonist reduces the anxiogenic phenotype induced by FKBP51 
overexpression in the BLA 
We then examined whether we could rescue the anxiogenic phenotype observed in 51OEBLA 
mice with a FKBP51 antagonist. Therefore, we overexpressed a mutant form of FKBP51with 
a single point mutation (51OEF67V-BLA mice) in the BLA and subsequently treated the animals 
with the specifically designed FKBP51 antagonist Ligand1 that only binds to the FKBP51-
mutant.  
At first we investigated the antagonist’s ability to cross the blood-brain barrier in C57/Bl6N 
mice. Ligand1 showed a dose-dependent accumulation in the plasma and the brain 1h after 
the injection (Suppl. Figure 2A and B). 
The stable FKBP51F67V overexpression in the BLA was quantified by in situ hybridization 
(MW-test: T = 351.000, p < 0.001) and was additionally validated by immunofluorescence 
(Figure 2A-C).  
The overexpression of FKBP51F67V in the BLA induced an anxiogenic phenotype in the EPM, 
which was reflected in a significantly reduced open arm time (2-Way ANOVA: main genotype 
effect, F1,41 = 4.696, p < 0.05) (Figure 2D). This finding was independent of the treatment 
groups. In the DaLi test 51OEF67V-BLA mice spent significantly less time in the lit compartment 
than the empty control groups (2-Way ANOVA: main genotype effect, F1,45 = 4.671, p < 0.05). 
However, in further post-hoc analysis this genotype effect is only significant within the 
vehicle treated groups (Tukey’s post-hoc: p < 0.05) (Figure 2E). This was further supported 
by a significantly reduced distance traveled in the lit compartment of 51OEF67V-BLA mice 
compared to control mice (2-Way ANOVA: main genotype effect, F1,45 = 4.514, p < 0.05), 
since further post-hoc analysis only revealed a slight genotype difference in the vehicle 
treated mice (Tukey’s post-hoc: Trend, p < 0.1) (Figure 2F). The OF test served again as 
control, and revealed that the anxiety-related phenotype of 51OEF67V-BLA mice is 
independent of general locomotion, which did not differ between the experimental groups 
(Figure 2G). Moreover we found no differences in anxiety-related behavior in naïve mice 
treated with Ligand1 compared to the vehicle treated group (Suppl. Figure 2C-F), to rule out 
potential side effects.  
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Figure 2: The FKBP51F67V antagonist Ligand1 reverses the anxiogenic phenotype induced by 
overexpression of FKBP51F67V in the amygdala. A, Representative immunohistochemistry of viral 
FKBP51F67V expression (Ha-tag Immuno) in the BLA 7 weeks after injection. B, Representative of 
autoradiographs of viral FKBP51F67V mRNA expression in the BLA 7 weeks after injection. C, Quantification 
of FKBP51 mRNA levels in the BLA. Infection with the viral construct induced a strong increase. D, 
FKBP51F67V overexpression in the BLA leads to significantly reduced open arm time, independent of 
treatment group in the EPM. E and F, Vehicle treated 51OEF67V-BLA mice spend significantly less time and 
travel less distance in the lit compartment of the DaLi compared to vehicle treated control animals. This 
effect is abolished in the Ligand1 treated groups. G, General locomotion in the OF does not differ between 
the experimental groups. * p < 0.05 (ANOVA genotype effect); # p < 0.05 (Tukey post-hoc test); data are 
expressed as mean + SEM. 
 
The specific FKBP51 antagonist SAFit2 induces anxiolytic behavior in naïve mice 
When we injected the selective and potent FKBP51 antagonist SAFit2 1 hr prior to testing, 
we did not find any differences in anxiety-related behavior (Suppl. Figure 3). However, 
SAFit2 treatment induced an anxiolytic phenotype in mice injected in the afternoon, 16 hrs 
prior testing, which was reflected in an increased open arm time in the EPM (MW-test: T = 
79.000, p < 0.05) (Figure 3A). This finding was further support by an increase in the number 
of entries to the lit compartment (t-test: T20 = 2.593, p < 0.01) as well as in the time spent in 
the lit compartment (t-test: T20 = -2,275, p < 0.05) in the DaLi (Figure 3B and C). Moreover, 
SAFit2 treatment led to a reduced latency to enter the lit compartment (MW-test: T = 
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161.000, p < 0.05) as well as an increased distance traveled in the lit compartment (t-test: 
T20 = -2.371 p < 0.05) (Figure 3D and E). 
 
Figure 3: Inhibition of wild-type FKBP51 by SAFit2 induces anxiolytic behavior 16 hrs after injection. A, 
Mice treated with SAFit2 show a significant increase in the open arm time of the EPM. B and C, SAFit2 
leads to significantly increased entries to the lit compartment and significantly more time spent in the lit 
compartment of the DaLi. D and E, Mice treated with SAFit2 showed a significantly decreased latency to 
enter and a significantly increased distance traveled in the lit compartment of the DaLi. # p < 0.05, data 
are expressed as mean + SEM. 
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Discussion 
In our study, we show that specific FKBP51 overexpression in the BLA by viral transfection is 
able to mimic a stress-induced anxiogenic phenotype in mice. We then blocked an 
overexpressed FKBP51 variant (FKBP51F67V) in the BLA, with a highly selective FKBP51 
antagonist (Ligand1) and could thereby reduce the induced phenotypes of increased 
anxiety-related behavior in the DaLi box. When applying a selective and potent FKBP51 
antagonist (SAFit2), an anxiolytic phenotype in naïve mice in the EPM and the DaLi box is 
induced. 
The first focus of the study was the investigation of anxiety-related behavior following 
specific FKBP51 overexpression in the amygdala. The amygdala is an important brain region 
for the mediation of stress responses, fear and anxiety (Joëls and Baram, 2009). 
Interestingly, alterations in FKBP51 levels have been observed in suicide victims (Pérez-Ortiz 
et al., 2012). In mice, FKBP51 mRNA levels were significantly upregulated after acute 
stressors or dexamethasone stimulation in the amygdala (Scharf et al., 2011). In line with 
this study, we found that mice with an FKBP51 overexpression in the BLA show an increase 
in anxiety-related behavior, suggesting that the natural induction of amygdala FKBP51 
following stress functionally mediates stress-induced anxiety. Moreover, the anxiogenic 
phenotype was independent of locomotion as we did not find any differences in the open 
field test. Furthermore the increased anxiety-related effects were BLA specific, as FKBP51 
overexpression in the dorsal hippocampus did not reveal any changes in such behavior. 
FKBP52 is a close homologue of FKBP51 and shares more than 75% sequence similarity, but 
acts as functional opponent: FKBP51 decreases GR nucleus translocation and subsequent 
GR signaling, while FKBP52 enhances GR translocation to the nucleus (Wochnik et al., 2005). 
We could previously show that FKBP51 knockout mice demonstrate a reduced 
corticosterone response to forced swim stress, while mice lacking one allele of FKBP52 
showed increased corticosterone levels to this stressor and an anxiogenic phenotype 
(Chapter 1 and 3). Thus, the selectivity of an FKBP51 antagonist is crucial. At first, we tackled 
this challenge by using a bump-and-hole approach, overexpressing a functionally fully active 
FKBP51 variant carrying a point mutation (FKBP51F67V), which can selectively be blocked by 
the specifically designed FKBP51F67V-antagonist, Ligand1 (Gaali and Kirschner et al., 
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unpublished data). We could show that overexpression of FKBP51F67V in the BLA induced a 
similar anxiogenic phenotype in mice as overexpression of wild-type FKBP51, thereby 
confirming our initial results. When we sub-chronically treated these mice with Ligand1, we 
could reduce the increased anxiety-related behavior in the DaLi box. However, we were not 
able to fully reverse the induced phenotype, especially in the EPM, indicating a potentially 
too low dose or unfavorable pharmacokinetics in relation to the robust AAV-mediated 
FKBP51 overexpression. 
When using the selective and potent novel antagonist for wild-type FKBP51, SAFit2, we 
found that naïve mice injected 16 hr prior to testing with SAFit2 showed a significant 
anxiolytic phenotype in the EPM and DaLi. These results are in line with the observation that 
knockdown of FKBP51 in the BLA reduces stress-induced anxiety in mice (Attwood et al., 
2011). Our pharmacological approach revealed an interesting time dependency, as injection 
of SAFit2 1 h prior testing was ineffective. This time dependency may point to a genomic 
effect, possibly mediated by enhanced GR signaling. The activity of the HPA-axis is 
characterized by a prominent circadian rhythm with peak glucocorticoid secretion occurring 
shortly before the onset of an animal's activity period and nadir levels during the beginning 
of the resting period (Engeland and Arnhold, 2005; Kriegsfeld and Silver, 2006). This daily 
variation of glucocorticoid concentration is critical for homeostatic regulation of neural 
processes and subsequently for behavior. We could previously show that FKBP51 regulates 
corticosterone levels, by attenuating the negative feedback loop of the HPA-axis (Touma et 
al., 2011; Chapter 1). In addition, we recently demonstrated that mice treated with SAFit2 
showed reduced corticosterone levels during the circadian peak (Gaali and Kirschner et al., 
unpublished data). Inhibition of FKBP51 during the circadian peak of glucocorticoid 
secretion, may thus lead to an improved negative feedback loop of the HPA axis, mediated 
by enhanced GR signaling, which might explain the anxiolytic phenotype 16 hrs after the 
injection. However, FKBP51 has been shown to be involved in various other pathways 
besides its regulatory function of the GR (Pei et al., 2009; Blair et al., 2013), thus a more 
detailed molecular analysis may lead to further insight in this respect. 
In summary, our results represent a cornerstone in the current development of FKBP51 
inhibitors, because they pinpoint the potential of potent FKBP51 inhibitors to modulate 
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anxiety in vivo. These results further pave the way for the development of FKBP51 
antagonists in the context of pharmacotherapy for stress-related psychiatric diseases. 
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Supplemental Figures 
 
Supplemental Figure 1: Overexpression of FKBP51 in the dorsal hippocampus (dHc). A, Schematic 
representation of the viral injection sites into the CA1 and dentate gyrus (DG) of the dHc. B, 
Representative immunohistochemistry of viral FKBP51 expression (Ha-tag Immuno) in the dHc 7 weeks 
after injection. C, Representative of autoradiographs of viral FKBP51 mRNA expression in the dHc 7 weeks 
after injection. D, Quantification of FKBP51 mRNA levels in the CA1, CA3 and DG of the dHc. Infection 
with the viral construct induced a strong increase. E-H, No differences between 51OEdHc and Empty 
groups were found in the EPM and Dali. # p < 0.05, data are expressed as mean + SEM. 
 
 
Supplemental Figure 2: A and B, Ligand1 pharmacokinetics. The compound was administered i.p. at the 
indicated dose and the plasma and brain concentrations were determined after 1h. Ligand1 accumulates 
in the brain in a dose-dependent manner. C-G, Ligand1 did not show any overt behavioral side effects in 
the EPM and DaLi in naïve mice. 
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Supplemental Figure 3: A-D, Mice treated with SAFit2 do not show any differences to the vehicle group 
in the EPM and DaLi 1 h after the injection. 
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4. General discussion 
Psychiatric disorders such as major depression are a major disease burden, affecting an 
estimated 350 million people worldwide (Kessler et al., 2009). Psychiatric phenotypes are of 
multifactorial and polygenic nature, resulting from a complex interaction of environmental 
and genetic factors (Zannas and Binder, 2014). However, the underlying molecular 
mechanisms are still not fully understood. One of the most robust biological characteristics 
in many depressed patients is an impaired negative feedback of the HPA axis, leading to 
partial glucocorticoid resistance (Holsboer, 2000; Pariante and Lightman, 2008). Therefore 
a growing number of clinical studies investigated gene x environment interactions occurring 
at genetic loci involved in the stress response. FKBP51 emerged as an interesting candidate 
gene, due to its role as negative regulator of GR signaling and its associations with 
psychiatric disorders such as major depression and PTSD.  
This thesis provides further substantial evidence that FKBP51 is crucially involved in GR-
dependent stress susceptibility/resilience and consequently in stress physiology and 
psychiatric diseases. Moreover, it significantly extends the role of GR-independent functions 
of FKBP51 in the context of psychiatric disorders and antidepressant actions. At first, we 
tested FKBP51 knockout male mice in the well-established chronic social defeat stress 
paradigm with respect to immediate consequences (Chapter 1). In chapter 2, we 
investigated the role of FKBP51 in female mice under basal and acute stress conditions to 
elucidate potential FKBP51-dependent gender differences. We then studied the 
involvement of FKBP52, the functional counter-player of FKBP51, in the immediate effects 
of chronic stress (Chapter 3). We continued to investigate the long term consequences of 
chronic social defeat stress in FKBP51 knockout males. SNPs in the FKBP51 gene have also 
been associated with antidepressant treatment efficacy. Thus, to mimic the clinical 
situation, we concurrently tested whether currently prescribed antidepressants reveal an 
altered treatment response in FKBP51 knockout mice (Chapter 4) and elucidated a possible 
FKBP51-dependent mechanism priming antidepressant efficacy (Chapter 5). FKBP51 also 
raised the attention as a potential novel treatment approach, however, up to date there 
were no potent and selective inhibitors available. By using a novel class of very recently 
developed ligands, we were the first that extensively investigated the potential of FKBP51 
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as a drug target in vivo with respect to psychiatric disorders and further elucidated brain-
region specific roles of FKBP51 (Chapter 6). In summary, this thesis substantially contributes 
to the broad functions and interactions of FKBP51 in the context of psychiatric disorders (for 
an overview see Figure 3.1., page 166). 
4.1. GR-dependent functions of FKBP51 
Altered function of the GR and consequently an impaired negative feedback regulation of 
the HPA axis have repeatedly been shown to be key features in the precipitation, 
development and resolution of psychiatric disorders (Anacker et al., 2011). FKBP51 has been 
shown to be a major regulator of GR signaling and stress physiology. When it is bound to the 
GR, the receptor’s affinity for glucocorticoids is reduced (Binder, 2009). Previous preclinical 
studies investigated FKBP51 knockout mice under basal and acute stress conditions with 
regard to behavioral and neuroendocrine parameters. Touma and colleagues showed that 
FKBP51 knockout mice spent more time struggling and less time floating in the forced swim 
test following an acute severe stressor, implicating an enhanced stress-coping phenotype. 
Moreover, lack of FKBP51 led to decreased HPA axis reactivity and GR expression changes 
in response to stressors (Touma et al., 2011). Along these lines, O’Leary et al. demonstrated 
that aged FKBP51 knockout mice revealed a similar behavioral anti-depressant like 
phenotype already under basal conditions, both in the forced swim test and tail suspension 
test, as well as a reduced corticosterone response to an acute stressor (O'Leary, III et al., 
2011). In addition, 51KO mice demonstrated a pro-resilience sleep phenotype and showed 
reduced hippocampal corticosterone levels during the circadian peak of glucocorticoid 
secretion (Albu et al., 2013). To gain further insight into the complex nature of psychiatric 
diseases, we here investigated the role of FKBP51 in GR-dependent (chronic) stress 
physiology, as chronic stress is a major risk factor for the development of such disorders. 
At first we subjected FKBP51 knockout mice to the chronic social defeat stress paradigm. In 
support of the existing literature, we could provide further evidence that FKBP51 is crucially 
involved in stress physiology as we convincingly demonstrated that this co-chaperone 
mediates the neuroendocrine and behavioral consequences of chronic stress. We found a 
more resilient phenotype of FKBP51 knockout mice, especially with regard to 
neuroendocrine parameters (Chapter 1). Chronically stressed 51KO mice demonstrated a 
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reduced basal HPA axis activity, a blunted corticosterone response to an acute stressor, as 
well as an enhanced recovery from such stressor. In addition, these mice had lower adrenal 
gland weights. Female 51KO mice displayed the same neuroendocrine phenotype as males 
under basal and acute stress conditions, pointing to gender-independent FKBP51 effects, at 
least under low aversive circumstances (Chapter 2). 51KO mice also demonstrated a more 
resilient behavioral phenotype with respect to long term consequences of chronic stress 
(Chapter 4). In contrast to wild type mice, social behavior assessed three weeks after the 
stress period was not affected in 51KO mice. Moreover, the blunted corticosterone 
phenotype of 51KO mice was present at numerous time points. Considering the fact that 
FKBP51 reduces GR sensitivity in cellular models (Wochnik et al., 2005; Westberry et al., 
2006; Albu et al., 2013), an enhanced GR sensitivity is the most likely explanation for the 
changes in HPA axis settings assessed here. In the long run, such changes might also be able 
to alter the behavioral outcome and favor a more resilient phenotype of 51KO mice 
subjected to stress (see Figure 3.1).  
Strikingly, our results mirror findings of human studies with depressed patients carrying 
genetic variants of FKBP51. Activation of the GR induces FKBP51 expression, which 
promotes an ultra-short feedback of GR sensitivity (Binder, 2009). Interestingly, 
polymorphisms of FKBP51 have been associated with an altered FKBP51 mRNA induction 
following GR activation (Binder et al., 2004). Allele-specific alterations of the 3-dimensional 
conformation in the FKBP51 gene leads to enhanced stressor-induced induction of FKBP51 
and an impaired GR-mediated negative feedback of the HPA axis in risk allele carriers of 
rs1360780 (Klengel et al., 2013). Indeed, healthy subjects, carrying the high induction allele 
of rs1360780 were associated with a prolonged cortisol response to psycho social stress, 
and thus increased GR resistance (Ising et al., 2008). Furthermore, the impaired negative 
feedback seems to predispose individuals to psychiatric disorders, as carriers of the high 
induction alleles have been associated with an increased susceptibility to develop major 
depression and bipolar disorder in numerous studies in the past (Binder et al., 2004; Lekman 
et al., 2008; Willour et al., 2009; Lavebratt et al., 2010; Zobel et al., 2010; Zimmermann et 
al., 2011; Menke et al., 2013). We found that FKBP51 knockout mice were less affected by 
stress, reflected in a stress-resistant HPA system (Chapter 1, 2 and 4). Inhibition of FKBP51 
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might thus constitute a promising novel pharmacological approach to ameliorate the 
neuroendocrine alterations observed in patients with stress-related psychiatric disorders.  
The selectivity of FKBP51 ligands is extremely crucial, as FKBP51 and its close homologue, 
FKBP52, share more than 75% sequence similarity, but act as functional opponents of GR 
signaling (Wochnik et al., 2005). Indeed, we could show that FKBP51 knockout mice 
demonstrated a reduced corticosterone response to forced swim stress (Chapter 1, 2 and 
4), while mice lacking one allele of FKBP52 showed increased corticosterone levels to this 
stressor (Chapter 3) (see also Figure 3.1). Very recently we could show that the use of a 
newly developed potent and highly selective FKBP51 antagonist, SAFit2, led to significantly 
decreased corticosterone levels in mice during the circadian peak of glucocorticoid 
secretion, improved the neuroendocrine feedback following a DEX-CRH test and resulted in 
a more active stress-coping phenotype in the FST (Gaali and Kirschner et. al., unpublished 
data). These findings strongly overlap with the behavioral and neuroendocrine phenotype 
of FKBP51 knockout mice. We continued to comprehensively elucidate the potential of 
FKBP51 as a drug target in vivo with respect to psychiatric disorders and further studied 
brain-region specific roles of FKBP51 (Chapter 6). Interestingly, virus-mediated 
overexpression of FKBP51 in the hippocampus did not reveal an overt behavioral phenotype 
in mice. Although, hippocampal FKBP51 mRNA expression is rather strong under basal 
conditions compared to other regions of the murine brain, the induction of FKBP51 
expression, following GR activation, is much more pronounced in regions with low baseline 
expression, such as the PVN or the amygdala (Scharf et al., 2011). Accordingly, we found 
that FKBP51 overexpression in the BLA led to an anxiogenic phenotype in mice (Chapter 6). 
Interestingly, knockdown of FKBP51 in the BLA resulted in reduced anxiety-related behavior 
in mice that were previously restraint stressed (Attwood et al., 2011). Along these lines, we 
found that pharmacological inhibition of FKBP51, using the potent and selective antagonist 
SAFit2, led to anxiolytic behavior 16 hrs after injection (Chapter 6). The pharmacological 
approach revealed an interesting time dependency, as injection of SAFit2 1 h prior testing 
was ineffective (see Figure 3.1). This time dependency may point to a genomic effect, 
possibly mediated by enhanced GR signaling.  
Taken together, our findings substantially contribute to the knowledge of GR-dependent 
effects of FKBP51 on stress-physiology and represent a cornerstone in the current 
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development of FKBP51 inhibitors in the context of pharmacotherapy for stress-related 
psychiatric diseases. 
4.2. GR-independent functions of FKBP51 
Besides the well-established association of FKBP51 polymorphisms with psychiatric 
disorders and the corresponding involvement of FKBP51 in GR-dependent stress-physiology, 
clinical studies suggested a link between genetic variants of FKBP51 and antidepressant 
treatment response. Binder and colleagues were the first to report that patients carrying 
the high induction/risk allele of FKBP51 SNP rs1360780 were associated with an enhanced 
antidepressant efficacy (Binder et al., 2004). Since then several other studies demonstrated 
significant correlations between FKBP51 SNPs and treatment outcome in independent 
samples (Lekman et al., 2008; Kirchheiner et al., 2008; Zou et al., 2010; Horstmann et al., 
2010; Ellsworth et al., 2013). However, the molecular basis for the FKBP51-dependent 
treatment response remained far from clear. 
In line with the clinical situation, we could show that lack of FKBP51 resulted in reduced 
response to acute and chronic administration of the antidepressant paroxetine (Chapter 4 
and 5). Paroxetine-induced bodyweight gain, as observed in wild-type mice, was absent in 
mice with a deletion of FKBP51. Moreover, in contrast to wild-type mice, FKBP51 knockout 
mice did not show an increase in time struggling and a reduction in time floating in the 
forced swim test. In addition, chronic paroxetine treatment was able to enhance social 
behavior under basal and chronically stressed conditions in wild-type mice, but showed no 
effects in 51KO mice (see Figure 3.1).  
Since the known GR-dependent functions of FKBP51 in stress physiology were unlikely to 
serve as link to antidepressant action, we searched for novel FKBP51 functions. Indeed, 
FKBP51 has been shown to be involved in various other pathways besides its regulatory role 
of the GR (Pei et al., 2009; Blair et al., 2013). Based on reports that some antidepressants 
alter at least the initial processes of autophagy (Rossi et al., 2009; Zschocke et al., 2011), we 
analyzed whether putative convergent molecular pathways addressed by both FKBP51 and 
antidepressants might explain and substantiate the suggested impact of FKBP51 on 
antidepressant efficacy. 
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We found that FKBP51 interacts with the autophagy executer Beclin1, alters protein 
interactions and phosphorylation of Beclin1, and thereby promotes autophagic pathways 
(Chapter 5).  
 
Figure 3.1: Schematic overview of major FKBP51 related pathways and their impact on different genetic 
and pharmacological outcomes. (1) FKBP51 is involved in both, GR signaling and autophagic pathways. 
(a) Following stress, circulating corticosterone binds to GR, but FKBP51 (which is important for GR 
maturation) lowers the receptor’s affinity for the stress hormone. (b) Upon corticosterone binding, a 
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switch from FKBP51 to FKBP52 promotes the translocation of the GR-hsp90 machinery into the nucleus 
(c) and subsequent DNA binding (d). FKBP51 itself is a GR target-gene and forms and ultra-short feedback 
loop, leading to increased FKBP51 transcription and translation (e), following GR activation. (f) Increased 
FKBP51 protein results in higher GR resistance, completing the ultra-short negative feedback loop on GR 
sensitivity. FKBP51 also interacts with PHLPP, Akt and Beclin1. (g) PHLPP de-phosphorylates Akt in Akt1. 
(h) Inactive Akt is recruited to Beclin 1, which results in lower phosphorylation of Beclin1, and thus (i) 
leading to the induction of autophagic pathways. (j) SSRIs act on the same pathways in an FKBP51-
dependent manner and change FKBP51-protein interactions. (2) Activation of both FKBP51-dependent 
mechanisms result in various physiological, neuroendocrine and behavioral alterations depending on the 
genetic and pharmacological manipulation. (I) FKBP52+/- mice show a mixed phenotype of stress 
susceptibility and resilience. (II) Following stress, FKBP51-/- mice demonstrate a more resilient phenotype. 
(III) Independent of condition, lack of FKBP51 results in lower SSRI treatment response. (IV) FKBP51 
overexpression in the hippocampus has no major effects, but overexpression in the BLA leads to an 
anxiogenic phenotype. (V) Pharmacological inhibition of FKBP51 results in a time-dependent anxiolytic 
phenotype.  
In line with our findings from chronic paroxetine treatment, we found that FKBP51 is not 
only required for the acute effects of the antidepressant paroxetine on behavior and 
synaptic function, but also for the effect on Beclin1 (see Figure 3.1). In human blood cells of 
healthy subjects, FKBP51 levels correlate with the potential of antidepressants to induce 
autophagic pathways. Further, data from patients suffering from depression show that the 
levels of both FKBP51 and Beclin1 in peripheral blood cells at admission correlate with the 
later antidepressant treatment outcome. Intriguingly, the antidepressant response of 
autophagic markers in ex vivo cultivated blood cells from inpatients predicts the clinical 
antidepressant response. Thus, we were able to unravel the first molecular correlate for the 
genetic association of FKBP51 with clinical antidepressant response. Moreover, the new 
molecular functions of FKBP51 are of high physiological and clinical relevance as they could 
serve as novel predictive markers. 
4.3. Implications for novel treatment options 
Depression is a devastating psychiatric disorder that raises the need for elaborated 
pharmacological interventions. Although, currently available antidepressants show an 
overall favorable benefit/risk balance, pharmacotherapy still suffers from modest efficacy, 
because less than 50% of patients achieve full remission following treatment, indicating a 
large inter-individual variability in treatment efficacy (Geddes and Miklowitz, 2013). Thus, 
the need for a personalized medicine in psychiatric disorders is stronger than ever. At its 
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root, personalized medicine is based on the assumption that an individual’s unique 
characteristics play a central role in both disease susceptibility and in response to specific 
therapies. Such characteristics include, among others, genetic variants and epigenetic 
modifications, environmental factors and the individual’s life history as well as observable 
biomarker changes. Thus, the major goal of personalized medicine is to predict the 
individuals disease vulnerability, achieve an accurate diagnosis, and optimize the most 
efficient and favorable response to treatment (Myers and Nemeroff, 2010; Ozomaro et al., 
2013). 
In recent years, FKBP51 has emerged as a promising new drug target for the development 
of mechanistically novel antidepressants. Our findings provide substantial evidence to the 
concept of FKBP51 as an important factor governing gene-environment interactions 
relevant for the etiology of psychiatric disorders and further promote the idea of FKBP51 
antagonists as novel treatment strategy in psychiatric disorders. FKBP51 inhibition could be 
most effective in depressed patients who suffer from an HPA axis insensitivity, as 
enhancement of the negative feedback of the HPA axis could accelerate remission, which is 
another major limitation of all known antidepressant treatments (Schmidt et al., 2012). 
The poor effectiveness of commonly used antidepressants, such as SSRIs, is also partially 
accounted for by their still largely unknown molecular mechanisms that are responsible for 
their clinical potency. In the search for antidepressants’ mechanisms of action beyond their 
influence on monoaminergic neurotransmission, antidepressant drugs have been shown to 
stimulate autophagic pathways (Zschocke et al., 2011). We now found that FKBP51 is 
involved in priming autophagic pathways, which are required for full antidepressant 
potency. Thus, the newly discovered functions of FKBP51 also provide novel predictive 
markers for treatment outcome, highlighting their physiological and clinical relevance in 
personalized medicine.  
It is important to note that FKBP51 is a multi-domain and multi-functional protein. Some of 
its functions such as the involvement in autophagic initiation are mediated by other domains 
than the PPIase pocket, in which novel FKBP51 ligands bind. Therefore, FKBP51-dependent 
autophagic pathways will most likely not be affected by the novel FKBP51 ligands. Indeed, it 
has been shown that none of the new class inhibitors of FKBP51 affected AktS473 
phosphorylation or downstream targets of Akt (Fabian et al., 2013; Hausch et al., 2013). 
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Thus, in the clinical situation, treatment with commonly used antidepressants would not 
necessarily exclude simultaneous pharmacotherapy with novel FKBP51 ligands.   
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4.4. Summary and future perspectives 
This thesis constitutes a compelling basis for the role of FKBP51 in stress-related psychiatric 
disorders. We thoroughly explored the implication of FKBP51 and its functional counter-
player FKBP52 in the context of environmental challenges, and could provide strong 
evidence that FKBP51 is involved in the neuroendocrine and the behavioral response and 
recovery to acute and chronic stress. Moreover, we identified and elucidated a novel role of 
FKBP51 in antidepressant treatment efficacy and investigated its potential as a novel and 
alternative drug target for psychiatric disorders (see Figure 3.1). Nonetheless, many open 
questions remain and should be addressed in future studies. It is important to continue with 
the identification of FKBP51’s role in brain regions other than the hippocampus and the 
amygdala. The PVN could be of special interest, because of its crucial involvement in the 
negative feedback of the HPA axis and its strong induction of FKBP51 mRNA following stress. 
Moreover, it is not clear which neuronal populations express FKBP51. The generation of 
brain region and or neurotransmitter-specific FKBP51 knockout and overexpressing mouse 
lines could be a useful tool to shed some light on these issues. Another important point 
includes experiments with chronic treatment of FKBP51 antagonists in combination with 
chronic stress models, as well as the simultaneous administration of FKBP51 compounds 
and SSRIs. In order to pursue the path of drug development of FKBP51 ligands, the 
underlying molecular mechanisms and actions of FKBP51 and its inhibitors need to be fully 
clarified, to subsequently be considered suitable to enter clinical trials.  
Taken together, this thesis will help to broaden the view of FKBP51 in the context of 
psychiatric diseases from strictly GR-dependent / HPA axis related functions to alternative 
roles of FKBP51, such as its convergent impact on autophagy and antidepressant action.  
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Abstract 
While anxiety disorders constitute a major disease and social burden worldwide, little is 
known about the underlying molecular mechanisms. Besides the involvement of the major 
excitatory (glutamate) and inhibitory (GABA) neurotransmitter systems in anxiety, the stress 
system has been directly implicated in the pathophysiology of these complicated mental 
disorders. Here, the main receptor for the stress hormone corticosterone, the glucocorticoid 
receptor (GR), seems to play a central role, but its function in glutamatergic and GABAergic 
neurons has not been addressed yet. We therefore generated mice with selective deletion 
of the GR in glutamatergic or GABAergic neurons and investigated their neuroendocrine, 
behavioral and neurotransmission profile. GR loss in glutamatergic, but not in GABAergic, 
neurons specifically promoted fear and anxiety, hypothalamic-pituitary-adrenal axis 
hyperactivity and electrophysiological neuroadaptations, while locomotion and stress-
coping behavior remained unaffected. Our data suggests a central and specific role of GR in 
the major excitatory neurotransmitter system for the regulation of fear and anxiety 
behaviors and sheds further light on the molecular mechanisms underlying anxiety 
disorders. 
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Introduction 
Anxiety disorders such as generalized anxiety disorder, panic disorder, obsessive-
compulsive disorder and post-traumatic stress disorder, represent the most common 
psychiatric illnesses, with a lifetime prevalence of approximately 30% in the U.S. (Kessler et 
al., 2005; Norrholm and Ressler, 2009; Vos et al., 2012).  
Dysfunctions of the major excitatory (glutamate) and inhibitory (gamma aminobutric acid, 
GABA) neurotransmitter circuits have been implicated in anxiety disorders. In particular, an 
imbalance between these neurotransmitter systems can lead to abnormal excitability of the 
anxiety-related neuronal network, thereby causing aberrant behavioral responses (Gross 
and Hen, 2004; Kalueff and Nutt, 2007; Wu et al., 2008; Sanacora et al., 2012; Zorumski et 
al., 2013). 
The major environmental risk factor for anxiety disorders is exposure to traumatic and 
stressful situations such as threats and social stress. These situations activate the 
hypothalamic-pituitary-adrenal (HPA) axis, which ultimately leads to the enhanced secretion 
of glucocorticoids (GCs). GCs alter neuronal activity in brain regions, such as the 
hippocampus and the basolateral amygdala, which are implicated in attention, vigilance and 
the determination of appropriate behavioral strategies. This mechanism allows the body to 
optimally face the stress challenges and adapt to environmental stimuli. GCs act via 
glucocorticoid receptors (GR) and mineralocorticoid receptors (MR), and proper GR 
signaling is critical for an appropriate stress response. Dysfunction of the HPA axis and 
altered GR signaling can trigger the development of psychiatric disorders such as depression 
and pathological anxiety (de Kloet et al., 2005a; Joëls and Baram, 2009; Joëls, 2011). 
Molecular and genetic approaches previously implicated the GR in the modulation of stress-
related behaviors (Tronche et al., 1999; Wei et al., 2004; Müller and Holsboer, 2006; Wagner 
et al., 2011; Barik et al., 2013). 
Interestingly, the fundamental question whether GR activation in glutamatergic and/or 
GABAergic neurons is involved in the modulation of anxiety still remains unsolved. 
Therefore, we set out to investigate the specific effect of GRs on stress system activity and 
emotional behavior by generating conditional mouse mutants lacking the receptor in 
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glutamatergic (GRGlu-CKO mice) or GABAergic neurons (GRGABA-CKO mice). Our models have the 
unique potential to specifically dissect the role of GR activation in the major excitatory and 
inhibitory neurotransmitter system of the CNS. 
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Materials and Methods 
Animals and housing 
In all experiments male mice were used, aged 2-4 month, singly housed two weeks prior to 
the experiment under standard conditions (12L:12D light cycle, lights on at 08:00 AM, 
temperature 23±2°C). Food (Altromin 1324, Altromin GmbH, Germany) and tap water were 
available ad libitum. mEPSC recordings were performed at the University Medical Center 
Utrecht, Rudolf Magnus Institute of Neuroscience, Utrecht, the Netherlands. All other 
experiments were carried out in the animal facilities of the Max Planck Institute of Psychiatry 
in Munich, Germany. The experiments were carried out in accordance with the European 
Communities' Council Directive 2010/63/EU. All efforts were made to minimize animal 
suffering during the experiments. The protocols were approved by the committee for the 
Care and Use of Laboratory animals of the Government of Upper Bavaria, Germany. 
 
Generation of neurotransmitter-specific GR conditional KO lines 
The generation of GR-floxed mice was previously described (Tronche et al., 1999). 
Conditional GR mutant mice were obtained by breeding GRflox/flox mice to the respective Cre-
expressing mouse lines using a three generation breeding scheme. 
For the selective disruption of GR in forebrain glutamatergic neurons, GRflox/flox mice were 
bred to Nex-cre mice (Goebbels et al., 2006). The helix-loop-helix transcription factor Nex 
(also known as NeuroD6/Math2) is a marker of embryonic cortical neuronal precursors (Wu 
et al., 2005). In the adult brain Nex is expressed in mature glutamatergic cortical neurons. 
Accordingly, in Nex-cre mice Cre mediated recombination is essentially restricted to 
glutamatergic neurons of the telencephalon: mitral and periglomerular layers of the 
olfactory bulb, projection neurons of the cortex, pyramidal neurons of the CA1 and CA3 
regions of the cornus ammoni, granule cells of dentate gyrus, glutamatergic mossy cells of 
the hilus of the dentate gyrus and the cortical-related amygdaloid nuclei (lateral and 
basolateral amygdala, basomedial amygdala and cortical amygdaloid nucleus) (Goebbels et 
al., 2006). Resulting GR+/flox Nex-cre offspring was bred to GRflox/flox mice and finally the line 
was maintained by breeding GRflox/flox Nex-cre (here called GRGlu-CKO) mice to GRflox/flox (here 
called GRGlu-Ctrl).  
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For the selective disruption of GR in forebrain GABAergic neurons GRflox/flox mice were bred 
to the Dlx5/Dlx6 (Dlx)-cre mice. In Dlx-cre mice the Cre-recombinase is expressed under the 
control of the regulatory sequences of the Dlx5/Dlx6 genes, which are homeobox genes 
expressed in migrating forebrain GABAergic neurons during development (Stühmer et al., 
2002). Indeed, in the adult brain Dlx-cre mice show a specific inactivation of floxed alleles in 
forebrain GABAergic neurons (Monory et al., 2006). GRflox/flox Dlx-cre mice (here called 
GRGABA-CKO) were obtained by breeding GRflox/flox (here called GRGABA-Ctrl) to Dlx-cre mice as 
described above.  
Genotyping 
Genotyping was performed by PCR using the following primers: GR-flox1, 5´- GGC-ATG-CAC-
ATT-ACG-GCC-TTC-T-3´; GR-flox8, 5´-CCT-TCT-CAT-TCC-ATG-TCA-GCA-TGT-3´ and GR-flox4, 
5´-GTG-TAG-CAG-CCA-GCT-TAC-AGG-A-3´. Standard PCR conditions resulted in a 225-bp 
wild-type and a 275-bp floxed PCR product. A premature deletion of the floxed allele would 
have been identified by the occurrence of a 390-bp PCR product. In Nex-cre and Dlx-cre mice, 
the presence of Cre was evaluated using the primers CRE-F 5′-GAT-CGC-TGC-CAG-GAT-ATA-
CG-3′, CRE-R 5′-AAT-CGC-CAT-CTT-CCA-GCA-G-3′, Thy-F 5´-TCT-GAG-TGG-CAA-AGG-ACC-
TTA-GG-3´ and Thy-R 5´- CCA-CTG-GTG-AGG-TTG-AGG-3´, resulting in a Cre-specific PCR 
product of 574 bp and a control PCR product of Thy1 of 372 bp. All mouse lines used were 
on a mixed 129S2/Sv×C57BL/6J genetic background. All animals used in single experiments 
were littermates. Experimenters were always blind to genotype. 
 
In situ hybridization 
Mice were sacrificed by decapitation in the morning (0830 to 0930 h) following quick 
anaesthesia by isoflurane. Brains were removed, snap-frozen in isopentane at -40 °C, and 
stored at -80 °C. Frozen brains were sectioned at -20 °C in a cryostat microtome at 18 µm, 
thaw mounted on Super Frost Plus slides, dried and stored at -80 °C. In-situ hybridization 
using 35S UTP labeled ribonucleotide probes (GR, MR and CRH) was performed as described 
previously (Schmidt et al., 2007). Briefly, sections were fixed in 4% paraformaldehyde and 
acetylated in 0.25% acetic anhydride in 0.1 M triethanolamine/ HCl. Subsequently, brain 
sections were dehydrated in increasing concentrations of ethanol. The antisense cRNA 
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probes were transcribed from a linearized plasmid. Tissue sections were saturated with 100 
ml of hybridization buffer containing approximately 1.5 x 106 cpm 35S labeled riboprobe. 
Brain sections were coverslipped and incubated overnight at 55 °C. The following day, the 
sections were rinsed in 2 x SSC (standard saline citrate), treated with RNAse A (20 mg/l) and 
washed in increasingly stringent SSC solutions at room temperature. Finally, sections were 
washed in 0.1 x SSC for 1 h at 65 °C and dehydrated through increasing concentrations of 
ethanol. The slides were exposed to Kodak Biomax MR films (Eastman Kodak Co., Rochester, 
NY) and developed. Autoradiographs were digitized, and expression was determined by 
optical densitometry utilizing the freely available NIH ImageJ software. The mean of four 
measurements of two different brain slices was calculated for each animal. The data were 
analyzed blindly, always subtracting the background signal of a nearby structure not 
expressing the gene of interest from the measurements.  
 
Immunohistochemistry 
Mice were deeply anesthetized with isoflurane and perfused intracardially with 4% 
paraformaldehyde. Brains were removed, post-fixed overnight in 4% paraformaldehyde 
following overnight incubation in 30% sucrose solution at 4 °C, and then stored at -80 °C. 
Frozen brains were coronally sectioned in a cryostat microtome at 30 µm and kept at -80 °C. 
Double-labeling immunofluorescence (rabbit anti-GR (M-20): 1:1000, Santa Cruz; 
Alexafluor) was performed on free-floating sections as described previously (Wang et al., 
2011a). Immunohistochemical analysis was carried out by a laser-scanning confocal 
microscope. Images were acquired simultaneously in two acquisition channels with the 
FLUOVIEW FV 1000 (version 3.3) acquisition analyzer program. 
 
Sampling procedure 
Organ sampling 
Mice were sacrificed by decapitation following quick anaesthesia by isoflurane. Brains were 
removed, snap-frozen in isopentane at -40 °C, and stored at -80 °C for in situ hybridization. 
Adrenal and thymus glands were removed, dissected from fat and weighed. 
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Hormone measurements 
To determine basal corticosterone and ACTH levels, blood sampling was performed in the 
early morning (0830 to 0930 h) and afternoon (0430 to 0530 h, only corticosterone) by 
collecting trunk blood from animals rapidly decapitated under isoflurane anesthesia, with 
the time from first handling of the animal to completion of bleeding not exceeding 45 sec. 
For evaluation of the corticosterone response and recovery to stress, we collected blood 
samples 30 min (response levels) and 90 min (recovery levels) after an acute stressor (a 
forced swim test) by tail cut (Fluttert et al., 2000). Stress experiments were performed in 
the morning (08:30–10:00 am). All blood samples were gathered in labeled 1.5 ml EDTA-
coated microcentrifuge tubes (Kabe Labortechnik, Germany) and kept on ice until 
centrifugation at 4 °C and 8000 rpm for 15 min. After centrifugation, the blood plasma was 
transferred to a new, labeled 1.5 ml microcentrifuge tube. All plasma samples were stored 
frozen at -20 °C until the determination of corticosterone or ACTH by commercially available 
RIA kits (MP Biomedicals Inc). 
 
Behavioral testing 
All behavioral tests were recorded using a videotracking system (Anymaze 4.20; Stoelting). 
The following behavioral tests were performed between 0830 and 1230 h in the same room 
in which the mice were housed: open field (OF), elevated plus maze (EPM), dark-light box 
(DaLi), forced swim test (FST), fear conditioning and extinction. The testing procedures were 
performed as described below. 
Open field 
The open-field test was performed to investigate general locomotor activity. Testing was 
carried out in an empty open-field arena (50 cm x 50 cm x 50 cm) made of gray polyvinyl 
chloride (PVC), under low light conditions (5 Lux). The low illumination of the open field 
arena was chosen to specifically investigate locomotion behavior and not create an aversive 
center region that may induce anxiety-related behavior. Testing time was 30 min and the 
distance travelled was recorded.  
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Elevated plus maze 
The EPM was conducted to assess changes in anxiety-related behavior. The device consisted 
of a plus-shaped platform with two opposing open arms (30 cm x 5 cm x 0.5 cm) and two 
opposing enclosed arms (30 cm x 5 cm x 15 cm), made of gray PVC, which were connected 
by a central area (5 cm x 5 cm). The whole device was elevated 50 cm above the floor, 
illumination was 5 Lux. Testing duration was 10 min. Mice were placed into the center zone 
facing one of the enclosed arms at the start of the test. The time spent in the open arms and 
the number of open arm entries were analyzed. 
Dark-Light box 
The DaLi was used as another test to measure anxiety-related behavior. The apparatus 
consisted of a rectangular box with two compartments, the dark compartment (15 cm x 20 
cm x 25 cm), with <10 lux and the light compartment (30 cm x 20 cm x 25 cm), lit with 700 
lux. Both compartments were connected by a 4 cm long tunnel. At the beginning of the test, 
each mouse was placed in the center of the dark compartment facing the back wall of the 
apparatus. Testing duration was 5 min. The time spent in the lit compartment, as well as the 
distance travelled in the lit compartment were analyzed. 
Forced swim test 
The FST was used to assess stress-coping behavior. Each mouse was put into the a 2 l glass 
beaker (diameter: 13 cm, height: 24 cm) filled with tap water (21 ± 1 °C) to a height of 15 
cm, so that the mouse could not touch the bottom with its hind paws or tail. Testing duration 
was 6 min. Time spent immobile (floating) and time spent struggling was scored by an 
experienced observer, blind to genotype of the animals.  
Fear conditioning and extinction procedures 
Fear conditioning: For conditioning, mice were placed into a conditioning chamber (Bioseb, 
France) with a cubic-like shape and a metal grid floor for shock application, and the chamber 
light was switched on. Three minutes later, a 20 s sine wave tone (80 dB, 9 kHz) was 
presented that co-terminated with a 2 s scrambled electric footshock of 0.7mA. Animals 
remained in the shock context for additional 60 s before they were returned to their home 
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cages. After each trial, the chamber was cleaned with 70% EtOH and the bedding (wood 
shavings) placed underneath the grid was changed. 
Fear extinction: To measure the freezing response to the tone without confounding 
influences of contextual memory, conditioned mice were tested in a neutral environment 1 
day (Ext. d1), 2 days (Ext. d2) and 7 days (Ext. d7) after conditioning, adapted from Plendl 
and Wotjak (Plendl and Wotjak, 2010). Briefly, mice were placed in the test context, which 
differed from the conditioning context in material, shape, surface texture, and odor of the 
cleaning solution (1% CH3COOH). After an initial 3 min of habituation (lights on), mice were 
confronted either with 30 x 20 s tones (9 kHz, 80 dB, Ext. d1) or with 10 x 20 s tones of the 
same characteristics (Ext. d2 and Ext. d7) presented with variable tone intervals ranging 
from 20 to 35 s. Mice returned to their home cage 60 s after the end of the exposure 
protocol.  
For a detailed overview of the conditioning and extinction protocols see supplemental table 
1. Stimuli (Light, tone and shock) for conditioning and extinction sessions were operated 
with commercially available software (Packwin V2.0.01; Panlab, Spain). Freezing responses 
over the course of tone presentations were averaged in tone bins of 5 tones and normalized 
to the length of the analysis interval (5 tone bins of Ext. d1, 2 tone bins each of Ext. d2 and 
Ext. d7). The first tone of extinction day1 was excluded, because mice displayed escape 
behavior during this tone, attempting to jump out of the chamber (Riddle et al., 2013). 
 
mEPSC recordings 
Animals (12-16 weeks old) were decapitated under rest in the morning. The brain was 
removed from the skull and chilled (4 °C) in artificial cerebrospinal fluid (aCSF) containging 
120 mmol/L NaCl, 3.5 mmol/L KCl, 5.0 mmol/L MgSO4, 1.25 mmol/L NaH2PO4, 0.2 mmol/L 
CaCl2, 10 mmol/L D-glucose, and 25.0 mmol/L NaHCO3 (gassed with 95% O2 and 5% CO2). 
Coronal slices (350 µm thick) containing the BLA were prepared with a vibrosclicer (Leica VT 
1000S). Slices were stored at room temperature until use in recording aCSF containing 120 
mmol/L NaCl, 3.5 mmol/L KCl, 1.3 mmol/L MgSO4, 1.25 mmol/L NaH2PO4, 2.5 mmol/L CaCl2, 
10 mmol/L D-glucose, and 25.0 mmol/L NaHCO3.  
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One slice at a time was placed in a recording chamber mounted on an upright microscope 
(Axioskop 2 FS plus; Zeiss) with differential interference contrast, water-immersion 
objective (63x), and 10x ocular. The slices were continuously perfused with aCSF (flowrate 
2-3 mL/min,, temperature 32 °C, pH 7.4) consisting of 120 mM NaCl, 3.5 mM KCl, 1.3 
mMMgCl2, 2.5 mM CaCl2, 25 mM NaHCO3, 1.25 mM KH2PO4, and 10 mM D-glucose; 
bicuculline methylchloride (20 µm; Tocris) and tetrodotoxin (o.5 µm; Latoxan) were added 
to block GABAA receptor-mediated signals and action potentials, respectively. For mEPSC 
recordings, the intracellular pipette solution contained 120 mM Cs methane sulphonate, 
17.5 mM CsCl, 10 mM Hepes, 5 mM BAPTA, 2 mM MgATP, and 0.1 mM Na GTP (295 mOsm, 
pH 7.4 adjusted with CsOH). BAPTA was obtained from Molecular Probes; all other chemicals 
were purchased from Sigma. Neurons in the BLA were selected for recording if they 
displayed a pyramidal- shaped cell body. All mEPSCs were recorded with a holding potential 
of −70 mV. If the neuron under study displayed stable mEPSC properties during baseline 
recording (at least 10 min), corticosteroids were applied for ≈10 min via the perfusion 
medium. In one set of cells, we compared cells 1 h after a 10 min application of 
corticosterone or vehicle, as described previously (Liebmann et al., 2008). Corticosterone, 
was prepared weekly in a stock solution (1 mM in 95% ethanol) and diluted to its final 
concentration in aCSF just before application. Corticosterone was dissolved directly in aCSF 
and freshly prepared on the day of the experiment. Series resistance compensation was 
>70% in all recordings. Series resistance and capacitance were monitored during the whole 
recording. Responses were filtered at 5 kHz and digitized at 10 kHz (Digidata 1322A; Axon 
Instruments). All data were acquired, stored, and analyzed on a PC using pClamp 9.0 and 
Clampfit 9.2 (Axon Instruments). Minimal cutoff for mEPSC analysis was 6 pA. 
 
Statistical Analysis 
The data presented are shown as means +SEM and were analyzed by the commercially 
available software SPSS 17.0 and Sigma Plot 11.0. When two groups were compared, the 
unpaired student’s t-test was applied. If data were not normally distributed the non-
parametric Mann-Whitney test was used. Comparisons between mEPSC properties 
determined during the final 5 min of baseline recording and the final 5 min of recording in 
the presence of corticosterone in the same cells, were analyzed by one-tailed paired t-test. 
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The courses of locomotor activity in the OF and the freezing responses during fear extinction 
were analyzed by repeated measure analysis of variance (ANOVA). P values of less than 0.05 
were considered significant. 
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Results 
GRs are largely expressed in glutamatergic neurons of the limbic system 
In situ hybridization demonstrated that lack of GR mRNA in GRGlu-CKO mice was most 
prominent in limbic regions such as the basolateral amygdala (BLA), PVN and dorsal and 
ventral hippocampus, but also in other regions such as cortex and piriform cortex. Deletion 
of GR in GABAergic neurons was mainly observed in caudate putamen, but also the central 
amygdala (Fig. 1 and suppl. Fig. 1).  
 
Figure 1: Neurotransmitter-specific GR-CKO lines lack GR expression in a cell type-specific manner. 
Expression of GR mRNA was assessed by ISH in wild-type and neurotransmitter-specific GR-CKO lines. 
Autoradiographs of GR mRNA expression pattern in brain sections of wild-type, GRGlu-CKO and GRGABA-CKO 
mice. Areas of interest are highlighted with arrowheads and dashed lines. CPu, caudate putamen; Pir, 
piriform cortex; Ctx, cortex; PVN, paraventricular nucleus; dHc, dorsal hippocampus, Coronal sections of 
control and mutant mice were stained for GR and DAPI. Amy, amygdala, CeA, central amygdala, BLA, 
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basolateral amygdala; PVN, paraventricular nucleus; dHc, dorsal hippocampus; CeA, central amygdala; 
BLA, basolateral amygdala; vHc, ventral hippocampus. 
 
This expression pattern was entirely recapitulated by applying immunohistochemistry using 
antibodies against GR (Fig. 2 and suppl. Fig. 1) in GRGlu-CKO and GRGABA-CKO mice. 
 
Figure 2: Coronal sections of control and mutant mice were stained for GR and DAPI. Amy, amygdala, 
CeA, central amygdala, BLA, basolateral amygdala; PVN, paraventricular nucleus; dHc, dorsal 
hippocampus; magnification x10. Scale bar, 250 µm. GR deletion in GRGlu-CKO mice is most prominent in 
limbic structures, such as the BLA, PVN and hippocampus, whereas lack of GR in GRGABA-CKO mice was 
mainly observed in the CeA. 
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Absence of GRs in glutamatergic neurons results in HPA axis hyperactivity 
One of the most robust biological abnormalities observed in many depressed patients is an 
impaired negative feedback regulation of the HPA axis and thus, to partial glucocorticoid 
resistance (Holsboer, 2000; Pariante and Miller, 2001). The expression pattern of GR in the 
glutamatergic system revealed substantial overlap with key players and regulators of the 
HPA axis and the limbic system, such as the PVN, the hippocampus and the BLA. We 
therefore studied whether neurotransmitter-specific deletion of GR in gluatmatergic or 
GABAergic pathways would have an effect on HPA axis regulation.  
We found that basal am and pm corticosterone levels were significantly increased in GRGlu-
CKO compared to GRGlu-Ctrl mice (Fig. 3A and B). Moreover, response levels taken 30 min after 
an acute stressor showed significantly increased corticosterone levels in GRGlu-CKO, while 
recovery levels assessed 90 min after the FST did not differ between the genotypes (Fig. 3C 
and D). Interestingly, we did not observe any changes in corticosterone levels in the GRGABA-
CKO mouse line (Fig. 3E-H). We then checked for adrenal and thymus gland weight, as 
alterations in these organs are often associated with HPA axis activity. Indeed, adrenal gland 
weight was significantly increased and thymus weight was significantly decreased in GRGlu-
CKO mice compared to controls (Fig. 3I and J), while there were no changes in GRGABA-CKO mice 
(Suppl. Fig. 2A and B).  
To discriminate whether the increased corticosterone levels in GRGlu-CKO mice are resulting 
from peripheral effects due the increased adrenal gland weight or whether the adrenal 
gland weight is the consequence of central effects, we assessed ACTH levels in the GRGlu-CKO 
mouse line. GRGlu-CKO mice showed significantly increased ACTH levels compared to GRGlu-Ctrl 
mice (Fig. 3K), with no differences in the GRGABA-CKO mouse line (Suppl. Fig. 2C). Along these 
lines, we detected significantly increased CRH mRNA levels in the PVN of GRGlu-CKO mice (Fig. 
3L).  
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Figure 3: GR signaling in glutamatergic neurons is necessary for appropriate HPA axis activity, while GR 
activity in GABAergic neurons is dispensable for such parameters. A and B, Basal am and pm 
corticosterone levels were increased in GRGlu-CKO mice (am: MW-test, T = 153.00, p < 0.001, ctrl n = 12, 
GRGlu-CKO n = 9; pm: t-test, T21 = -2.697, p < 0.05, ctrl n = 12, GRGlu-CKO n = 11). C, Corticosterone response 
levels, assessed 30 min after an acute stressor, were increased in GRGlu-CKO mice (t-test, T19 = -3.309, p < 
0.05, ctrl n = 12, GRGlu-CKO n = 9). D, Recovery levels, assessed 90 min after the stressor, did not differ in 
the GRGlu-CKO mouse line. E-H, Basal am and pm, as well as response and recovery corticosterone levels 
did not differ between GRGABA-CKO and control littermates (n = 10-12 per group). I, Thymus weight was 
decreased in GRGlu-CKO mice (t-test, T19 = 3.190, p < 0.01, ctrl n = 12, GRGlu-CKO n = 9). J, Adrenal gland weight 
was increased in GRGlu-CKO mice (t-test, T19 = -9.484, p < 0.01, ctrl n = 12, GRGlu-CKO n = 9). K, ACTH levels 
were increased in GRGlu-CKO mice (MW-test, T = 171.00, p < 0.001, ctrl n = 12, GRGlu-CKO n = 9). L, CRH mRNA 
levels were increased in GRGlu-CKO mice (t-test, T17 = -2.226, p < 0.05, ctrl n = 11, GRGlu-CKO n = 8). # p < 0.05, 
data are expressed as mean + SEM. 
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Glucocorticoid receptor activity in glutamatergic neurons controls anxiety 
Malfunction of the HPA axis and altered GR signaling have been shown to be crucially 
involved in the development of psychiatric disorders characterized by pathological anxiety. 
In addition, imbalance of the glutamatergic and GABAergic neurotransmitter systems can 
critically add to aberrant behavioral responses. To functionally dissect the glutamatergic and 
GABAergic subpopulations of neurons that may mediate such effects of GR signaling on 
emotional behavior, GRGlu-CKO and GRGABA-CKO mice were subjected to a series of tests, to 
assess anxiety-related behavior and fear memory, stress-coping and locomotion. 
In the elevated plus-maze test, GRGlu-CKO mice showed reduced anxiety-like behavior as 
compared to control littermates, which is depicted in increased open arm time entries (Fig. 
4A and B). The low-anxiety phenotype of GRGlu-CKO mice was further confirmed in the dark-
light box test, as GRGlu-CKO mice spent more time in the lit compartment and showed an 
increased distance travelled in the lit compartment compared to GRGlu-Ctrl mice (Fig. 4C and 
D). The anxiolytic phenotype was independent of general locomotion, as total distance 
traveled did not differ between the two genotypes in the open field test (Suppl. Fig. 3A and 
B). Moreover, stress-coping behavior in the forced swim test was not altered in GRGlu-CKO 
mice (Suppl. Fig. 3C and D). No changes in anxiety-related and stress-coping behavior were 
observed in GRGABA-CKO mice (Fig. 4E-H; Suppl. Fig. 3E and F); only general locomotion was 
increased in GRGABA-CKO mice compared to control littermates in the open field (Suppl. Fig 3G 
and H). 
A key feature of clinical anxiety disorders is a failure to appropriately inhibit, or extinguish, 
fear (Graham and Milad, 2011). Therefore, we subjected GRGlu-CKO and GRGABA-CKO mice to a 
fear extinction paradigm to investigate their fear responses. GRGlu-CKO mice demonstrated an 
enhanced fear extinction compared to GRGlu-Ctrl mice, as depicted in the total time freezing 
during the sum of tone presentations of day 1 as well as the time freezing over the course 
of the 3 extinction sessions (Fig. 4I and J). GRGABA-CKO mice did not exhibit alterations in fear 
extinction (Fig. 4K and L).  
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Figure 4: GR in glutamatergic, but not in GABAergic neurons, selectively drives anxiety-related 
behavior. A and B, GRGlu-CKO mice spent more time in (t-test, T17 = -3.823, p < 0.001) and showed more 
entries into the open arms (t-test, T17 = -2.602, p < 0.05) of the EPM (ctrl n = 11, GRGlu-CKO n = 8). C and D, 
GRGlu-CKO mice spent more time in (MW-test, T = 131.00, p < 0.05) and showed an increased distance 
traveled (MW-test, T = 128.00, p < 0.05) in the lit compartment of the DaLi box (ctrl n = 12, GRGlu-CKO n = 
9). E-H, Anxiety-related behavior was not altered in GRGABA-CKO mice in the EPM and DaLi (n = 11-12 per 
group). I and J, GRGlu-CKO mice showed a reduced freezing response to the tone in a neutral environment 
during the first day of extinction (t-test, T22 = 2.304, p < 0.05) and during the course of all extinction trials 
(repeated measures ANOVA, F1, 22 = 4.976, p < 0.05) after conditioning with foot shocks (ctrl n = 13, GRGlu-
CKO n = 12). K and L, freezing behavior did not differ in in GRGABA-CKO mice (n = 11-12 per group). # p < 0.05, 
data are expressed as mean + SEM. 
 
GR deletion in glutamatergic neurons prevents metaplasticity of BLA responses to 
corticosterone 
The fact that GRGlu-CKO mice showed less anxiety-like behavior and lack GR expression in the 
basolateral amygdala, which is a critical limbic region in the neurobiology of mood disorders, 
made us question, whether these animals would show any changes of glutamatergic 
transmission in this structure. Therefore we assessed miniature excitatory postsynaptic 
currents (mEPSCs) in GRGlu-CKO mice. 
Interestingly, the basal mEPSC frequency of principal neurons of the BLA was significantly 
increased in coronal slices of GRGlu-CKO mice compared to slices of GRGlu-Ctrl mice (Fig. 5A). As 
expected, cells of control slices responded to corticosterone exposure with an increase in 
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mEPSC frequency (Fig. 5B). In contrast, BLA neurons of GRGlu-CKO mice did not respond to the 
first corticosterone application (Fig. 5D), which was surprising, as the rapid effect of 
glutamatergic transmission has previously been shown to be mineralocorticoid receptor-
dependent (Karst et al., 2010). However, we did not observe alterations in MR mRNA levels 
in the BLA of GRGlu-CKO mice (Fig. 5F). On the other hand, we found significantly decreased 
MR mRNA levels of GRGlu-CKO mice compared to controls in the ventral hippocampus, which 
is another critical limbic region in the neurocircuitry of anxiety disorders, projecting to the 
BLA (Fig. 5G). 
 
Figure 5: GR signaling in glutamatergic neurons is essential for the metaplasticity of BLA responses to 
corticosterone. A, GRGlu-CKO mice showed an increased basal mEPSC frequency (t-test, T14 = -2.192, p < 
0.05; ctrl n = 8, GRGlu-CKO n = 8). B and C, BLA neurons of controls responded to the first pulse with 
increased mEPSC frequency (p < 0.05, n = 8) and with a decreased mEPSC frequency to a second pulse (p 
< 0.05, n = 6) of corticosterone. D and E, Metaplasticity of BLA responses to corticosterone was not 
present in GRGlu-CKO mice (n = 8). F, MR mRNA levels did not differ in the BLA of GRGlu-CKO mice, but were 
increased in the CA1, CA3 and dentate gyrus region of the ventral hippocampus (G) (t-test, CA1: T15 = 
2.616; p < 0.05; CA3: T15 = 3.477, p < 0.01; DG: T15 = 4.284, p < 0.001). H, CRH mRNA levels were increased 
in the central amygdala (CeA) of GRGlu-CKO mice (t-test: T17 = -2.185, p < 0.05) # p < 0.05, data are expressed 
as mean + SEM. 
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Renewed exposure of BLA neurons to corticosterone caused a decrease in mEPSC frequency 
in controls (Fig. 5C). This quick suppression of glutamatergic transmission, which is 
glucocorticoid receptor dependent (Karst et al., 2010), was absent after the second 
corticosterone pulse in GRGlu-CKO mice (Fig 5E). Thus, responses of basolateral amygdala 
neurons to the stress hormone corticosterone might fail to switch from excitatory to 
inhibitory transmission, which could be a functional explanation of the anxiolytic phenotype 
in GRGlu-CKO mice. In addition, we observed elevated CRH mRNA levels in the CeA of GRGlu-CKO, 
which might further potentiate the excitatory drive (Fig 5F).  
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Discussion 
In our study, we investigated whether and how GR activation in the major excitatory and 
inhibitory neurotransmitter systems of the CNS is involved in the modulation of stress 
system activity and anxiety. Therefore, we generated conditional mouse mutants lacking the 
GR in glutamatergic or GABAergic neurons. GR deletion in glutamatergic neurons was 
strongly observed in limbic regions, while GR depletion in GABAergic neurons was mainly 
apparent in the CPu and the CeA, in line with previous reports on the prevalence of 
glutamatergic and GABAergic neurons in those regions, respectively (Refojo et al., 2011). 
We first investigated neuroendocrine parameters in both mouse lines, as altered HPA axis 
activity can have a major impact on pathogenesis of mood and anxiety disorders. We found 
that lack of GR in glutamatergic neurons leads to HPA axis hyperactivity, while there was no 
neuroendocrine effect in GRGABA-CKO mice. Furthermore, GRGlu-CKO mice demonstrated an 
anxiolytic phenotype in several behavioral tasks, while GR deletion in GABAergic neurons 
did not lead to an overt behavioral outcome. In line with the behavioral observations, we 
found that metaplasticity of BLA responses to corticosterone is inhibited in GRGlu-CKO mice. 
Our results provide substantial evidence that GR signaling in the glutamatergic, but not in 
the GABAergic neurotransmitter system is crucially involved in the modulation of stress 
system activity and anxiety.  
The glucocorticoid receptor is widely distributed throughout the brain, especially in limbic 
structures. However, besides the region specificity of GR expression, little is known on which 
kind of neurons the receptor is expressed. By generating conditional GR knockout mice 
lacking the receptor either in glutamatergic or GABAergic neurons, we found that GR was 
present in glutamatergic neurons of the PVN, Hippocampus and BLA and in GABAergic 
neurons of CPu and the CeA.  
Glucocorticoids regulate the activity of the HPA axis through negative feedback via the GR 
mainly in the PVN, but also at the level of the hippocampus and other limbic structures (De 
Kloet et al., 1998; Ulrich-Lai and Herman, 2009). Several conditional GR knockout mouse 
studies further contributed to this knowledge. In particular, conditional deletion of GR in the 
CNS (GRNesCre mice) resulted in HPA axis hyperactivity, possibly due to GR deletion in the PVN 
(Tronche et al., 1999). Moreover, disruption of GR limited to adult forebrain neurons 
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(GRCaMKIIα-Cre mice) led to a mild form of HPA axis hyperactivity (Boyle et al., 2005). More 
recently, PVN-specific GR knockout mice (Sim1Cre-GRe3Δ mice) demonstrated 
hypercorticosterolemia (Laryea et al., 2013). The deletion pattern in limbic structures such 
as the PVN in GRGlu-CKO mice and the increased HPA axis activity, are along these lines. It 
becomes clear that especially the GR in glutamatergic neurons plays a prominent role in 
mediating the negative feedback on the HPA axis.  
Limbic dysfunction and HPA axis dysregulation, due to altered GR signaling, are key features 
of affective disorders (Herman et al., 2005). Numerous transgenic mouse models of altered 
GR expression have demonstrated a role for GR in mediating neuroendocrine responses, but 
have also highlighted its crucial involvement on emotional behavior (Müller and Holsboer, 
2006). Mice with a deletion of the GR in the anterior pituitary (GRPOMC-Cre mice) were less 
affected by chronic social defeat stress, which was reflected in reduced anxiety-related 
behavior (Wagner et al., 2011). Moreover, conditional overexpression of GR in the forebrain 
and the limbic system (GRov mice) led to increased anxiety-like behavior (Wei et al., 2004), 
while conditional GR deletion in the CNS (GRNesCre) demonstrated reduced anxiety-related 
behavior (Tronche et al., 1999).  
However, while previous studies focused on region specific influences of GR on 
neuroendocrine, physiological and behavioral responses, we were able to isolate the specific 
contribution of GR activation in glutamatergic and GABAergic neurons on neuroendocrine 
and behavioral outcomes. We found that GRGlu-CKO mice demonstrate an anxiolytic 
phenotype, which was reflected in decreased anxiety-related behavior in the EPM and DaLi 
and an enhanced fear extinction. These findings are glutamatergic system specific, as GRGABA-
CKO mice, but also mice lacking the GR in dopamine-releasing neurons (GRDat-Cre mice) or in 
dopaminoceptive neurons (GRD1-Cre mice) did not show any overt anxiety-related phenotype 
(Barik et al., 2013). Our data are in line with the proposed abnormalities in glutamatergic 
and GABAergic neurotransmitter systems in the pathophysiology of psychiatric disorders 
(Norrholm and Ressler, 2009; Millan et al., 2012; Murrough et al., 2013). In addition, 
disruption of glutamatergic neurotransmission has been implicated in increased anxiety-like 
behavior in mice (Wu et al., 2007). 
The amygdala is a key player in the neurocircuitry of fear and anxiety disorders (Davis, 1992; 
LeDoux, 2007; Dias et al., 2013). This brain region is also important in modulating the HPA-
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axis through negative feedback mediated by the GR (Gray, 1993; McEwen and Sapolsky, 
1995; Herman et al., 2005).  
Interestingly, postmortem studies reported lower GR expression in the amygdala of patients 
with mood disorders (Pérez-Ortiz et al., 2012; Wang et al., 2013a). GRGlu-CKO mice lack GR 
expression in the basolateral amygdala and showed less anxiety-like behavior. Therefore we 
investigated a possible mechanism whereby the lack of GR expression in glutamatergic BLA 
neurons could lead to a decreased emotional reactivity. We assessed miniature excitatory 
postsynaptic currents, which reflect the spontaneous release of a glutamate-containing 
vesicle, in principal neurons of the BLA in GRGlu-CKO mice. Responses of BLA neurons to 
corticosterone can switch from excitatory to inhibitory, depending on the recent stress 
history of the organism (Karst et al., 2010). In particular, high levels of corticosterone quickly 
and long-lastingly enhance glutamatergic transmission in basolateral amygdala neurons, via 
nongenomic actions requiring mineralocorticoid receptors, possibly allowing an extended 
timeframe for encoding of emotional aspects during stressful events. The long-lasting 
change in state of BLA neurons crucially affects the responsiveness to subsequent pulses of 
corticosterone, leading to a quick suppression of glutamatergic transmission, which is 
glucocorticoid receptor-dependent. This metaplasticity of amygdalar responses to 
corticosterone was completely abolished in GRGlu-CKO mice. Interestingly, even the rapid 
effect of glutamatergic transmission, which has been shown to be MR-dependent, was 
absent in GRGlu-CKO mice. Although we did not observe any MR mRNA expression changes in 
the BLA of these mice, we found decreased MR mRNA levels in the ventral hippocampus, 
another limbic region involved in the neurocircuitry of anxiety, projecting to the amygdala. 
Thus, the increased basal mEPSC frequency and the suppression of metaplasticity responses 
to corticosterone in the BLA might functionally explain the anxiolytic phenotype of GRGlu-CKO 
mice. 
Taken together, our study introduces the glucocorticoid receptor in glutamatergic neurons 
as a major mediator of fear and anxiety. We also provide evidence that GR signaling in 
glutamatergic neurons plays a critical role in the regulation of HPA axis activity. These 
findings underline the importance of GR-dependent glutamatergic pathways in the 
development of psychopathologies that are related to anxiety. 
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Supplemental Figures 
 
Suppl. Figure 1: Coronal sections of control and mutant mice were stained for GR and DAPI. Piriform 
cortex, cortex: magnification x10; caudate putamen (CPu): magnification x20; Scale bar, 250 µm. 
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Suppl. Figure 2: Physiological parameters of GRGABA-CKO mice. Relative thymus (A) and adrenal gland 
weight (B), as well as ACTH level (C) did not differ in GRGABA-CKO mice (n = 11 and 14 per group). Data are 
expressed as mean + SEM. 
 
 
Suppl. Figure 3: General locomotion in the open field test (OF) and stress-coping behavior in the forced 
swim test (FST). Total distance traveled (A) and distance traveled divided in 5 min segments (B) did not 
differ in GRGLU-CKO mice. Time struggling (C) and time floating (D) were not different in GRGLU-CKO mice (n = 
9-12 per group). (E and F) GRGABA-CKO mice traveled significantly more in the OF (30 min: t-test, T20 = -
2.583, p < 0.05; 5 min segments: repeated measures ANOVA, main genotype effect: F1, 20 = 6.671, p < 
0.05; ctrl n = 11, GRGABA-CKO n = 11). (G and H) No differences in stress-coping behavior were observed in 
GRGABA-CKO mice (n = 11-12 per group). # p < 0.05, data are expressed as mean + SEM. 
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Suppl. Table 1. Fear conditioning protocol.  
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